
<html lang="en"     class="pb-page"  data-request-id="bf9aca46-13e9-4407-879b-570a2ca590b1"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.6b00943;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2016.59.issue-21;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer" /></meta><meta name="dc.Creator" content="Chun-Hui  Zhang" /></meta><meta name="dc.Creator" content="Kai  Chen" /></meta><meta name="dc.Creator" content="Yan  Jiao" /></meta><meta name="dc.Creator" content="Lin-Li  Li" /></meta><meta name="dc.Creator" content="Ya-Ping  Li" /></meta><meta name="dc.Creator" content="Rong-Jie  Zhang" /></meta><meta name="dc.Creator" content="Ming-Wu  Zheng" /></meta><meta name="dc.Creator" content="Lei  Zhong" /></meta><meta name="dc.Creator" content="Shen-Zhen  Huang" /></meta><meta name="dc.Creator" content="Chun-Li  Song" /></meta><meta name="dc.Creator" content="Wan-Ting  Lin" /></meta><meta name="dc.Creator" content="Jiao  Yang" /></meta><meta name="dc.Creator" content="Rong  Xiang" /></meta><meta name="dc.Creator" content="Bing  Peng" /></meta><meta name="dc.Creator" content="Jun-Hong  Han" /></meta><meta name="dc.Creator" content="Guang-Wen  Lu" /></meta><meta name="dc.Creator" content="Yu-Quan  Wei" /></meta><meta name="dc.Creator" content="Sheng-Yong  Yang" /></meta><meta name="dc.Description" content="Herein we report the sophisticated process of structural optimization toward a previously disclosed Src inhibitor, compound 1, which showed high potency in the treatment of triple negative breast c..." /></meta><meta name="Description" content="Herein we report the sophisticated process of structural optimization toward a previously disclosed Src inhibitor, compound 1, which showed high potency in the treatment of triple negative breast c..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 26, 2016" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b00943" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00943" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b00943" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00943" /></link>
        
    
    

<title>From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b00943" /></meta><meta property="og:title" content="From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0022.jpeg" /></meta><meta property="og:description" content="Herein we report the sophisticated process of structural optimization toward a previously disclosed Src inhibitor, compound 1, which showed high potency in the treatment of triple negative breast cancer (TNBC) both in vitro and in vivo but had considerable toxicity. A series of 3-(phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine derivatives were synthesized. In vitro cell-based phenotypic screening together with in vivo assays and structure–activity relationship (SAR) studies finally led to the discovery of N-(3-((4-amino-1-(trans-4-hydroxycyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-4-methyl-3-(trifluoromethyl)benzamide (13an). 13an is a multikinase inhibitor, which potently inhibited Src (IC50 = 0.003 μM), KDR (IC50 = 0.032 μM), and several kinases involved in the MAPK signal transduction. This compound showed potent anti-TNBC activities both in vitro and in vivo, and good pharmacokinetic properties and low toxicity. Mechanisms of action of anti-TNBC were also investigated. Collectively, the data obtained in this study indicate that 13an could be a promising drug candidate for the treatment of TNBC and hence merits further studies." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b00943"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00943">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b00943&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b00943&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b00943&amp;href=/doi/10.1021/acs.jmedchem.6b00943" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 21</span><span class="cit-fg-pageRange">, 9788-9805</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/21" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b00890" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b01038" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chun-Hui++Zhang">Chun-Hui Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kai++Chen">Kai Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yan++Jiao">Yan Jiao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lin-Li++Li">Lin-Li Li</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol "><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ya-Ping++Li">Ya-Ping Li</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rong-Jie++Zhang">Rong-Jie Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ming-Wu++Zheng">Ming-Wu Zheng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lei++Zhong">Lei Zhong</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shen-Zhen++Huang">Shen-Zhen Huang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chun-Li++Song">Chun-Li Song</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wan-Ting++Lin">Wan-Ting Lin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jiao++Yang">Jiao Yang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rong++Xiang">Rong Xiang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bing++Peng">Bing Peng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jun-Hong++Han">Jun-Hong Han</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Guang-Wen++Lu">Guang-Wen Lu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yu-Quan++Wei">Yu-Quan Wei</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sheng-Yong++Yang">Sheng-Yong Yang</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative Innovation Center for Biotherapy, Sichuan University, Sichuan 610041, China</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Key Laboratory of Drug Targeting and Drug Delivery System of Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, Sichuan 610041, China</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Department of Clinical Medicine, School of Medicine, Nankai University, Tianjin 300071, China</span></div><div class="corresp-info"><strong>*</strong>Tel: +86-28-85164063. Fax: +86-28-85164060. E-mail: <a href="/cdn-cgi/l/email-protection#0a736b646d79734a79697f246f6e7f246964"><span class="__cf_email__" data-cfemail="6b120a050c18122b18081e450e0f1e450805">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00943&amp;href=/doi/10.1021%2Facs.jmedchem.6b00943" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 21</span><span class="cit-pageRange">, 9788–9805</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 14, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>26 June 2016</li><li><span class="item_label"><b>Published</b> online</span>26 October 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 November 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b00943" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00943</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9788%26pageCount%3D18%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DChun-Hui%2BZhang%252C%2BKai%2BChen%252C%2BYan%2BJiao%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D21%26contentID%3Dacs.jmedchem.6b00943%26title%3DFrom%2BLead%2Bto%2BDrug%2BCandidate%253A%2BOptimization%2Bof%2B3-%2528Phenylethynyl%2529-1H-pyrazolo%255B3%252C4-d%255Dpyrimidin-4-amine%2BDerivatives%2Bas%2BAgents%2Bfor%2Bthe%2BTreatment%2Bof%2BTriple%2BNegative%2BBreast%2BCancer%26numPages%3D18%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9805%26publicationDate%3DNovember%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b00943"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2863</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">12</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b00943" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Chun-Hui&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Kai&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Yan&quot;,&quot;last_name&quot;:&quot;Jiao&quot;},{&quot;first_name&quot;:&quot;Lin-Li&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Ya-Ping&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Rong-Jie&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Ming-Wu&quot;,&quot;last_name&quot;:&quot;Zheng&quot;},{&quot;first_name&quot;:&quot;Lei&quot;,&quot;last_name&quot;:&quot;Zhong&quot;},{&quot;first_name&quot;:&quot;Shen-Zhen&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Chun-Li&quot;,&quot;last_name&quot;:&quot;Song&quot;},{&quot;first_name&quot;:&quot;Wan-Ting&quot;,&quot;last_name&quot;:&quot;Lin&quot;},{&quot;first_name&quot;:&quot;Jiao&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Rong&quot;,&quot;last_name&quot;:&quot;Xiang&quot;},{&quot;first_name&quot;:&quot;Bing&quot;,&quot;last_name&quot;:&quot;Peng&quot;},{&quot;first_name&quot;:&quot;Jun-Hong&quot;,&quot;last_name&quot;:&quot;Han&quot;},{&quot;first_name&quot;:&quot;Guang-Wen&quot;,&quot;last_name&quot;:&quot;Lu&quot;},{&quot;first_name&quot;:&quot;Yu-Quan&quot;,&quot;last_name&quot;:&quot;Wei&quot;},{&quot;first_name&quot;:&quot;Sheng-Yong&quot;,&quot;last_name&quot;:&quot;Yang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;26&quot;,&quot;issue&quot;:&quot;21&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;9788-9805&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b00943&quot;},&quot;abstract&quot;:&quot;Herein we report the sophisticated process of structural optimization toward a previously disclosed Src inhibitor, compound 1, which showed high potency in the treatment of triple negative breast cancer (TNBC) both in vitro and in vivo but had considerable toxicity. A series of 3-(phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine derivatives were synthesized. In vitro cell-based phenotypic screening together with in vivo assays and structure–activity relationship (SAR) studies finally led to the discovery of N-(3-((4-amino-1-(trans-4-hydroxycyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-4-methyl-3-(trifluoromethyl)benzamide (13an). 13an is a multikinase inhibitor, which potently inhibited Src (IC50 = 0.003 μM), KDR (IC50 = 0.032 μM), and several kinases involved in the MAPK signal transduction. This compound showed potent anti-TNBC activities both in vitro and in vivo, and good pharmacokinetic properties and low toxicity. Mechanisms of action of anti-TNBC were also investigated. Collec&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00943&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00943" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00943&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00943" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00943&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00943" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00943&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00943&amp;href=/doi/10.1021/acs.jmedchem.6b00943" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b00943" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b00943" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (9 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00943&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b00943%26sid%3Dliteratum%253Aachs%26pmid%3D27739679%26genre%3Darticle%26aulast%3DZhang%26date%3D2016%26atitle%3DFrom%2BLead%2Bto%2BDrug%2BCandidate%253A%2BOptimization%2Bof%2B3-%2528Phenylethynyl%2529-1H-pyrazolo%255B3%252C4-d%255Dpyrimidin-4-amine%2BDerivatives%2Bas%2BAgents%2Bfor%2Bthe%2BTreatment%2Bof%2BTriple%2BNegative%2BBreast%2BCancer%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D21%26spage%3D9788%26epage%3D9805%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=290808" title="Toxicity">Toxicity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/21" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/jmcmar.2016.59.issue-21/20161110/jmcmar.2016.59.issue-21.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/medium/jm-2016-00943q_0022.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00943&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Herein we report the sophisticated process of structural optimization toward a previously disclosed Src inhibitor, compound <b>1</b>, which showed high potency in the treatment of triple negative breast cancer (TNBC) both in vitro and in vivo but had considerable toxicity. A series of 3-(phenylethynyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine derivatives were synthesized. In vitro cell-based phenotypic screening together with in vivo assays and structure–activity relationship (SAR) studies finally led to the discovery of <i>N</i>-(3-((4-amino-1-(<i>trans</i>-4-hydroxycyclohexyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-4-methyl-3-(trifluoromethyl)benzamide (<b>13an</b>). <b>13an</b> is a multikinase inhibitor, which potently inhibited Src (IC<sub>50</sub> = 0.003 μM), KDR (IC<sub>50</sub> = 0.032 μM), and several kinases involved in the MAPK signal transduction. This compound showed potent anti-TNBC activities both in vitro and in vivo, and good pharmacokinetic properties and low toxicity. Mechanisms of action of anti-TNBC were also investigated. Collectively, the data obtained in this study indicate that <b>13an</b> could be a promising drug candidate for the treatment of TNBC and hence merits further studies.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">1 Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02137" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02137" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Triple-negative breast cancers (TNBCs), which do not express any of the markers of an estrogen receptor (ER), a progesterone receptor (PR), and a human epidermal growth factor receptor 2 (HER2), constitute 15%–20% of all breast cancers.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> A typical characteristic of TNBCs is a lack of specific biomarkers.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3, 4)</a> Conventional chemotherapy is the only systemic therapy, and the prognosis remains poor.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5, 6)</a> Recently, molecular profiling efforts have revealed several potential molecular targets of TNBCs.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Among them, Src is one of the most promising targets.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Src is a nonreceptor tyrosine kinase. It has been demonstrated to play a role in the proliferation, migration, and invasion of breast cancer cell lines.<a onclick="showRef(event, 'ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11">(9-11)</a> Further, the abnormal activation or amplification of Src has also been detected in tumor tissues of TNBC patients.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Therefore, Src represents a rational molecular target for TNBCs. However, dasatinib, the only Src inhibitor that is in clinical trials for treating TNBCs, just showed a limited efficacy in TNBCs.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13, 14)</a> The fact that dasatinib has subnanomolar inhibitory activity against Src (IC<sub>50</sub> = 0.0003 μM)<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> implies that it is impractical to further enhance the anti-TNBC activity of a compound by only improving the Src inhibitory potency.</div><div class="NLM_p">A multitarget strategy could be a better choice to enhance the anti-TNBC activity of a Src inhibitor because of the highly heterogeneous property of TNBC.<a onclick="showRef(event, 'ref16 ref17 ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18 ref19 ref20">(16-20)</a> In a recent study, we developed a multikinase inhibitor, 3-((4-amino-1-ethyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methyl-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl) phenyl)benzamide (<b>1</b>, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>), which potently inhibits Src and RAF kinases with IC<sub>50</sub> values of 0.0009 μM for Src, 0.092 μM for B-Raf, and 0.027 μM for C-Raf.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> This compound indeed showed a much higher anti-TNBC activity than dasatinib both in vitro and in vivo. Nevertheless, in preliminary acute toxicity tests with rats, compound <b>1</b> caused multiple organ toxicities after a single oral dose of 100 mg/kg (see <a href="/doi/suppl/10.1021/acs.jmedchem.6b00943/suppl_file/jm6b00943_si_001.pdf" class="ext-link">Figure S1</a>). To reduce the toxicity of compound <b>1</b>, we subsequently performed structural optimization, which led to the discovery of compound <b>13b</b> (<i>N</i>-(3-((4-amino-1-(1-methylpiperidin-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-3-(trifluoromethyl)benzamide) (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). <b>13b</b> showed anti-TNBC activity very similar to that of <b>1</b> but a lower toxicity than that of <b>1</b>. Unfortunately, <b>13b</b> displayed considerable ability to block the hERG (human Ether-a-go-go Related Gene) channel, which is a risk factor of cardiotoxicity.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Thus, further structural optimization was carried out to remove the hERG activity of this compound. Finally, we obtained a new compound, <i>N</i>-(3-((4-amino-1-(<i>trans</i>-4-hydroxycyclohexyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-4-methyl-3-(trifluoromethyl)benzamide (<b>13an</b>) (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). This compound not only exhibited potent anti-TNBC activity both in vitro and in vivo but also had a lower toxicity than compound <b>1</b> in acute toxicity tests and no hERG activity. In this account, we shall report the sophisticated process of structural optimization from compound <b>1</b> to <b>13an</b>. Evaluations of pharmacodynamic and pharmacokinetic properties and toxicities of <b>13an</b>, and its mechanisms of action of anti-TNBCs will also be presented.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/medium/jm-2016-00943q_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Schematic showing the lead optimization process.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00943&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">2 Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64344" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64344" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Synthetic routes of compounds <b>8a</b>–<b>g</b> with a “forward direction” amide are illustrated in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Briefly, benzoic acids <b>2a</b>–<b>c</b> were coupled with 3-(trifluoromethyl)aniline to afford amide <b>3a</b>–<b>c</b>, followed by a classical Sonogashira reaction and deprotection to produce intermediates <b>4a</b>–<b>c</b>. Iodination of 1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>5</b>) yielded compound <b>6</b>, which was subsequently coupled with commercially available haloalkanes or self-prepared methanesulfonates to afford <b>7a</b>–<b>h</b>. Intermediates <b>7i</b>–<b>l</b> containing a tertiary amine were prepared by deprotection of <b>7a</b>–<b>d</b> and subsequent reductive amination. Stereoisomers <b>7m</b> and <b>7n</b> were produced by deprotection of <b>7e</b> and a succeeding reduction. The target compounds <b>8a</b>–<b>g</b> were finally obtained by Sonogashira reactions between <b>4a</b>–<b>c</b> and <b>7f</b> or <b>7i</b>–<b>l</b>.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/medium/jm-2016-00943q_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0010.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Routes for Compounds <b>8a</b>–<b>g</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00943&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (i) SOCl<sub>2</sub>, 80 °C, (ii) DIPEA, EA, 0 °C to rt; (b) ethynyltrimethylsilane, CuI, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, DIPEA, THF, rt, N<sub>2</sub>; (c) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt; (d) NIS, DMF, 80 °C, N<sub>2</sub>; (e) R<sub>1</sub>-X(Br, I) or R<sub>1</sub>-OMs, K<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, N<sub>2</sub>; (f) 5 N HCl in 1,4-dioxane, MeOH, 0 °C to rt; (g) formaldehyde, acetic acid, sodium cyanoborohydride, 1,2-dichloroethane/methanol, rt; (h) 1 N HCl, acetone, 70 °C to rt; (i) sodium borohydride, MeOH, 0 °C to rt; (j) (PPh<sub>3</sub>)<sub>2</sub>PdCl<sub>2</sub>, CuI, DIPEA, DMF, 80 °C, N<sub>2</sub>.</p></p></figure><div class="NLM_p">Compounds <b>13a</b>–<b>aq</b> containing a reversed amide linker were prepared according to the routes shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. First, the starting material iodobenzenes <b>9a</b>–<b>b</b> underwent a Sonogashira reaction to give <b>10a</b>–<b>b</b>, followed by reduction to produce 3-ethynylaniline derivatives (<b>11a</b>–<b>b</b>). Then, <b>11a</b>–<b>b</b> together with 3-ethynylaniline (<b>11c</b>), which was purchased from a market, were coupled with commercially available or self-prepared aromatic carboxylic acid under basic conditions to afford intermediate <b>12a</b>–<b>z</b>. Finally, the target products <b>13a</b>–<b>aq</b> were obtained through procedures similar to that in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/medium/jm-2016-00943q_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0011.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Routes for Compounds <b>1i</b>–<b>r</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00943&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) ethynyltrimethylsilane, CuI, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, triethylamine, THF, rt, N<sub>2</sub>; (b) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt; (c) Fe, NH<sub>4</sub>Cl, 70% EtOH, 80 °C; (d) (i) aromatic carboxylic acid, SOCl<sub>2</sub>, 80 °C, (ii) DIPEA, EA, 0 °C to rt; (e) (PPh<sub>3</sub>)<sub>2</sub>PdCl<sub>2</sub>, CuI, DIPEA, DMF, 80 °C, N<sub>2</sub>.</p></p></figure><div class="NLM_p">Synthetic routes of compounds <b>17a</b>–<b>c</b> with a urea linker are outlined in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. First, 1-isocyanato-3-(trifluoromethyl)benzene <b>15</b> was prepared using the starting material 3-(trifluoromethyl)aniline <b>14</b>, followed by coupling with <b>11a</b>–<b>c</b> to yield <b>16a</b>–<b>c</b>. Again, target compounds <b>17a</b>–<b>c</b> were readily synthesized using procedures similar to that in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>.</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/medium/jm-2016-00943q_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0012.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthetic Routes for Compounds <b>14a</b>–<b>g</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00943&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) triphosgene, DIPEA, EA, 0 °C to rt; (b) <b>11a</b>–<b>c</b>, EA, 70 °C; (c) (PPh<sub>3</sub>)<sub>2</sub>PdCl<sub>2</sub>, CuI, DIPEA, DMF, 80 °C, N<sub>2</sub>.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">3 Results and Discussions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88426" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88426" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">3.1 Shift of the Lead Compound from Original Compound <b>1</b> to <b>8c</b></h3><div class="NLM_p">A multikinase inhibitor often inevitably bears some toxicity, and the structural optimization for reducing the toxicity is not an easy task because of the following reasons. Mechanisms responsible for the toxicity of a multikinase inhibitor are often much more complicated; the toxicity might be due to inhibition of kinases that each one could cause toxicity, or inhibition of kinases that each one is safe but that combination of their inhibition could induce toxicity.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Additionally, due to the high similarity of kinase structures, a multikinase inhibitor often has potency against many kinases, not just few of the kinases.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> For the toxicity optimization of a multikinase inhibitor, the most ideal strategy is to carry out kinase inhibition profiling against all of the kinase family members for compounds synthesized. However, this is too expensive, and it is often difficult to draw a consistent and meaningful conclusion from the complex data of kinase inhibition profiling. To screen for compounds with potent anti-TNBC activity but low toxicity, we in this investigation adopted a cheaper combination strategy, namely, an in vitro cell-based phenotypic screening together with an in vivo assay. In the cell-based phenotypic screening, three cell lines were selected, including MDA-MB-231, MDA-MB-435, and HepG2. MDA-MB-231 and MDA-MB-435 are typical human TNBC cell lines, which express a high level of Src and are sensitive to Src inhibition.<a onclick="showRef(event, 'ref13 ref21 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref13 ref21 ref25 ref26">(13, 21, 25, 26)</a> HepG2 is a human liver cancer cell line, which expresses a very low level of Src;<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> the use of HepG2 is to help determine the toxicity effect due to the inhibition of targets except Src. Compounds with potent activity against MDA-MB-231 and MDA-MB-435 and low cell toxicity against HepG2 were selected to perform in vivo assays.</div><div class="NLM_p">With the aim to optimize compound <b>1</b>, computational studies were first performed to investigate the binding mode of <b>1</b> with Src. The predicted binding mode is shown in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>A. Obviously, compound <b>1</b> is a typical type II kinase inhibitor. The moiety 1-ethyl-3-(o-tolylethynyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine suitably resides in the ATP binding site of the kinase domain, and 1-methyl-4-(2-(trifluoromethyl)benzyl)piperazine occupies the allosteric pocket. The two moieties are linked through an amide group. Many studies have shown that, despite a high conservation of the kinase domain, there are still some regions that have a big variation in amino acids among all the kinases, which could be exploited in the structural optimization of ligands to adjust the kinase inhibition profiling, hence achieving the purpose of reducing toxicity.<a onclick="showRef(event, 'ref24 ref28 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref24 ref28 ref29 ref30">(24, 28-30)</a> The region where the ethyl group of 1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine resides (the entrance of the ATP binding site, region I) and the allosteric pocket (region II) belong to this type of region. In our previous study that led to the discovery of compound <b>1</b>, subgroups corresponding to region I and region II have been optimized. However, a retrospective analysis showed that the region I and II subgroups have not been sufficiently optimized. Therefore, the two regions are still the focus of this investigation. In the first step, we used some new fragments, which have not been employed in our previous study, to replace the ethyl group in region I. Here, the fragments selected are all hydrophilic because region I is actually a solvent accessible region. For simplification, the region II subgroup was temporarily fixed as (trifluoromethyl)benzene because (trifluoromethyl)benzene is structurally simple and also one of the most preferred fragments in this region; of course, structural optimization toward this region would be carried out in the subsequent steps. A total of five compounds (compound <b>8a</b>–<b>e</b>) were synthesized, and their chemical structures and bioactivities are given in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>. From <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>, we can see that compounds <b>8b</b> and <b>8c</b> have antiproliferation activities against TNBC cells comparable to that of compound <b>1</b> and that others are obviously weak. Further, compared with <b>8b</b>, compound <b>8c</b> showed a relatively poor activity against HepG2, implying low toxicity. We therefore took compound <b>8c</b> (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>B) as a new starting compound or in other words a new lead to carry out further structural optimization.</div><figure id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/medium/jm-2016-00943q_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Predicted binding mode of <b>1</b> with Src. The crystal structure of Src was taken from the RCSB Protein Data Bank (PDB entry: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3EL7">3EL7</a>). (B) The structure of compound <b>8c</b>. (C) Schematic showing regions that are the focuses of structural modifications.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00943&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Anti-Proliferation Activities of Compounds <b>1</b>, Dasatinib, and <b>8a</b>–<b>e</b> against MDA-MB-231, MDA-MB-435, and HepG2 Cells</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/medium/jm-2016-00943q_0013.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/medium/jm-2016-00943q_0014.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Each compound was tested in triplicate; the data are presented as the mean ± SD.</p></div></div><div></div></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">3.2 SAR Analyses of 3-(Phenylethynyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine Derivatives</h3><div class="NLM_p">The structural optimization of compound <b>8c</b> was focused on the following three regions (see <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>C): substituents on the phenyl ring attached to the 1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine core (Ring A; R<sub>2</sub>), the aromatic ring at the “head” of the compound and its substituents (ring B; R<sub>3</sub>), and the linker between the phenyl ring A and aromatic ring B. In this step, the R<sub>1</sub> position was fixed as the optimal subgroup 1-methylpiperidine.</div><div id="sec3_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i10" class="anchor-spacer"></div><h4 class="article-section__title" id="_i10">3.2.1 Impact of Substituents on Ring A and the Linker Groups</h4><div class="NLM_p">To explore the possible influence of different substituents at the C-4 position (R<sub>2</sub>) of the phenyl ring and the effects of different linker groups, we varied these two subgroups using different combinations of fragments. R<sub>2</sub> substituents include hydrogen, methyl, and chlorine, and the linker groups include forward and reversed amide, and urea. Bioactivities of the resultant compounds are shown in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>. From <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>, we can see that only compound <b>13b</b>, which contains a methyl group at the R<sub>2</sub> position and a reversed amide as the linker, maintained comparable potency against MDA-MB-231 and MDA-MB-435 cells with that of compound <b>8c</b>. More importantly, the activity against HepG2 was further reduced, implying a decreased toxicity. These data indicate that the presence of the methyl group at the R<sub>2</sub> position and a reversed amide in the linker region might be beneficial to reduce the toxicity and maintain the anti-TNBC activity. Here, it is important to mention that in the same case of reversed amide, compound <b>13b</b>, which contains a methyl group at the R<sub>2</sub> position, showed a more potent activity and a lower toxicity compared with that of compound <b>13a</b>, which has no such a methyl group. A reasonable explanation is that the methyl group in <b>13b</b> likely constrains conformation, interacts with the gatekeeper side chains, and narrows the kinome profile, making <b>13b</b> more active and less toxic than <b>13a</b>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Antiviability Activities of Compounds <b>8f</b>–<b>g</b>, <b>13a</b>–<b>c</b>, <b>17a</b>–<b>c</b>, and <b>8c</b> against MDA-MB-231, MDA-MB-435, and HepG2 Cells</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/medium/jm-2016-00943q_0015.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/medium/jm-2016-00943q_0016.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">Each compound was tested in triplicate; the data are presented as the mean ± SD.</p></div></div><div></div></div></div><div id="sec3_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12">3.2.2 Influences of Various Substituents on Ring B (<b>R</b><sub><b>3</b></sub>)</h4><div class="NLM_p">In this section, we explore the effects of different substituents on ring B. First, various hydrophobic groups were placed at the meta or para position on ring B. Bioactivities of the synthesized derivatives are shown in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>. From <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>, we can see that bioactivities of compounds with a bulky substituent at the meta position are much higher than corresponding ones substituted at the para position (<b>13b</b> vs <b>13d</b>; <b>13e</b> vs <b>13f</b>). On the contrary, compounds with a small substituent at the para position are more active than those with the same substituent at the meta position (<b>13g</b> vs <b>13h</b>). Second, various hydrophobic substituents, including fluorine (<b>13i</b>), trifluoromethoxyl (<b>13j</b>), methyl (<b>13k</b>), and <i>tert</i>-butyl (<b>13l</b>), were used to replace the original trifluoromethyl moiety at the meta position, which led to a series of compounds with lower bioactivities. These data indicate that the trifluoromethyl group is the most suitable substituent at the meta position. Third, more hydrophobic substituents were introduced on ring B with the trifluoromethyl group fixed at the meta position (<b>13m</b>–<b>v</b>). As shown in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>, compared with <b>13b</b>, all resulting compounds showed reduced activities against both cell lines, except compound <b>13r</b> and <b>13s</b>, which have comparable potencies with <b>13b</b>. Fourthly, to examine the possible influences of different aromatic rings at the ring B position, a trifluoromethyl-substituted pyridine derivatives (<b>13w</b>–<b>y</b>) and a <i>tert</i>-butyl-substituted five-membered heterocycle (<b>13z</b> and <b>13aa</b>–<b>ab</b>) were design and synthesized. As shown in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>, the bioactivities of the resulting compounds did not exceed that of compound <b>13b</b>. Therefore, in subsequent structural modifications, ring B and R<sub>3</sub> were maintained as a 3-trifluoromethylphenyl group.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Anti-Proliferation Activities of Compounds <b>13b</b>–<b>v</b> against MDA-MB-231, MDA-MB-435, and HepG2 Cells</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/medium/jm-2016-00943q_0017.gif" alt="" id="fx5" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">cellular inhibition (IC<sub>50</sub>, μM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Cpd</th><th class="colsep0 rowsep0" align="center">R<sub>3</sub></th><th class="colsep0 rowsep0" align="center">MDA-MB-231</th><th class="colsep0 rowsep0" align="center">MDA-MB-435</th><th class="colsep0 rowsep0" align="center">HepG2</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13b</b></td><td class="colsep0 rowsep0" align="left">3-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">0.013 ± 0.002</td><td class="colsep0 rowsep0" align="left">0.080 ± 0.011</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13d</b></td><td class="colsep0 rowsep0" align="left">4-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">0.854 ± 0.185</td><td class="colsep0 rowsep0" align="left">5.135 ± 1.222</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13e</b></td><td class="colsep0 rowsep0" align="left">3-OMe</td><td class="colsep0 rowsep0" align="left">0.101 ± 0.023</td><td class="colsep0 rowsep0" align="left">0.285 ± 0.138</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13f</b></td><td class="colsep0 rowsep0" align="left">4-OMe</td><td class="colsep0 rowsep0" align="left">1.358 ± 0.333</td><td class="colsep0 rowsep0" align="left">8.901 ± 1.432</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13g</b></td><td class="colsep0 rowsep0" align="left">3-Cl</td><td class="colsep0 rowsep0" align="left">0.060 ± 0.021</td><td class="colsep0 rowsep0" align="left">0.733 ± 0.289</td><td class="colsep0 rowsep0" align="left">9.2 ± 2.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13h</b></td><td class="colsep0 rowsep0" align="left">4-Cl</td><td class="colsep0 rowsep0" align="left">0.033 ± 0.013</td><td class="colsep0 rowsep0" align="left">0.111 ± 0.031</td><td class="colsep0 rowsep0" align="left">7.6 ± 1.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13i</b></td><td class="colsep0 rowsep0" align="left">3-F</td><td class="colsep0 rowsep0" align="left">0.812 ± 0.162</td><td class="colsep0 rowsep0" align="left">2.066 ± 0.078</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13j</b></td><td class="colsep0 rowsep0" align="left">3-OCF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">0.075 ± 0.018</td><td class="colsep0 rowsep0" align="left">0.093 ± 0.082</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13k</b></td><td class="colsep0 rowsep0" align="left">3-Me</td><td class="colsep0 rowsep0" align="left">0.133 ± 0.209</td><td class="colsep0 rowsep0" align="left">0.422 ± 0.172</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13l</b></td><td class="colsep0 rowsep0" align="left">3-<i>t</i>Bu</td><td class="colsep0 rowsep0" align="left">0.059 ± 0.012</td><td class="colsep0 rowsep0" align="left">0.020 ± 0.009</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13m</b></td><td class="colsep0 rowsep0" align="left">2-F-3-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">0.296 ± 0.077</td><td class="colsep0 rowsep0" align="left">0.273 ± 0.111</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13n</b></td><td class="colsep0 rowsep0" align="left">3-CF<sub>3</sub>-4-F</td><td class="colsep0 rowsep0" align="left">0.523 ± 0.220</td><td class="colsep0 rowsep0" align="left">0.621 ± 0.180</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13o</b></td><td class="colsep0 rowsep0" align="left">3-F-5-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">0.671 ± 0.121</td><td class="colsep0 rowsep0" align="left">1.430 ± 0.309</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13p</b></td><td class="colsep0 rowsep0" align="left">2-F-5-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">0.201 ± 0.057</td><td class="colsep0 rowsep0" align="left">0.117 ± 0.212</td><td class="colsep0 rowsep0" align="left">2.7 ± 0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13q</b></td><td class="colsep0 rowsep0" align="left">3-Cl-5-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">0.085 ± 0.015</td><td class="colsep0 rowsep0" align="left">0.063 ± 0.017</td><td class="colsep0 rowsep0" align="left">2.6 ± 0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13r</b></td><td class="colsep0 rowsep0" align="left">4-Cl-3-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">0.031 ± 0.012</td><td class="colsep0 rowsep0" align="left">0.027 ± 0.008</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13s</b></td><td class="colsep0 rowsep0" align="left">4-Me-3-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">0.044 ± 0.009</td><td class="colsep0 rowsep0" align="left">0.040 ± 0.016</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13t</b></td><td class="colsep0 rowsep0" align="left">4-OMe-3-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">0.024 ± 0.010</td><td class="colsep0 rowsep0" align="left">0.832 ± 0.177</td><td class="colsep0 rowsep0" align="left">2.2 ± 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13u</b></td><td class="colsep0 rowsep0" align="left">3,5-diCF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">0.051 ± 0.020</td><td class="colsep0 rowsep0" align="left">0.094 ± 0.026</td><td class="colsep0 rowsep0" align="left">7.1 ± 1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13v</b></td><td class="colsep0 rowsep0" align="left">2-F-3-Cl-5-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">1.877 ± 0.443</td><td class="colsep0 rowsep0" align="left">3.377 ± 1.009</td><td class="colsep0 rowsep0" align="left">>10</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">Each compound was tested in triplicate; the data are presented as the mean ± SD.</p></div></div></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Antiviability Activities of Compounds <b>13w-ab</b> against MDA-MB-231, MDA-MB-435, and HepG2 Cells</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/medium/jm-2016-00943q_0018.gif" alt="" id="fx6" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/medium/jm-2016-00943q_0019.gif" alt="" id="fx7" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">Each compound was tested in triplicate; the data are presented as the mean ± SD.</p></div></div><div></div></div></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15">3.3 Preliminary in Vivo Assays for Screening of Compounds with Potent Anti-TNBC Activity and Low Toxicity</h3><div class="NLM_p">The SAR analyses above led to the discovery of a number of compounds that exhibited potent antiviability potency against TNBC cell lines MDA-MB-231 and MDA-MB-435, and low cytotoxicity in the HepG2 cell assay. To further screen for compounds with potent anti-TNBC activity and tolerable toxicity in vivo, a preliminary in vivo anti-TNBC evaluation in a MDA-MB-231 xenograft mouse model was carried out. Six compounds, namely, <b>8c</b>, <b>13b</b>, <b>13h</b>, <b>13r</b>, <b>13s</b>, and <b>13aa</b>, were selected to do the tests because these compounds showed higher anti-TNBC activity and lower toxicity in in vitro assays. As shown in <a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>, among all the compounds tested, only compound <b>13b</b> exhibited a high tumor inhibition rate (90.7%) and a low body weight loss of mice (−3.1%) at an oral dose of 40 mg/kg/d. However, in a further safety evaluation, <b>13b</b> showed a considerable ability to inhibit the hERG channel with an IC<sub>50</sub> value of 0.60 μM; substantial evidence has indicated that blockade of the hERG channel has a high risk of cardiotoxicity.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Therefore, further structural optimization has to be done to rule out the potential cardiac toxicity of <b>13b</b>.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Preliminary in Vivo Anti-TNBC Assays of Compounds <b>8c</b>, <b>13b</b>, <b>13h</b>, <b>13r</b>, <b>13s</b>, and <b>13aa</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Cpd</th><th class="colsep0 rowsep0" align="center">oral dose (mg/kg)</th><th class="colsep0 rowsep0" align="center">treatment days</th><th class="colsep0 rowsep0" align="center">in vivo tumor inhibition rate</th><th class="colsep0 rowsep0" align="center">body weight change rate</th><th class="colsep0 rowsep0" align="center">death/total</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8c</b></td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">91.2%</td><td class="colsep0 rowsep0" align="left">–13.2%</td><td class="colsep0 rowsep0" align="left">0/3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13b</b></td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="left">21</td><td class="colsep0 rowsep0" align="left">90.7%</td><td class="colsep0 rowsep0" align="left">–3.1%</td><td class="colsep0 rowsep0" align="left">0/3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13h</b></td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="left">21</td><td class="colsep0 rowsep0" align="left">90.1%</td><td class="colsep0 rowsep0" align="left">–16.0%</td><td class="colsep0 rowsep0" align="left">0/3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13r</b></td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="left">21</td><td class="colsep0 rowsep0" align="left">70.5%</td><td class="colsep0 rowsep0" align="left">–6.7%</td><td class="colsep0 rowsep0" align="left">0/3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13s</b></td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="left">21</td><td class="colsep0 rowsep0" align="left">69.8%</td><td class="colsep0 rowsep0" align="left">–4.5%</td><td class="colsep0 rowsep0" align="left">0/3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13aa</b></td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="left">21</td><td class="colsep0 rowsep0" align="left">87.0%</td><td class="colsep0 rowsep0" align="left">–5.3%</td><td class="colsep0 rowsep0" align="left">0/3</td></tr></tbody></table></div></div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17">3.4 Structural Optimization to Remove the Activity against hERG</h3><div class="NLM_p">According to the mapping of the chemical structure of <b>13b</b> with available pharmacophore models<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31, 32)</a> of hERG inhibitors (see <a href="/doi/suppl/10.1021/acs.jmedchem.6b00943/suppl_file/jm6b00943_si_001.pdf" class="ext-link">Figure S2</a>), the basic nitrogen in the 1-methylpiperidin-4-yl moiety might play a critical role, which corresponds to the positive charge feature in the pharmacophore hypothesis. The basic nitrogen (or generally the positive charge feature) could possibly form a good interaction with an aromatic ring of the residue (for example, phenylalanine and tyrosine), or an interaction with a negatively charged residue (for example, aspartic acid and glutamic acid) in the binding pocket of hERG. To test and verify this hypothesis, we used some different hydrophilic groups with and without basic nitrogen to replace the original 1-methylpiperidin-4-yl moiety (the R<sub>1</sub> position). A total of 8 compounds were synthesized. Bioactivities and hERG activities of these compounds (<b>13ac</b>–<b>ai</b>) are shown in <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>. As shown in <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>, all of the compounds containing a basic nitrogen (<b>13ac</b>–<b>ae</b>) in R<sub>1</sub> had considerable activities against hERG. On the contrary, activities of compounds without such a basic nitrogen (<b>13af</b>–<b>ai</b>) were dramatically reduced. This is consistent with the pharmacophore hypothesis, for instance, compound <b>13ai</b> was not mapped with the positive charge feature of the pharmacophore model (see <a href="/doi/suppl/10.1021/acs.jmedchem.6b00943/suppl_file/jm6b00943_si_001.pdf" class="ext-link">Figure S2</a>). Importantly, antiviability activities of these compounds against MDA-MB-231 and MDA-MB-435 were kept very well.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Antiproliferation Activities of Compounds <b>13ac-aq</b> and <b>13b</b> against MDA-MB-231, MDA-MB-435, and HepG2 Cells and Their Inhibitory Potency against hERG</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/medium/jm-2016-00943q_0020.gif" alt="" id="fx8" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/medium/jm-2016-00943q_0021.gif" alt="" id="fx9" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>Table a</sup><p class="last">Each compound was tested in triplicate; the data are presented as the mean ± SD.</p></div><div class="footnote" id="t6fn2"><sup>Table b</sup><p class="last">IC<sub>50</sub> values were determined using the service of ChemPartner. The data represent the mean values of three independent experiments.</p></div><div class="footnote" id="t6fn3"><sup>Table c</sup><p class="last">nt means not tested.</p></div></div><div></div></div><div class="NLM_p">Further, the 3-trifluoromethylphenyl moiety in the head part was also replaced by some other fragments, which was performed for discovering more potent compounds. The fragments include 4-(<i>tert</i>-butyl)thiazole-2-yl, 3-(<i>tert</i>-butyl)phenyl, 4-methyl-3-trifluoromethylphenyl, and 4-chloro-3-trifluoromethylphenyl; these groups have been shown to be beneficial for enhancing the bioactivity (see <a class="ref internalNav" href="#tbl3" aria-label="Tables 3">Tables 3</a> and <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). We then synthesized a total of 8 compounds. The bioactivities and hERG activities are also presented in <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a> (<b>13aj</b>–<b>aq</b>). As expected, the hERG activities were all low for the newly synthesized compounds, and the antiviability potencies against TNBC cells were the same or enhanced compared with those of their counterparts.</div><div class="NLM_p">Then, compounds <b>13af</b>–<b>ai</b>, <b>13am</b>, <b>13an</b>, and <b>13aq</b> were selected to carry out a preliminary in vivo anti-TNBC study in a MDA-MB-231 xenograft mouse model, whose results are summarized in <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>. Among them, oral dosing of <b>13ai</b> and <b>13an</b> at 40 mg/kg/d inhibited the tumor growth with an inhibition rate of 89.1 and 96.2%, respectively. There were no body weight changes or other obvious side effects observed. These data indicate that compound <b>13ai</b> and <b>13an</b> are ideal inhibitors, which can potently inhibit the proliferation of TNBC cells both in vitro and in vivo without causing cytotoxicity against HepG2 cells and severe side effects in the treated mice.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Preliminary in Vivo Anti-TNBC Assays of Compounds <b>13af</b>–<b>i</b>, <b>13am</b>, <b>13an</b>, and <b>13aq</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Cpd</th><th class="colsep0 rowsep0" align="center">oral dose (mg/kg)</th><th class="colsep0 rowsep0" align="center">treatment days</th><th class="colsep0 rowsep0" align="center">in vivo tumor inhibition rate</th><th class="colsep0 rowsep0" align="center">body weight change rate</th><th class="colsep0 rowsep0" align="center">death/total</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13af</b></td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">78.1%</td><td class="colsep0 rowsep0" align="left">–3.2%</td><td class="colsep0 rowsep0" align="left">0/3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13ag</b></td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">77.3%</td><td class="colsep0 rowsep0" align="left">–8.2%</td><td class="colsep0 rowsep0" align="left">0/3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13ah</b></td><td class="colsep0 rowsep0" align="left">20</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">70.2%</td><td class="colsep0 rowsep0" align="left">–2.0%</td><td class="colsep0 rowsep0" align="left">0/3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13ai</b></td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">89.1%</td><td class="colsep0 rowsep0" align="left">3.1%</td><td class="colsep0 rowsep0" align="left">0/3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13ai</b></td><td class="colsep0 rowsep0" align="left">20</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">79.6%</td><td class="colsep0 rowsep0" align="left">3.5%</td><td class="colsep0 rowsep0" align="left">0/3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13am</b></td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">97.1%</td><td class="colsep0 rowsep0" align="left">–11.3%</td><td class="colsep0 rowsep0" align="left">0/3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13an</b></td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">96.2%</td><td class="colsep0 rowsep0" align="left">3.4%</td><td class="colsep0 rowsep0" align="left">0/3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13aq</b></td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">96.1%</td><td class="colsep0 rowsep0" align="left">–13.4%</td><td class="colsep0 rowsep0" align="left">0/3</td></tr></tbody></table></div></div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20">3.5 Pharmacokinetic Properties of <b>13ai</b> and <b>13an</b> in Rats</h3><div class="NLM_p">Considering the excellent anti-TNBC activities of compounds <b>13ai</b> and <b>13an</b> both in vitro and in vivo, pharmacokinetic (PK) properties of these compounds were further evaluated. Key PK parameters are summarized in <a class="ref internalNav" href="#tbl8" aria-label="Table 8">Table 8</a>. Compared with <b>13ai</b>, <b>13an</b> had a longer half-life (<i>T</i><sub>1/2</sub>) (4.7 h vs 18.99 h) and a larger area under the concentration–time curve (AUC<sub>0-∞</sub>, h × ng/mL) (975.7 vs 2946). <b>13an</b> achieved a maximum plasma concentration (<i>C</i><sub>max</sub>) of 143.0 ng/mL within approximately 4 h, which is relatively larger and more rapid than <b>13ai</b>. The microsome stabilities of <b>13an</b> were also evaluated using liver microsome preparations from mouse, rat, dog, monkey, and human. The results (see <a href="/doi/suppl/10.1021/acs.jmedchem.6b00943/suppl_file/jm6b00943_si_001.pdf" class="ext-link">Table S1</a>) showed that <b>13an</b> was very stable; the percentage parent remaining was greater than 90% in all species. These data indicated that <b>13an</b> had better pharmacokinetic properties than <b>13ai</b>. Collectively, among all the compounds synthesized, <b>13an</b> is the most promising candidate for the treatment of TNBCs. In-depth studies including in vitro and in vivo anti-TNBC studies and mechanism of action studies were then carried out on <b>13an</b>.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. In Vivo Pharmacokinetic Parameters of <b>13ai</b> and <b>13an</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">rat (p.o, 10 mg/kg)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameters</th><th class="colsep0 rowsep0" align="center"><b>13ai</b></th><th class="colsep0 rowsep0" align="center"><b>13an</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h)<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">4.7</td><td class="colsep0 rowsep0" align="left">18.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0-t</sub> (h × ng/mL)<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">959.6</td><td class="colsep0 rowsep0" align="left">2861</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0-∞</sub> (h × ng/mL)</td><td class="colsep0 rowsep0" align="left">975.7</td><td class="colsep0 rowsep0" align="left">2946</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (h)<a class="ref internalNav" href="#t8fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (ng/mL)<a class="ref internalNav" href="#t8fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">128.1</td><td class="colsep0 rowsep0" align="left">143.0</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup>a</sup><p class="last">Mean half-life associated with the terminal slope.</p></div><div class="footnote" id="t8fn2"><sup>b</sup><p class="last">Mean area under the plasma concentration–time curve.</p></div><div class="footnote" id="t8fn3"><sup>c</sup><p class="last">Mean time to reach maximum plasma concentration.</p></div><div class="footnote" id="t8fn4"><sup>d</sup><p class="last">Mean peak plasma concentration.</p></div></div></div></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22">3.6 Predicted Binding Mode of <b>13an</b> with Src</h3><div class="NLM_p">Computational studies were performed again to investigate the possible binding mode of <b>13an</b> with Src. The predicted binding mode is shown in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A. For comparison, the binding mode of <b>13an</b> was superimposed on that of <b>1</b>, which is depicted in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>B. As shown in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A and B, <b>13an</b> could tightly bind to the ATP-binding site of Src in a binding mode similar to that of compound <b>1</b>. The 1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin core occupies the adenine region of Src kinase and forms hydrogen bonds with residues Glu-339 and Met-341 in the hinge region. The <i>trans</i>-4-hydroxycyclohexyl group forms a hydrogen bonding interaction with Asp-348. The amide moiety of <b>13an</b> also forms hydrogen bonds with Glu-310, which is a common case for type II kinase inhibitors.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> The 3-trifluoromethylphenyl group locates in the allosteric pocket and makes favorable van der Waals interactions with residues Leu-322, Val-402, Val-377, and Leu-317. From <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>B, we can see that, compared with compound <b>1</b>, <b>13an</b> loses two hydrogen bonding interactions (between 1-methyl-4-(2-(trifluoromethyl)benzyl)piperazine and VAL383/HIS-384) but gains another hydrogen bonding interaction (between <i>trans</i>-4-hydroxycyclohexyl and ASP-348), which could be used to interpret the phenomena that <b>13an</b> showed a slightly weaker activity against the Src kinase than <b>1</b>.</div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/medium/jm-2016-00943q_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Predicted binding mode of <b>13an</b> with Src. (B) A comparison of the binding modes of <b>13an</b> (dark slate blue) and compound <b>1</b> (cyan) with Src. Hydrogen bonding interactions between the compounds and Src are indicated by dashed yellow lines for compound <b>1</b> and dashed green lines for <b>13an</b>. The crystal structure of Src was taken from the RCSB Protein Data Bank (PDB entry: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3EL7">3EL7</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00943&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23">3.7 Biochemical Activities of <b>13an</b> against Various Recombinant Human Protein Kinases</h3><div class="NLM_p">To investigate the kinase inhibitory activities and selectivity, kinase inhibition profiling assays with a fixed concentration of 10 μM <b>13an</b> against a panel of 335 kinases were first carried out through the Eurofins kinase profiling service. The data are presented in <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a> and <a href="/doi/suppl/10.1021/acs.jmedchem.6b00943/suppl_file/jm6b00943_si_001.pdf" class="ext-link">Table S2</a>. To kinases that showed a high inhibitory rate at 10 μM, further half-maximal inhibitory concentrations (IC<sub>50</sub>s) were examined, and the results are shown in <a class="ref internalNav" href="#tbl9" aria-label="Table 9">Table 9</a>. <b>13an</b> potently inhibited Src (IC<sub>50</sub> = 0.003 μM), Yes (IC<sub>50</sub> = 0.001 μM), Hck (IC<sub>50</sub> = 0.003 μM), Lyn (IC<sub>50</sub> = 0.004 μM), Fyn (IC<sub>50</sub> = 0.006 μM), Lck (IC<sub>50</sub> = 0.014 μM), Blk (IC<sub>50</sub> = 0.016 μM), and PTK5 (IC<sub>50</sub> = 0.019 μM); all of them belong to the Src family kinases (SFKs). <b>13an</b> also exhibited considerable potency against KDR (IC<sub>50</sub> = 0.032 μM) and several kinases involved in the MAPK signal transduction, including members of the P38, RAF, and DDR families of kinases.<a onclick="showRef(event, 'ref33 ref34 ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref33 ref34 ref35 ref36">(33-36)</a><b>13an</b> did not inhibit mitogen-activated protein kinase 1 (ERK2), aurora kinase family members, cyclin-dependent kinases, or phosphatidylinositide 3-kinases. These data demonstrate that <b>13an</b> is a multikinase inhibitor with high potencies against Src family kinases, KDR, and several kinases that are involved in the MAPK signaling cascade.</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/medium/jm-2016-00943q_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0005.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Kinase binding selectivity for <b>13an</b> shown on the human kinome dendrogram. The inhibition rates were determined using the KinaseProfiler of Eurofins. The figure was generated by using an online Kinome Render program (<a href="http://bcb.med.usherbrooke.ca/kinomerenderLig.php" class="extLink">http://bcb.med.usherbrooke.ca/kinomerenderLig.php</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00943&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Kinase Inhibition Profile of <b>13an</b> against Selected Protein Kinases<a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Src</td><td class="colsep0 rowsep0" align="left">0.003</td><td class="colsep0 rowsep0" align="left">Ret</td><td class="colsep0 rowsep0" align="left">0.004</td><td class="colsep0 rowsep0" align="left">TAK1</td><td class="colsep0 rowsep0" align="left">0.050</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Yes</td><td class="colsep0 rowsep0" align="left">0.001</td><td class="colsep0 rowsep0" align="left">Txk</td><td class="colsep0 rowsep0" align="left">0.006</td><td class="colsep0 rowsep0" align="left">ACK1</td><td class="colsep0 rowsep0" align="left">0.175</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Hck</td><td class="colsep0 rowsep0" align="left">0.003</td><td class="colsep0 rowsep0" align="left">Bmx</td><td class="colsep0 rowsep0" align="left">0.021</td><td class="colsep0 rowsep0" align="left">Mer</td><td class="colsep0 rowsep0" align="left">0.052</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Lyn</td><td class="colsep0 rowsep0" align="left">0.004</td><td class="colsep0 rowsep0" align="left">FGFR1</td><td class="colsep0 rowsep0" align="left">0.007</td><td class="colsep0 rowsep0" align="left">Rse</td><td class="colsep0 rowsep0" align="left">0.351</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Fyn</td><td class="colsep0 rowsep0" align="left">0.006</td><td class="colsep0 rowsep0" align="left">FGFR2</td><td class="colsep0 rowsep0" align="left">0.040</td><td class="colsep0 rowsep0" align="left">P38α</td><td class="colsep0 rowsep0" align="left">0.342</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Lck</td><td class="colsep0 rowsep0" align="left">0.014</td><td class="colsep0 rowsep0" align="left">FGFR3</td><td class="colsep0 rowsep0" align="left">0.120</td><td class="colsep0 rowsep0" align="left">P38β</td><td class="colsep0 rowsep0" align="left">0.084</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Blk</td><td class="colsep0 rowsep0" align="left">0.016</td><td class="colsep0 rowsep0" align="left">ErbB2</td><td class="colsep0 rowsep0" align="left">0.165</td><td class="colsep0 rowsep0" align="left">EphB2</td><td class="colsep0 rowsep0" align="left">0.033</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PTK5</td><td class="colsep0 rowsep0" align="left">0.019</td><td class="colsep0 rowsep0" align="left">ErbB4</td><td class="colsep0 rowsep0" align="left">0.122</td><td class="colsep0 rowsep0" align="left">EphA7</td><td class="colsep0 rowsep0" align="left">0.143</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BRK</td><td class="colsep0 rowsep0" align="left">0.121</td><td class="colsep0 rowsep0" align="left">EGFR</td><td class="colsep0 rowsep0" align="left">0.651</td><td class="colsep0 rowsep0" align="left">EphA4</td><td class="colsep0 rowsep0" align="left">0.227</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Abl</td><td class="colsep0 rowsep0" align="left">0.002</td><td class="colsep0 rowsep0" align="left">EGFR <sup>T790M, L858R</sup></td><td class="colsep0 rowsep0" align="left">0.008</td><td class="colsep0 rowsep0" align="left">LIMK1</td><td class="colsep0 rowsep0" align="left">0.255</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Abl <sup>T315I</sup></td><td class="colsep0 rowsep0" align="left">0.003</td><td class="colsep0 rowsep0" align="left">EGFR <sup>T790M</sup></td><td class="colsep0 rowsep0" align="left">0.019</td><td class="colsep0 rowsep0" align="left">Rsk1</td><td class="colsep0 rowsep0" align="left">0.559</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Arg</td><td class="colsep0 rowsep0" align="left">0.004</td><td class="colsep0 rowsep0" align="left">CSK</td><td class="colsep0 rowsep0" align="left">0.009</td><td class="colsep0 rowsep0" align="left">Rsk2</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Flt1</td><td class="colsep0 rowsep0" align="left">0.015</td><td class="colsep0 rowsep0" align="left">Tie2</td><td class="colsep0 rowsep0" align="left">0.010</td><td class="colsep0 rowsep0" align="left">PDGFRα</td><td class="colsep0 rowsep0" align="left">1.287</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Flt4</td><td class="colsep0 rowsep0" align="left">0.016</td><td class="colsep0 rowsep0" align="left">Pyk2</td><td class="colsep0 rowsep0" align="left">0.116</td><td class="colsep0 rowsep0" align="left">PDGFRβ</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KDR</td><td class="colsep0 rowsep0" align="left">0.032</td><td class="colsep0 rowsep0" align="left">B-Raf</td><td class="colsep0 rowsep0" align="left">0.110</td><td class="colsep0 rowsep0" align="left">ERK2</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DDR1</td><td class="colsep0 rowsep0" align="left">0.015</td><td class="colsep0 rowsep0" align="left">B-Raf <sup>V600E</sup></td><td class="colsep0 rowsep0" align="left">0.087</td><td class="colsep0 rowsep0" align="left">TrkA</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DDR2</td><td class="colsep0 rowsep0" align="left">0.065</td><td class="colsep0 rowsep0" align="left">C-Raf</td><td class="colsep0 rowsep0" align="left">0.052</td><td class="colsep0 rowsep0" align="left">TrkB</td><td class="colsep0 rowsep0" align="left">0.899</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup>a</sup><p class="last">IC<sub>50</sub> values were determined using KinaseProfiler by Eurofins. The data represent the mean values of two independent experiments.</p></div></div></div></div><div id="sec3_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25">3.8 Antiviability Activities of <b>13an</b> against Various Cell Lines</h3><div class="NLM_p">Antiviability activities of <b>13an</b> against various cell lines, including those for TNBCs and a number of other cancer types, as well as two normal cell lines, were examined. As shown in <a class="ref internalNav" href="#tbl10" aria-label="Table 10">Table 10</a>, <b>13an</b> potently inhibited the proliferation of the TNBC cell lines MDA-MB-231, MDA-MB-435, Hs 578T, and HCC1937, with IC<sub>50</sub> values of 0.030 μM, 0.008 μM, 0.032 μM, and 0.455 μM, respectively. It also exhibited considerable potency against several other cell lines, including PC-9 (lung cancer, IC<sub>50</sub> = 0.152 μM), A375 (melanoma, IC<sub>50</sub> = 0.031 μM), and MV4–11 (leukemia, IC<sub>50</sub> = 0.138 μM). Negligible activity was observed for other selected cell lines, including BT474 (breast cancer), H1437 (lung cancer), HCT116 (colorectal carcinoma), HepG2 (hepatocarcinoma), SMMC7721 (hepatocarcinoma), DU145 (prostate carcinoma), L929 (mouse fibroblast), and LO2 (human hepatic cells). These results indicate that <b>13an</b> has a considerable selectivity for TNBC cells and almost no activity for the normal cells tested.</div><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. Antiviability Activities of <b>13an</b> against Various Cell Lines<a class="ref internalNav" href="#t10fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center">cell type</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MDA-MB-231</td><td class="colsep0 rowsep0" align="left">TNBC</td><td class="colsep0 rowsep0" align="left">0.030</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MDA-MB-435</td><td class="colsep0 rowsep0" align="left">TNBC</td><td class="colsep0 rowsep0" align="left">0.008</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Hs 578T</td><td class="colsep0 rowsep0" align="left">TNBC</td><td class="colsep0 rowsep0" align="left">0.032</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HCC1937</td><td class="colsep0 rowsep0" align="left">TNBC</td><td class="colsep0 rowsep0" align="left">0.455</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BT474</td><td class="colsep0 rowsep0" align="left">breast cancer</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MDA-MB-415</td><td class="colsep0 rowsep0" align="left">breast cancer</td><td class="colsep0 rowsep0" align="left">∼10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ZR-75-1</td><td class="colsep0 rowsep0" align="left">breast cancer</td><td class="colsep0 rowsep0" align="left">∼10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">H1437</td><td class="colsep0 rowsep0" align="left">lung cancer</td><td class="colsep0 rowsep0" align="left">2.34</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PC-9</td><td class="colsep0 rowsep0" align="left">lung cancer</td><td class="colsep0 rowsep0" align="left">0.152</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A375</td><td class="colsep0 rowsep0" align="left">melanoma</td><td class="colsep0 rowsep0" align="left">0.031</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Miapaca-2</td><td class="colsep0 rowsep0" align="left">pancreatic cancer</td><td class="colsep0 rowsep0" align="left"><0.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HCT116</td><td class="colsep0 rowsep0" align="left">colorectal crcinoma</td><td class="colsep0 rowsep0" align="left">3.89</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HT29</td><td class="colsep0 rowsep0" align="left">colorectal crcinoma</td><td class="colsep0 rowsep0" align="left">0.231</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HepG2</td><td class="colsep0 rowsep0" align="left">hepatocarcinoma</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">plc/prf/5</td><td class="colsep0 rowsep0" align="left">hepatocarcinoma</td><td class="colsep0 rowsep0" align="left">∼10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SMMC7721</td><td class="colsep0 rowsep0" align="left">hepatocarcinoma</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RAMOS</td><td class="colsep0 rowsep0" align="left">lymphoma</td><td class="colsep0 rowsep0" align="left">∼10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MV4-11</td><td class="colsep0 rowsep0" align="left">leukemia</td><td class="colsep0 rowsep0" align="left">0.138</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Hela</td><td class="colsep0 rowsep0" align="left">cervical cancer</td><td class="colsep0 rowsep0" align="left">6.30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">H4</td><td class="colsep0 rowsep0" align="left">neuroglioma</td><td class="colsep0 rowsep0" align="left">0.670</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DU145</td><td class="colsep0 rowsep0" align="left">prostate carcinoma</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">L929</td><td class="colsep0 rowsep0" align="left">mouse fibroblast</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LO2</td><td class="colsep0 rowsep0" align="left">human hepatic cells</td><td class="colsep0 rowsep0" align="left">>10</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t10fn1"><div class="footnote" id="t10fn1"><sup>a</sup><p class="last">Each cell line was tested in triplicate.</p></div></div></div></div><div id="sec3_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27">3.9 Effects of <b>13an</b> on Colony Formation, Cell Apoptosis, and Migration</h3><div class="NLM_p">Colony-forming assays were then used to examine the antiproliferation activity of <b>13an</b>. It was found that <b>13an</b> at concentrations larger than 0.1 μM completely inhibited the colony formation of MDA-MB-231 cells (see <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A). The induction of apoptosis following the treatment of MDA-MB-231 cells by <b>13an</b> was examined using AnnexinV/PI staining assays. As shown in <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>B, <b>13an</b> treatment led to a concentration-dependent change in the number of apoptotic MDA-MB-231 cells, and approximately 17.35% of the TNBC cells were apoptotic after 24 h of treatment with 0.1 μM <b>13an</b>. In a wound healing assay, as shown in <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>C, after treatment with <b>13an</b> at a concentration of 0.3 μM for 20 h, the migration of MDA-MB-231 cells was significantly inhibited. As a positive control, dasatinib also exhibited the same effects in the three assays but was relatively weaker than <b>13an</b> in terms of potency. These data demonstrated that <b>13an</b> could efficiently induce cellular apoptosis and inhibit the migration of tumor cells.</div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/medium/jm-2016-00943q_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0006.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) <b>13an</b> inhibited colony formation of MDA-MB-231 cells. MDA-MB-231 cells were seeded in 6-well plates and treated with <b>13an</b> or dasatinib for 12 days. Colonies were stained with crystal violet, and pictures were taken. (B) <b>13an</b> induced apoptosis in MDA-MB-231 cells. MDA-MB-231 cells were harvested after treatment with various concentrations of <b>13an</b> and dasatinib for 24 h. Cells were stained using an Annexin V-FITC Apoptosis Detection Kit. (C) <b>13an</b> inhibited MDA-MB-231 cell migration in a wound healing assay. Cells were wounded by a pipet and then treated with various concentrations of compounds for 20 h. Scale bar, 100 μm.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00943&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28">3.10 Inactivation of Key Signaling Proteins in Intact TNBC Cells in Vitro</h3><div class="NLM_p">Western blot analysis was performed to assess the ability of <b>13an</b> to inhibit the activation of Src and its downstream signaling proteins, as well as MAPK signaling proteins in intact MDA-MB-231 cells. After a 24 h treatment with increasing concentrations of <b>13an</b>, MDA-MB-231 cells were harvested and lysed for an IP/wt assay. As shown in <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>, a dose-dependent reduction in the phosphorylation level of Src was observed following <b>13an</b> treatment, with an estimated IC<sub>50</sub> value of 0.03 μM. Consistent with the inhibition of Src activation, the activation of its downstream signaling proteins FAK and STAT3 was also efficiently inhibited at concentrations higher than 0.1 μM. Additionally, the phosphorylation of the MAPK signaling proteins MEK and ERK was also strongly inhibited, indicating a blockade of the MAPK signaling pathway.</div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/medium/jm-2016-00943q_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0007.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. <b>13an</b> inhibited the activation of multiple signaling pathways in intact cells. MDA-MB-231 cells were treated with <b>13an</b> or dasatinib for 20 h. The cells were lysed, and the proteins were analyzed by Western blot analysis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00943&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">It is also noteworthy that <b>13an</b> significantly inhibited both the expression and phosphorylation of Fra1 at concentrations larger than 0.03 μM; Fra1 is a key regulator of epithelial-to-mesenchymal transition (EMT), which is an important factor responsible for tumor metastasis.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> In addition, <b>13an</b> increased the level of cleaved-caspase-3 in a dose-dependent manner, indicating the induction of apoptosis.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> In contrast, though dasatinib also efficiently inhibited Src and FAK, it had very weak effects on the MAPK signaling pathway, Fra1, and caspase-3.</div></div><div id="sec3_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29">3.11 In Vivo Effects and Mechanisms of Action of <b>13an</b> in TNBC Xenograft Models</h3><div class="NLM_p">The in vivo anti-TNBC efficacies of <b>13an</b> were assessed using both MDA-MB-231 and MDA-MB-435 xenograft models. Oral dosing of <b>13an</b> at 10, 20, and 40 mg/kg/d inhibited tumor growth in a dose-dependent manner in both models (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>A and B), with tumor growth completely inhibited at a dose of 40 mg/kg/d. As a positive control, 40 mg/kg/q.d. dasatinib and 10 mg/kg/week (iv) paclitaxel showed even weaker antitumor activities compared with that of the 10 mg/kg/q.d. <b>13an</b>. During the treatment period, no weight loss (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>C and D) or other side effects were observed in all the treatment groups.</div><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/medium/jm-2016-00943q_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0008.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. In vivo antitumor efficacies of <b>13an</b> against MDA-MB-231 (A) and MDA-MB-435 (B) tumor xenograft models, and average body weights for treated mice in the MDA-MB-231 (C) and MDA-MB-435 (D) xenograft models. Mice implanted with MDA-MB-231 or MDA-MB-435 cells were treated when the tumor grew to about 200 mm<sup>3</sup>. Animals (6 per group) were treated with solvent control, <b>13an</b> at oral doses of 10, 20, and 40 mg/kg/d, dasatinib at an oral dose of 40 mg/kg/day, or paclitaxel at a dose of 10 mg/kg/week through a tail vein injection. Points indicate mean tumor volumes (mm<sup>3</sup>) or mean body weights (g); bars indicate SD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00943&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To determine the in vivo antitumor mechanisms of action of <b>13an</b>, immunohistochemical staining assays were carried out on the tumor tissues. <a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>A shows the immunohistochemical analysis results of the tumor tissues in the MDA-MB-231 xenograft models. Tumor tissues from the <b>13an</b> treatment groups (40 mg/kg/q.d.) all showed a decrease in the phosphorylation levels of Src, MEK, and ERK and in the tumor mitotic index (Ki67) compared with those from the corresponding control groups. In addition, a significant increase in the level of cleaved caspase-3 was observed in the <b>13an</b> treatment groups compared with that in the control groups (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>A), indicating the induction of apoptosis. Moreover, compared with the control groups, an obvious reduction of CD31 was observed in the <b>13an</b> treatment groups, which indicated considerable antiangiogenic effects. The antiangiogenic effects of <b>13an</b> was further validated by transgenic Tg (flk1: EGFP) zebrafish experiments. As shown in <a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>B, treatment of live fish embryos with <b>13an</b> completely blocked the formation of intersegmental vessels at all three concentrations (1.25, 2.5, and 5 μM) while preserving fluorescence in the dorsal aorta and major cranial vessels. These results are consistent with the biochemical activity of <b>13an</b> against KDR (see <a class="ref internalNav" href="#tbl9" aria-label="Table 9">Table 9</a>); KDR is one of the key regulators of angiogenesis. Taken together, <b>13an</b> exerted its antitumor effects in vivo by inhibiting both the Src and MAPK signal pathways. Undeniably, the antiangiogenic effects of <b>13an</b> also played a role in anti-TNBC efficacy.</div><figure id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/medium/jm-2016-00943q_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0009.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Mechanisms of action of <b>13an</b> in human tumor xenograft models. Mice bearing a MDA-MB-231 tumor xenograft treated with <b>13an</b> at 40 mg/kg/q.d. were humanely euthanized at the end of the experiment, and the tumor tissues were removed for further immunohistochemistry analysis. Scale bar, 100 μm. (B) 30 hpf zebrafish embryos were treated with a blank control or 1.25, 2.5, or 5 μM <b>13an</b>. ISV budding and outgrowth were completely inhibited by treatment with 1.25 μM <b>13an</b>. Scale bar, 200 μm. (C) The health status of rats in the acute toxicity evaluation. Average body weights of rats were monitored every 3 days after a single dose of <b>13an</b> at 200 mg/kg; <i>n</i> = 3; bars indicate SD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00943&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30">3.12 Preliminary Toxicity Evaluation of <b>13an</b></h3><div class="NLM_p last">A single dose toxicity study was carried out to determine the acute toxicity of <b>13an</b>. After an oral administration of <b>13an</b> at 200 mg/kg in male rats, the rate of increase of average body weight slowed down in the first 9 days and then recovered to normal (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>C). In female rats, the same dose of <b>13an</b> did not bring an obvious change in the rate of increase of the body weight. In addition, histological and immunohistochemical techniques were used to detect the pathological changes in the organs of rats after a single dose of <b>13an</b> at 100 mg/kg. No pathological changes in the major organs (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00943/suppl_file/jm6b00943_si_001.pdf" class="ext-link">Figure S1</a>) were observed in the treatment groups. All of these indicated that <b>13an</b> had low toxicity.</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i31">4 Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73233" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73233" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Through a complicated process of structural optimization toward compound <b>1</b>, we finally discovered a new compound, <b>13an</b>. <b>13an</b> is a multikinase inhibitor, which potently inhibited Src and KDR with IC<sub>50</sub> values of 0.003 μM and 0.032 μM, respectively. <b>13an</b> also inhibited several kinases involved in the MAPK signal transduction, including members of the P38, RAF, and DDR families of kinases. Even so, it is not a promiscuous agent and still displayed good selectivity in a kinase profiling assay against 335 kinases. In in vitro antiviability assays, <b>13an</b> showed potent activities against human TNBC cell lines MDA-MB-231, MDA-MB-435, and Hs 578T with IC<sub>50</sub> values of 0.030 μM, 0.008 μM, and 0.032 μM, respectively, but weak activity against other tumor cell lines tested, except A375. In in vivo assays, it completely suppressed tumor growth in MDA-MB-231 and MDA-MB-435 xenograft models at a dose of 40 mg/kg/q.d. Studies of mechanisms of action indicated that <b>13an</b> down-regulated the activity of Src kinase and the phosphorylation of the MAPK signaling proteins MEK and ERK both in vitro and in vivo. In addition, <b>13an</b> significantly suppressed the expression of Fra1, which has been demonstrated to play an important role in EMT and hence in tumor metastasis. <b>13an</b> also inhibited the expression of Ki67 and increased the level of cleaved-caspase-3. It also exhibited very good antiangiogenesis activity in a transgenic zebrafish model [Tg (flk1: EGFP)]. Importantly, <b>13an</b> did not show an obvious hERG toxicity and had a low acute toxicity at an oral single dose of 200 mg/kg in rats. It also displayed good pharmacokinetic properties. All of the data presented here support <b>13an</b> as a novel drug candidate for the treatment of TNBCs and deserve further research and development.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i32">5 Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65037" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65037" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33">5.1 Computational Studies</h3><div class="NLM_p last">Molecular docking studies were carried out by GOLD (version 5.0). GOLD adopts the genetic algorithm to dock flexible ligands into protein binding sites. The crystal structure of the Src kinase domain in complex with the pyrazolopyrimidine analogue (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3EL7">3EL7</a>) was used for the docking studies. Hydrogen atoms were added to the protein by using Discovery Studio 3.1 (Accelrys Inc., San Diego, CA, USA). The Charmm force field was assigned. The binding site was defined as a sphere containing the residues that stay within 10 Å from its original ligand, which is large enough to cover the ATP binding region at the active site. GoldScore was selected as the scoring function, and other parameters were set as default. The image was created using PyMOL.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> The 3D pharmacophore model was carried out by Discovery Studio 3.1 (Accelrys Inc., San Diego, CA, USA). The training set is established according to the reference,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> the features of pharmacophore, hydrogen bond acceptor, hydrogen bond donor, hydrophobic, positive ionizable, and negative ionizable were selected, and other parameters were set as default.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34">5.2 Cell Lines and Cell Culture Conditions</h3><div class="NLM_p last">All of the cell lines used were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). These cell lines were cultured in the designated medium containing 10% fetal bovine serum (FBS) (v/v) at 37 °C in a humidified 5% CO<sub>2</sub> incubator according to ATCC guidelines.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35">5.3 Cell Viability Assays</h3><div class="NLM_p last">The viability of cells was determined using the MTT assay method. Cells were seeded (1500–30000 cells per well, depending on the cell type) in 96-well plates. After incubation for 24 h in serum-containing media, the cells were treated with inhibitors (0–10 μg/mL) diluted with culture medium for 72 h at 37 °C under a 5% CO<sub>2</sub> atmosphere. Then, 20 μL of the MTT reagent (5 mg/mL) was added to each well, and the plates were incubated for 2–4 h at 37 °C. For the adherent cells, the media and MTT were carefully aspirated from each well, and the formazan crystals were dissolved in 150 μL of 100% DMSO. For the suspended cells, 50 μL of 20% acidified SDS (w/v) was used to dissolve the oxidative product, and the cells were incubated overnight. Finally, the absorbance at 570 nm was read using a Multiskan MK3 ELISA photometer (Thermo Scientific). All experiments were performed in triplicate. IC<sub>50</sub> values were calculated using GraphPad Prism software.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36">5.4 In Vivo Models</h3><div class="NLM_p last">The animal studies were conducted under the approval of the Experimental Animal Management Committee of Sichuan University. MDA-MB-231 and MDA-MB-435 cells were harvested during exponential-growth phase, washed 3 times with serum-free medium, followed by resuspension at a concentration of 5 × 10<sup>7</sup> per mL. A total of 100 μL of cell suspension was injected into SCID mice (5–6 weeks) subcutaneously. After the tumors grew to volumes of 150–200 mm<sup>3</sup>, all the mice were randomized into groups (3 or 6 mice for each group) and dosed with indicated compounds, dasatinib (40 mg/kg/q.d.), paclitaxel (10 mg/kg/week (iv)), or vehicle. The compounds were dissolved in sterilization water with 25% (v/v) PEG400 plus 5% DMSO and administered orally. Mice were monitored for side effects every day. Tumor growth and body weight were measured every 3 days. The volume was calculated as follows: tumor size = <i>a</i> × <i>b</i><sup>2</sup>/2 (<i>a</i>, long diameter; <i>b</i>, short diameter). The tumor inhibition rate was calculated as (<i>c</i> – <i>d</i>)/<i>c</i> × 100% (<i>c</i>, the tumor volume of the control group; <i>d</i>, the tumor volume of the treatment group).</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37">5.5 Assessments of Pharmacokinetic Properties</h3><div class="NLM_p last">The pharmacokinetics analysis of <b>13ai</b> and <b>13an</b> was conducted in male Sprague–Dawley rats (Chinese Academy of Medical Science, Beijing, China). Briefly, catheters were surgically placed into the jugular veins of the rats to collect serial blood samples. <b>13ai</b> was dissolved in saline with 12.5% (v/v) ethanol plus 12.5% kolliphor EL, <b>13an</b> was dissolved in 20% hydroxypropyl-beta-cyclodextrin saline solution with 12.5% (v/v) ethanol plus 12.5% kolliphor EL. The animals were administered a single dose of 10 mg/kg <b>13ai</b> or <b>13an</b> by oral gavage after fasting overnight. Blood was collected and centrifuged immediately to isolate plasma. The plasma concentrations were determined using high performance liquid chromatography with tandem mass spectrometric detection (3200 QTRAP system, Applied Biosystems). Noncompartmental pharmacokinetic parameters were fitted using DAS software (Enterprise, version 2.0, Mathematical Pharmacology Professional Committee of China).</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38">5.6 Inhibition Evaluation on hERG K<sup>+</sup> Channel</h3><div class="NLM_p last">The hERG inhibition was measured in hERG-expressing CHO cells using a Qpatch 16× assay as described previously.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a></div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39">5.7 Microsomal Stability Assay</h3><div class="NLM_p last"><b>13an</b> (1 μM) was incubated with 0.5 mg/mL indicated liver microsomes (liver microsomes of micee, rats, monkeys, and humans were purchased from BD Gentest; liver microsomes of dogs were purchased from GIBCO). NADPH was maintained at 1 mM in 1000 μL of reaction volume. The reaction was then evaluated at 0, 10, 15, 30, 45, and 60 min and was terminated by the addition of acetonitrile. Samples were centrifuged for 5 min at 15000 rpm and the supernatant analyzed using HPLC-MS/MS. Percentage parent remaining was calculated considering percent parent area at 0 min as 100%.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40">5.8 Kinase Inhibition Assays</h3><div class="NLM_p last">Kinase inhibition profiles were determined using KinaseProfiler services provided by Eurofins, and ATP concentrations used are the <i>K</i><sub>m</sub> of corresponding kinases. The binding affinities of <b>13an</b> projected on the human kinome tree were generated using the online Kinome Render program.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a></div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41">5.9 Colony Formation Assay</h3><div class="NLM_p last">Cells were seeded in six-well plates at a density of 5000 per well and treated with vehicle, dasatinib, or <b>13an</b> the next day. The medium containing vehicle or <b>13an</b> was replaced every 4 days. Cells were fixed with methanol and stained with crystal violet after treatment for 12 days.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42">5.10 Apoptosis Assays</h3><div class="NLM_p last">A total of 2 × 10<sup>5</sup> MDA-MB-231 cells were plated in a six-well plate and treated with vehicle, dasatinib, or <b>13an</b> for 24 h at 37 °C. After incubation, the cells were harvested and washed with ice-cold PBS. Then an Annexin V-FITC Apoptosis Detection Kit (keygentec) was used for apoptosis analysis by flow cytometry as indicated.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43">5.11 Wound Healing Assay</h3><div class="NLM_p last">MDA-MB-231 cells were cultured to confluence in 24-well plates and wounded using a sterilized pipet tip to make a straight scratch. Cells were rinsed with physiological saline gently, and then PBS was replaced with DMEM medium containing vehicle, dasatinib, or <b>13an</b>. Pictures were taken by an OLYMPUS digital camera and analyzed by AxioVision Rel 4.8(Carl Zeiss) after 20 h.</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44">5.12 Western Blot Analysis</h3><div class="NLM_p last">After treatment with a series of concentrations of <b>13an</b> for 20 h at 37 °C, MDA-MB-231 cells were harvested, washed with ice-cold physiological saline, and lysed with RIPA lysis buffer (Beyotime) including 1% cocktail (Sigma-Aldrich). Whole-cell protein lysates were prepared and centrifuged for 10 min at 12000 rpm and 4 °C to remove any insoluble material. The total proteins were determined using the Bradford method, and an equivalent quantity of protein was combined with an SDS–PAGE loading buffer (Beyotime) in boiled water for 5 min. Cell lysates were separated by SDS–PAGE and electrotransferred onto PVDF membranes (Millipore). The PVDF membranes were incubated with each antibody and detected according to the immunoblot analysis principle. The antibodies were purchased from Cell Signaling Technology (CST, Danvers, MA, USA), and the dilutions of the antibodies were according to the instructions from CST.</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45">5.13 Immunohistochemistry</h3><div class="NLM_p last">SCID mice bearing tumors were treated with control or <b>13an</b> as described before. At the indicated time points after dosing, individual mice were humanly euthanized. The tumors were fixed with formalin and embedded in paraffin. Then, the immunohistochemistry assays were performed as indicated.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> All of the antibodies were purchased from Cell Signaling Technology or Abcam, except Ki67 (Thermo Fisher Scientific, Fremont, CA) and CD31 (BD Biosciences). Images were captured with a Carl Zeiss digital camera attached to a light microscope.</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46">5.14 Transgenic Zebrafish</h3><div class="NLM_p last">The transgenic zebrafish (FLK: EGFP) assay was conducted according to the protocol reported previously.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Transgenic zebrafish (FLK: EGFP) were maintained normally (temperature, 28 °C; pH 7.2–7.4; 14 h on and 10 h off light cycle). The 30 hpf zebrafish embryos were incubated overnight with <b>13an</b>. The image was acquired after the zebrafish were anaesthetized by a fluorescence microscope.</div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47">5.15 Acute Toxicity</h3><div class="NLM_p last">The animal studies were conducted in Sprague–Dawley rats (Chinese Academy of Medical Science, Beijing, China) and under the approval of the Experimental Animal Management Committee of Sichuan University. Compound <b>1</b> and <b>13an</b> were dissolved in sterilization water with 25% (v/v) PEG400 plus 5% DMSO and administered orally at indicated doses. The behavior changes of animals upon drug treatment were monitored, and the side effects were checked every day. The body weights of treated rats were measured every 3 days. Three animals were used in each experiment.</div></div><div id="sec5_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48">5.16 Chemistry Methods</h3><div class="NLM_p">All reagents and solvents were obtained from commercial suppliers and used without further purification unless otherwise indicated. Anhydrous solvents were dried and purified by conventional methods prior to use. Column chromatography was carried out on silica gel (300–400 mesh). All reactions were monitored by thin-layer chromatography (TLC), and silica gel plates with fluorescence F-254 were used and visualized with UV light. All of the final compounds were purified to >95% purity, as determined by high-performance liquid chromatography (HPLC). HPLC analysis was performed on a Waters 2695 HPLC system with the use of a Kromasil C18 reversed-column (4.6 mm × 250 mm, 5 μm). The binary solvent system (A/B) was chosen between I and II (I, 10 mmol of ammonium acetate in water (pH 9) (A) and acetonitrile (B), A/B = 50/50; II, water (A) and acetonitrile (B), A/B = 40/60) The absorbance was detected at 273 nm, and the flow rate was 1 mL/min. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded on a Bruker AV-400 spectrometer at 400 and 100 MHz, respectively. Coupling constants (<i>J</i>) are expressed in hertz (Hz). Spin multiplicities are described as s (singlet), br. s (broad singlet), t (triplet), q (quartet), and m (multiplet). Chemical shifts (δ) are listed in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard. Mass spectral (MS) data were acquired on a Waters Q-TOF Premier mass spectrometer (Micromass, Manchester, U.K.).</div><div id="sec5_16_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49">5.16.1 3-((4-Amino-1-(1-methylpiperidin-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methyl-<i>N</i>-(3-(trifluoromethyl)phenyl)benzamide (<b>8c</b>)</h4><div class="NLM_p">3-Ethynyl-4-methyl-<i>N</i>-(3-(trifluoromethyl)phenyl)benzamide <b>4b</b> (159 mg, 0.53 mmol, 1.05 equiv), 3-iodo-1-(1-methylpiperidin-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine <b>7i</b> (179.1 mg, 0.5 mmol, 1.0 equiv), CuI (9.5 mg, 0.05 mmol, 0.1 equiv), and (PPh<sub>3</sub>)<sub>2</sub>PdCl<sub>2</sub> (35.1 mg, 0.05 mmol, 0.1 equiv) were suspended in anhydrous DMF (5 mL). The mixture underwent three cycles of vacuum/filling with N<sub>2</sub>. Then, DIPEA (0.16 mL, 1 mmol, 2.0 equiv) was added with a syringe. The mixture was stirred at 80 °C for 8 h and then quenched with water. DCM (3× 30 mL) and 5% ammonia (30 mL) were added for extraction. The combined organic layer was concentrated in vacuo, and the crude product was purified using silica gel chromatography with a methanol/dichloromethane gradient to afford the title compound <b>8c</b> as a white solid (131 mg, yield 49.1%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.61 (s, 1H), 8.36 (d, <i>J</i> = 1.6 Hz, 1H), 8.26 (s, 2H), 8.09 (d, <i>J</i> = 8.2 Hz, 1H), 7.97 (dd, <i>J</i> = 8.2, 1.6 Hz, 1H), 7.62 (t, <i>J</i> = 8.0 Hz, 1H), 7.56 (d, <i>J</i> = 8.1 Hz, 1H), 7.48 (d, <i>J</i> = 7.5 Hz, 1H), 4.69–4.56 (m, 1H), 2.92 (d, <i>J</i> = 10.1 Hz, 2H), 2.59 (s, 3H), 2.23 (s, 3H), 2.20–2.02 (m, 4H), 1.90 (d, <i>J</i> = 13.2 Hz, 2H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>28</sub>H<sub>27</sub>F<sub>3</sub>N<sub>7</sub>O [M + H]<sup>+</sup> 534.2229; found, 534.2240.</div><div class="NLM_p last">Compounds <b>8a</b>–<b>b</b> and <b>8d</b>–<b>g</b> were prepared in a manner similar to that described for <b>8c</b> from <b>7f</b>, <b>7i</b>–<b>l</b>, and <b>4a</b>–<b>c</b>. Yield 43.2–62.3%.</div></div><div id="sec5_16_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50">5.16.2 3-((4-Amino-1-ethyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methyl-<i>N</i>-(3-(trifluoromethyl)phenyl)benzamide (<b>8a</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.60 (s, 1H), 8.35 (d, <i>J</i> = 1.7 Hz, 1H), 8.27 (s, 1H), 8.26 (s, 1H), 8.09 (d, <i>J</i> = 8.2 Hz, 1H), 7.97 (dd, <i>J</i> = 8.0, 1.8 Hz, 1H), 7.62 (t, <i>J</i> = 8.0 Hz, 1H), 7.55 (d, <i>J</i> = 8.1 Hz, 1H), 7.47 (d, <i>J</i> = 7.7 Hz, 1H), 4.38 (q, <i>J</i> = 7.2 Hz, 2H), 2.59 (s, 3H), 1.42 (t, <i>J</i> = 7.2 Hz, 3H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>24</sub>H<sub>20</sub>F<sub>3</sub>N<sub>6</sub>O [M + H]<sup>+</sup> 465.1651; found, 465.1650.</div></div><div id="sec5_16_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51">5.16.3 (<i>R</i>)-3-((4-amino-1-(1-methylpyrrolidin-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide (<b>8b</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.60 (s, 1H), 8.35 (d, <i>J</i> = 1.9 Hz, 1H), 8.27 (s, 2H), 8.09 (d, <i>J</i> = 8.2 Hz, 1H), 7.97 (dd, <i>J</i> = 8.0, 1.9 Hz, 1H), 7.62 (t, <i>J</i> = 8.0 Hz, 1H), 7.55 (d, <i>J</i> = 8.1 Hz, 1H), 7.47 (d, <i>J</i> = 7.8 Hz, 1H), 5.43–5.36 (m, 1H), 3.05–2.97 (m, 1H), 2.78–2.63 (m, 3H), 2.59 (s, 3H), 2.41–2.36 (m, 1H), 2.32 (s, 3H), 2.29–2.21 (m, 1H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>27</sub>H<sub>25</sub>F<sub>3</sub>N<sub>7</sub>O [M + H]<sup>+</sup> 520.2073; found, 520.2073.</div></div><div id="sec5_16_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52">5.16.4 3-((4-Amino-1-((1-methylpyrrolidin-3-yl)methyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methyl-<i>N</i>-(3-(trifluoromethyl)phenyl)benzamide (<b>8d</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.61 (s, 1H), 8.35 (d, <i>J</i> = 1.7 Hz, 1H), 8.28 (s, 1H), 8.26 (s, 1H), 8.09 (d, <i>J</i> = 8.1 Hz, 1H), 7.97 (dd, <i>J</i> = 8.0, 1.7 Hz, 1H), 7.62 (t, <i>J</i> = 8.0 Hz, 1H), 7.55 (d, <i>J</i> = 8.1 Hz, 1H), 7.47 (d, <i>J</i> = 7.7 Hz, 1H), 4.30 (d, <i>J</i> = 7.6 Hz, 2H), 2.82–2.68 (m, 1H), 2.59 (s, 3H), 2.55–2.52 (m, 1H), 2.42–2.31 (m, 3H), 2.21 (s, 3H), 1.91–1.75 (m, 1H), 1.57–1.49 (m, 1H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>28</sub>H<sub>27</sub>F<sub>3</sub>N<sub>7</sub>O [M + H]<sup>+</sup> 534.2229; found, 534.2232.</div></div><div id="sec5_16_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53">5.16.5 3-((4-Amino-1-((1-methylpiperidin-4-yl)methyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methyl-<i>N</i>-(3-(trifluoromethyl)phenyl)benzamide hydrochloride salt (<b>8e</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.68 (s, 1H), 10.21 (s, 1H), 8.38 (d, <i>J</i> = 1.8 Hz, 1H), 8.28 (s, 2H), 8.12 (d, <i>J</i> = 8.2 Hz, 1H), 8.00 (dd, <i>J</i> = 8.0, 1.8 Hz, 1H), 7.62 (t, <i>J</i> = 8.0 Hz, 1H), 7.55 (d, <i>J</i> = 8.1 Hz, 1H), 7.47 (d, <i>J</i> = 7.8 Hz, 1H), 4.30 (d, <i>J</i> = 6.1 Hz, 2H), 3.29 (s, 2H), 2.85 (s, 2H), 2.66 (s, 3H), 2.58 (s, 3H), 2.20 (s, 1H), 1.69 (d, <i>J</i> = 13.0 Hz, 2H), 1.60–1.52 (m, 2H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>28</sub>H<sub>27</sub>F<sub>3</sub>N<sub>7</sub>O [M + H]<sup>+</sup> 548.2386; found, 548.2383.</div></div><div id="sec5_16_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54">5.16.6 3-((4-Amino-1-(1-methylpiperidin-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-<i>N</i>-(3-(trifluoromethyl)phenyl)benzamide (<b>8f</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.74 (s, 1H), 8.41 (s, 1H), 8.28 (s, 1H), 8.26 (s, 1H), 8.10 (d, <i>J</i> = 8.4 Hz, 1H), 8.06 (d, <i>J</i> = 7.9 Hz, 1H), 7.99 (d, <i>J</i> = 7.9 Hz, 1H), 7.65 (d, <i>J</i> = 7.8 Hz, 1H), 7.62 (t, <i>J</i> = 8.2 Hz, 1H), 7.47 (d, <i>J</i> = 7.8 Hz, 1H), 4.84–4.78 (m, 1H), 3.20 (d, <i>J</i> = 11.6 Hz, 2H), 2.67 (br. s, 2H), 2.49 (s, 3H), 2.31 (dd, <i>J</i> = 22.6, 11.2 Hz, 2H), 2.02 (d, <i>J</i> = 11.4 Hz, 2H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>27</sub>H<sub>25</sub>F<sub>3</sub>N<sub>7</sub>O [M + H]<sup>+</sup> 520.2073; found, 520.2088.</div></div><div id="sec5_16_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55">5.16.7 3-((4-Amino-1-(1-methylpiperidin-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-chloro-<i>N</i>-(3-(trifluoromethyl)phenyl)benzamide (<b>8g</b>)</h4><div class="NLM_p"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.79 (s, 1H), 8.57 (d, <i>J</i> = 1.8 Hz, 1H), 8.30 (s, 1H), 8.27 (s, 1H), 8.19 (br. s, 1H), 8.12–8.07 (m, 2H), 7.84 (d, <i>J</i> = 8.5 Hz, 1H), 7.63 (t, <i>J</i> = 8.0 Hz, 1H), 7.49 (d, <i>J</i> = 7.6 Hz, 1H), 6.65 (br. s, 1H), 4.93 (t, <i>J</i> = 10.8 Hz, 1H), 3.37 (br. s, 2H), 2.95 (br. s, 2H), 2.64 (s, 3H), 2.40 (dd, <i>J</i> = 22.9, 11.2 Hz, 2H), 2.11 (d, <i>J</i> = 12.0 Hz, 2H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>27</sub>H<sub>24</sub>ClF<sub>3</sub>N<sub>7</sub>O [M + H]<sup>+</sup> 554.1683; found, 554.1691.</div><div class="NLM_p last">Compound <b>13a</b>–<b>z</b> and <b>13aa</b>–<b>aq</b> were prepared in a manner similar to that described for <b>8c</b> from <b>12a</b>–<b>z</b> and <b>7g</b>–<b>n</b>, yield 46.9–67.2%.</div></div><div id="sec5_16_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56">5.16.8 <i>N</i>-(3-((4-Amino-1-(1-methylpiperidin-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)phenyl)-3-(trifluoromethyl)benzamide (<b>13a</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.63 (s, 1H), 8.33 (s, 1H), 8.29 (d, <i>J</i> = 7.9 Hz, 1H), 8.25 (s, 1H), 8.13 (s, 1H), 8.00 (d, <i>J</i> = 7.9 Hz, 1H), 7.86 (d, <i>J</i> = 7.8 Hz, 1H), 7.82 (t, <i>J</i> = 7.8 Hz, 1H), 7.50 (dt, <i>J</i> = 15.5, 7.7 Hz, 2H), 4.79–4.55 (m, 1H), 2.96 (br. s, 2H), 2.28 (s, 3H), 2.18 (t, <i>J</i> = 8.1 Hz, 4H), 1.92 (d, <i>J</i> = 4.8 Hz, 2H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>27</sub>H<sub>25</sub>F<sub>3</sub>N<sub>7</sub>O [M + H]<sup>+</sup> 520.2073; found, 520.2117.</div></div><div id="sec5_16_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57">5.16.9 <i>N</i>-(3-((4-Amino-1-(1-methylpiperidin-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (<b>13b</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.56 (s, 1H), 8.32 (s, 1H), 8.29 (d, <i>J</i> = 7.9 Hz, 1H), 8.26 (s, 1H), 8.08 (d, <i>J</i> = 2.2 Hz, 1H), 7.99 (d, <i>J</i> = 7.9 Hz, 1H), 7.81 (t, <i>J</i> = 7.8 Hz, 1H), 7.76 (dd, <i>J</i> = 8.3, 2.2 Hz, 1H), 7.38 (d, <i>J</i> = 8.5 Hz, 1H), 4.68–4.61 (m, 1H), 2.94 (d, <i>J</i> = 8.4 Hz, 2H), 2.48 (s, 3H), 2.24 (s, 3H), 2.19 (dd, <i>J</i> = 24.6, 12.0 Hz, 4H), 1.91 (d, <i>J</i> = 9.0 Hz, 2H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>28</sub>H<sub>27</sub>F<sub>3</sub>N<sub>7</sub>O [M + H]<sup>+</sup> 534.2229; found, 534.2239.</div></div><div id="sec5_16_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58">5.16.10 <i>N</i>-(3-((4-Amino-1-(1-methylpiperidin-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-chlorophenyl)-3-(trifluoromethyl)benzamide (<b>13c</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.72 (s, 1H), 8.32 (s, 1H), 8.29 (d, <i>J</i> = 7.9 Hz, 2H), 8.26 (d, <i>J</i> = 2.4 Hz, 1H), 8.01 (d, <i>J</i> = 7.9 Hz, 1H), 7.89 (dd, <i>J</i> = 8.9, 2.4 Hz, 1H), 7.83 (t, <i>J</i> = 7.8 Hz, 1H), 7.66 (d, <i>J</i> = 8.9 Hz, 1H), 4.75–4.59 (m, 1H), 2.95 (d, <i>J</i> = 7.5 Hz, 2H), 2.26 (s, 3H), 2.23–2.08 (m, 4H), 1.92 (d, <i>J</i> = 9.3 Hz, 2H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>27</sub>H<sub>24</sub>ClF<sub>3</sub>N<sub>7</sub>O [M + H]<sup>+</sup> 554.1683; found, 554.1695.</div></div><div id="sec5_16_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59">5.16.11 <i>N</i>-(3-((4-Amino-1-(1-methylpiperidin-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-4-(trifluoromethyl)benzamide (<b>13d</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.59 (s, 1H), 8.27 (s, 1H), 8.18 (d, <i>J</i> = 7.2 Hz, 2H), 8.11 (s, 1H), 7.94 (d, <i>J</i> = 7.2 Hz, 2H), 7.76 (d, <i>J</i> = 7.2 Hz, 1H), 7.37 (d, <i>J</i> = 7.2 Hz, 1H), 4.77–4.68 (m, 1H), 2.87 (br. s, 2H), 2.61 (s, 3H), 2.48 (s, 3H), 2.42–2.23 (m, 4H), 2.09 (d, <i>J</i> = 11.7 Hz, 2H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>28</sub>H<sub>27</sub>F<sub>3</sub>N<sub>7</sub>O [M + H]<sup>+</sup> 534.2229; found, 534.2069.</div></div><div id="sec5_16_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60">5.16.12 <i>N</i>-(3-((4-Amino-1-(1-methylpiperidin-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-3-methoxybenzamide (<b>13e</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.31 (s, 1H), 8.29 (s, 1H), 8.12 (s, 1H), 7.73 (d, <i>J</i> = 8.4 Hz, 1H), 7.55 (d, <i>J</i> = 7.4 Hz, 1H), 7.50 (s, 1H), 7.47 (t, <i>J</i> = 7.9 Hz, 1H), 7.36 (d, <i>J</i> = 8.4 Hz, 1H), 7.18 (d, <i>J</i> = 7.6 Hz, 1H), 5.06–4.87 (m, 1H), 3.85 (s, 3H), 3.58–3.39 (m, 2H), 3.22–2.99 (m, 2H), 2.76 (s, 3H), 2.47 (s, 3H), 2.44–2.28 (m, 2H), 2.22–2.06 (m, 2H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>28</sub>H<sub>30</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 496.2461; found, 496.2453</div></div><div id="sec5_16_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61">5.16.13 <i>N</i>-(3-((4-Amino-1-(1-methylpiperidin-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-4-methoxybenzamide (<b>13f</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.18 (s, 1H), 8.29 (s, 1H), 8.12 (s, 1H), 7.98 (d, <i>J</i> = 8.6 Hz, 2H), 7.72 (d, <i>J</i> = 8.4 Hz, 1H), 7.34 (d, <i>J</i> = 8.4 Hz, 1H), 7.08 (d, <i>J</i> = 8.6 Hz, 2H), 5.08–4.80 (m, 1H), 3.85 (s, 3H), 3.58–3.44 (m, 2H), 3.21–2.92 (m, 2H), 2.72 (s, 3H), 2.47 (s, 3H), 2.43–2.29 (m, 2H), 2.20–2.08 (m, 2H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>28</sub>H<sub>30</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 496.2461; found, 496.2454</div></div><div id="sec5_16_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62">5.16.14 <i>N</i>-(3-((4-Amino-1-(1-methylpiperidin-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-3-chlorobenzamide (<b>13g</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.43 (s, 1H), 8.26 (s, 1H), 8.08 (s, 1H), 8.03 (s, 1H), 7.94 (d, <i>J</i> = 7.5 Hz, 1H), 7.75 (d, <i>J</i> = 8.2 Hz, 1H), 7.69 (d, <i>J</i> = 7.6 Hz, 1H), 7.59 (t, <i>J</i> = 7.8 Hz, 1H), 7.36 (d, <i>J</i> = 8.2 Hz, 1H), 4.67–4.60 (m, 1H), 2.94 (d, <i>J</i> = 8.3 Hz, 2H), 2.48 (s, 3H), 2.26 (s, 3H), 2.23–2.05 (m, 4H), 1.91 (d, <i>J</i> = 9.9 Hz, 2H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>27</sub>H<sub>27</sub>ClN<sub>7</sub>O [M + H]<sup>+</sup> 500.1966; found, 500.1956.</div></div><div id="sec5_16_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63">5.16.15 <i>N</i>-(3-((4-Amino-1-(1-methylpiperidin-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-4-chlorobenzamide (<b>13h</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.59 (s, 1H), 8.30 (s, 1H), 8.19 (s, 1H), 8.13 (d, <i>J</i> = 9.0 Hz, 1H), 8.11 (s, 1H), 8.02 (s, 1H), 8.00 (d, <i>J</i> = 8.1 Hz, 1H), 7.72 (d, <i>J</i> = 8.1 Hz, 1H), 7.39 (d, <i>J</i> = 8.5 Hz, 1H), 5.18–4.88 (m, 1H), 3.54 (d, <i>J</i> = 10.8 Hz, 2H), 3.29–3.13 (m, 2H), 2.82 (s, 3H), 2.49 (s, 3H), 2.46–2.29 (m, 2H), 2.19 (d, <i>J</i> = 12.3 Hz, 2H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>27</sub>H<sub>27</sub>ClN<sub>7</sub>O [M + H]<sup>+</sup> 500.1966; found, 500.1968.</div></div><div id="sec5_16_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64">5.16.16 <i>N</i>-(3-((4-Amino-1-(1-methylpiperidin-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-3-fluorobenzamide (<b>13i</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.40 (s, 1H), 8.26 (s, 1H), 8.08 (d, <i>J</i> = 1.9 Hz, 1H), 7.84 (d, <i>J</i> = 7.8 Hz, 1H), 7.79 (d, <i>J</i> = 9.3 Hz, 1H), 7.75 (dd, <i>J</i> = 8.3, 1.9 Hz, 1H), 7.61 (dd, <i>J</i> = 13.9, 7.9 Hz, 1H), 7.48 (dd, <i>J</i> = 11.7, 5.3 Hz, 1H), 7.36 (d, <i>J</i> = 8.4 Hz, 1H), 4.76–4.52 (m, 1H), 2.95 (d, <i>J</i> = 6.7 Hz, 2H), 2.48 (s, 3H), 2.27 (s, 3H), 2.21–2.16 (m, 4H), 1.91 (d, <i>J</i> = 7.8 Hz, 2H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>27</sub>H<sub>27</sub>FN<sub>7</sub>O [M + H]<sup>+</sup> 484.2261; found, 484.2242.</div></div><div id="sec5_16_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65">5.16.17 <i>N</i>-(3-((4-Amino-1-(1-methylpiperidin-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-3-(trifluoromethoxy)benzamide (<b>13j</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.47 (s, 1H), 8.29 (s, 1H), 8.11 (d, <i>J</i> = 1.8 Hz, 1H), 8.04 (d, <i>J</i> = 7.7 Hz, 1H), 7.93 (s, 1H), 7.71 (t, <i>J</i> = 7.9 Hz, 2H), 7.63 (d, <i>J</i> = 8.0 Hz, 1H), 7.37 (d, <i>J</i> = 8.4 Hz, 1H), 5.03–4.92 (m, 1H), 3.51 (d, <i>J</i> = 11.7 Hz, 2H), 3.18 (t, <i>J</i> = 11.0 Hz, 2H), 2.79 (s, 3H), 2.48 (s, 3H), 2.39 (dd, <i>J</i> = 23.1, 11.4 Hz, 2H), 2.17 (d, <i>J</i> = 12.2 Hz, 2H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>28</sub>H<sub>27</sub>F<sub>3</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 550.2178; found, 550.2185.</div></div><div id="sec5_16_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66">5.16.18 <i>N</i>-(3-((4-Amino-1-(1-methylpiperidin-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-3-methylbenzamide (<b>13k</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.28 (s, 1H), 8.26 (s, 1H), 8.09 (s, 1H), 7.79 (s, 1H), 7.76 (d, <i>J</i> = 6.9 Hz, 2H), 7.42 (s, 2H), 7.34 (d, <i>J</i> = 8.2 Hz, 1H), 4.73–4.54 (m, 1H), 2.92 (d, <i>J</i> = 9.4 Hz, 2H), 2.47 (s, 3H), 2.41 (s, 3H), 2.24 (s, 3H), 2.22–2.03 (m, 4H), 1.90 (d, <i>J</i> = 10.3 Hz, 2H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>28</sub>H<sub>30</sub>N<sub>7</sub>O [M + H]<sup>+</sup> 480.2512; found, 480.2500.</div></div><div id="sec5_16_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67">5.16.19 <i>N</i>-(3-((4-Amino-1-(1-methylpiperidin-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-3-(<i>tert</i>-butyl)benzamide (<b>13l</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.30 (s, 1H), 8.29 (s, 1H), 8.11 (d, <i>J</i> = 2.0 Hz, 1H), 7.96 (s, 1H), 7.80 (d, <i>J</i> = 7.8 Hz, 1H), 7.75 (dd, <i>J</i> = 8.3, 2.0 Hz, 1H), 7.64 (d, <i>J</i> = 7.9 Hz, 1H), 7.47 (t, <i>J</i> = 7.8 Hz, 1H), 7.36 (d, <i>J</i> = 8.5 Hz, 1H), 5.04–4.98 (m, 1H), 3.56 (br. s, 2H), 3.28 (br. s, 2H), 2.84 (s, 3H), 2.48 (s, 3H), 2.43 (d, <i>J</i> = 12.9 Hz, 2H), 2.20 (d, <i>J</i> = 11.9 Hz, 2H), 1.35 (s, 9H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>31</sub>H<sub>36</sub>N<sub>7</sub>O [M + H]<sup>+</sup> 522.2981; found, 522.2980.</div></div><div id="sec5_16_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68">5.16.20 <i>N</i>-(3-((4-Amino-1-(1-methylpiperidin-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-2-fluoro-3-(trifluoromethyl)benzamide (<b>13m</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.40 (s, 1H), 8.29 (s, 1H), 8.11 (d, <i>J</i> = 2.0 Hz, 1H), 8.00 (d, <i>J</i> = 8.5 Hz, 2H), 7.72 (dd, <i>J</i> = 8.4, 2.0 Hz, 1H), 7.63 (d, <i>J</i> = 8.5 Hz, 2H), 7.36 (d, <i>J</i> = 8.4 Hz, 1H), 5.04–4.88 (m, 1H), 3.47 (d, <i>J</i> = 11.4 Hz, 2H), 3.11 (t, <i>J</i> = 11.0 Hz, 2H), 2.76 (s, 3H), 2.47 (s, 3H), 2.38 (t, <i>J</i> = 12.0 Hz, 2H), 2.16 (d, <i>J</i> = 12.0 Hz, 2H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>28</sub>H<sub>26</sub>F<sub>4</sub>N<sub>7</sub>O [M + H]<sup>+</sup> 552.2135; found, 552.2135</div></div><div id="sec5_16_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69">5.16.21 <i>N</i>-(3-((4-Amino-1-(1-methylpiperidin-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-4-fluoro-3-(trifluoromethyl)benzamide (<b>13n</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.56 (s, 1H), 8.39–8.35 (m, 2H), 8.29 (s, 1H), 8.09 (d, <i>J</i> = 2.0 Hz, 1H), 7.80–7.67 (m, 2H), 7.38 (d, <i>J</i> = 8.4 Hz, 1H), 5.00–4.84 (m, 1H), 3.39 (br. s, 2H), 3.00 (br. s, 2H), 2.69 (s, 3H), 2.48 (s, 3H), 2.35 (d, <i>J</i> = 12.0 Hz, 2H), 2.13 (d, <i>J</i> = 11.7 Hz, 2H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>28</sub>H<sub>26</sub>F<sub>4</sub>N<sub>7</sub>O [M + H]<sup>+</sup> 552.2135; found, 552.2145.</div></div><div id="sec5_16_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70">5.16.22 <i>N</i>-(3-((4-Amino-1-(1-methylpiperidin-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-3-fluoro-5-(trifluoromethyl)benzamide (<b>13o</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.73 (s, 1H), 8.29 (s, 1H), 8.06 (d, <i>J</i> = 2.0 Hz, 1H), 8.05–7.94 (m, 2H), 7.64 (dd, <i>J</i> = 8.3, 2.0 Hz, 1H), 7.57 (t, <i>J</i> = 7.8 Hz, 1H), 7.38 (d, <i>J</i> = 8.4 Hz, 1H),5.03–4.87 (m, 1H), 3.49 (d, <i>J</i> = 11.6 Hz, 2H), 3.15 (t, <i>J</i> = 11.0 Hz, 2H), 2.78 (s, 3H), 2.48 (s, 3H), 2.38 (dd, <i>J</i> = 23.1, 11.3 Hz, 2H), 2.16 (d, <i>J</i> = 12.0 Hz, 2H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>28</sub>H<sub>26</sub>F<sub>4</sub>N<sub>7</sub>O [M + H]<sup>+</sup> 552.2135; found, 552.2127.</div></div><div id="sec5_16_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71">5.16.23 <i>N</i>-(3-((4-Amino-1-(1-methylpiperidin-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-2-fluoro-5-(trifluoromethyl)benzamide (<b>13p</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.69 (s, 1H), 8.26 (s, 1H), 8.09 (d, <i>J</i> = 4.6 Hz, 1H), 8.02 (s, 2H), 7.79–7.57 (m, 2H), 7.37 (d, <i>J</i> = 4.0 Hz, 1H), 4.67–4.60 (m, 1H), 2.93 (d, <i>J</i> = 8.3 Hz, 2H), 2.48 (s, 3H), 2.25 (s, 3H), 2.21–2.05 (m, 4H), 1.90 (d, <i>J</i> = 10.7 Hz, 2H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>28</sub>H<sub>26</sub>F<sub>4</sub>N<sub>7</sub>O [M + H]<sup>+</sup> 552.2135; found, 552.2173.</div></div><div id="sec5_16_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72">5.16.24 <i>N</i>-(3-((4-Amino-1-(1-methylpiperidin-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-3-chloro-5-(trifluoromethyl)benzamide (<b>13q</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.62 (s, 1H), 8.34 (s, 1H), 8.31 (s, 1H), 8.27 (s, 1H), 8.15 (s, 1H), 8.10 (d, <i>J</i> = 1.8 Hz, 1H), 7.72 (dd, <i>J</i> = 8.3, 1.8 Hz, 1H), 7.39 (d, <i>J</i> = 8.3 Hz, 1H), 5.03–4.98 (m, 1H), 3.56 (d, <i>J</i> = 9.5 Hz, 2H), 3.26 (d, <i>J</i> = 11.0 Hz, 2H), 2.85 (s, 3H), 2.49 (s, 3H), 2.40 (dd, <i>J</i> = 23.4, 11.6 Hz, 2H), 2.20 (d, <i>J</i> = 11.9 Hz, 2H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>28</sub>H<sub>26</sub>ClF<sub>3</sub>N<sub>7</sub>O [M + H]<sup>+</sup> 568.1839; found, 568.1842.</div></div><div id="sec5_16_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73">5.16.25 <i>N</i>-(3-((4-Amino-1-(1-methylpiperidin-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-4-chloro-3-(trifluoromethyl)benzamide (<b>13r</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.61 (s, 1H), 8.41 (s, 1H), 8.28 (d, <i>J</i> = 10.8 Hz, 2H), 8.11 (s, 1H), 7.96 (d, <i>J</i> = 8.4 Hz, 1H), 7.71 (d, <i>J</i> = 8.2 Hz, 1H), 7.39 (d, <i>J</i> = 8.4 Hz, 1H), 5.03–4.97 (m, 1H), 3.55 (d, <i>J</i> = 10.6 Hz, 2H), 3.24 (d, <i>J</i> = 11.2 Hz, 2H), 2.83 (s, 3H), 2.48 (s, 3H), 2.39 (dd, <i>J</i> = 21.0, 9.5 Hz, 2H), 2.20 (d, <i>J</i> = 12.6 Hz, 2H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>28</sub>H<sub>26</sub>ClF<sub>3</sub>N<sub>7</sub>O [M + H]<sup>+</sup> 568.1839; found, 568.1836.</div></div><div id="sec5_16_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74">5.16.26 <i>N</i>-(3-((4-Amino-1-(1-methylpiperidin-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-4-methyl-3-(trifluoromethyl)benzamide (<b>13s</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.52 (s, 1H), 8.28 (s, 1H), 8.27 (s, 1H), 8.19 (d, <i>J</i> = 7.5 Hz, 1H), 8.11 (s, 1H), 7.75 (d, <i>J</i> = 7.5 Hz, 1H), 7.65 (d, <i>J</i> = 8.3 Hz, 1H), 7.37 (d, <i>J</i> = 8.3 Hz, 1H), 5.06–4.80 (m, 1H), 3.38 (br. s, 2H), 3.00 (br. s, 2H), 2.68 (s, 3H), 2.54 (s, 3H), 2.48 (s, 3H), 2.39 (d, <i>J</i> = 12.9 Hz, 2H), 2.12 (d, <i>J</i> = 12.8 Hz, 2H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>29</sub>H<sub>29</sub>F<sub>3</sub>N<sub>7</sub>O [M + H]<sup>+</sup> 548.2386; found, 548.2392.</div></div><div id="sec5_16_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75">5.16.27 <i>N</i>-(3-((4-Amino-1-(1-methylpiperidin-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-4-methoxy-3-(trifluoromethyl)benzamide (<b>13t</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.39 (s, 1H), 9.49 (br. s, 1H), 8.30 (s, 2H), 8.27 (s, 1H), 8.11 (s, 1H), 7.72 (d, J = 7.9 Hz, 1H), 7.45 (d, J = 8.7 Hz, 1H), 7.37 (d, J = 8.3 Hz, 1H), 6.70 (br. s, 1H), 5.02–4.97 (m, 1H), 4.00 (s, 3H), 3.54 (d, J = 9.9 Hz, 2H), 3.25 (d, J = 11.4 Hz, 2H), 2.83 (s, 3H), 2.48 (s, 3H), 2.40 (dd, J = 11.4, 12.9 Hz, 2H), 2.19 (d, J = 12.4 Hz, 2H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>29</sub>H<sub>29</sub>F<sub>3</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 564.2335; found, 564.2333.</div></div><div id="sec5_16_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76">5.16.28 <i>N</i>-(3-((4-Amino-1-(1-methylpiperidin-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-3,5-bis(trifluoromethyl)benzamide (<b>13u</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.71 (s, 1H), 8.57 (s, 2H), 8.33 (s, 1H), 8.22 (s, 1H), 8.00 (d, <i>J</i> = 1.5 Hz, 1H), 7.70 (d, <i>J</i> = 8.3 Hz, 1H), 7.34 (d, <i>J</i> = 8.4 Hz, 1H), 4.64–4.58 (m, 1H), 2.90 (d, <i>J</i> = 7.9 Hz, 2H), 2.44 (s, 3H), 2.21 (s, 3H), 2.11 (q, <i>J</i> = 13.2 Hz, 4H), 1.87 (d, <i>J</i> = 9.0 Hz, 2H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>29</sub>H<sub>26</sub>F<sub>6</sub>N<sub>7</sub>O [M + H]<sup>+</sup> 602.2103; found, 602.2123.</div></div><div id="sec5_16_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77">5.16.29 <i>N</i>-(3-((4-Amino-1-(1-methylpiperidin-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-3-chloro-2-fluoro-5-(trifluoromethyl)benzamide (<b>13v</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.79 (s, 1H), 8.33 (d, <i>J</i> = 4.5 Hz, 1H), 8.30 (s, 1H), 8.09 (d, <i>J</i> = 3.4 Hz, 1H), 8.04 (d, <i>J</i> = 2.0 Hz, 1H), 7.63 (dd, <i>J</i> = 8.4, 2.0 Hz, 1H), 7.39 (d, <i>J</i> = 8.4 Hz, 1H), 4.94 (m, 1H), 3.42 (s, 2H), 3.04 (s, 2H), 2.73 (s, 3H), 2.48 (s, 3H), 2.35 (dd, <i>J</i> = 22.9, 11.0 Hz, 2H), 2.14 (d, <i>J</i> = 12.5 Hz, 2H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>28</sub>H<sub>25</sub>ClF<sub>4</sub>N<sub>7</sub>O [M + H]<sup>+</sup> 586.1745; found, 586.1752.</div></div><div id="sec5_16_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78">5.16.30 <i>N</i>-(3-((4-Amino-1-(1-methylpiperidin-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-6-(trifluoromethyl)picolinamide (<b>13w</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.50 (s, 1H), 8.44–8.33 (m, 2H), 8.29 (s, 1H), 8.23–8.16 (m, 2H), 7.87 (dd, <i>J</i> = 8.4, 1.8 Hz, 1H), 7.39 (d, <i>J</i> = 8.4 Hz, 1H),5.06–4.78 (m, 1H), 3.44 (d, <i>J</i> = 11.5 Hz, 2H), 3.06 (t, <i>J</i> = 11.1 Hz, 2H), 2.73 (s, 3H), 2.49 (s, 3H), 2.37 (dd, <i>J</i> = 22.7, 11.1 Hz, 2H), 2.15 (d, <i>J</i> = 11.8 Hz, 2H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>27</sub>H<sub>26</sub>F<sub>3</sub>N<sub>8</sub>O [M + H]<sup>+</sup> 535.2182; found, 535.2178.</div></div><div id="sec5_16_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79">5.16.31 <i>N</i>-(3-((4-Amino-1-(1-methylpiperidin-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-5-(trifluoromethyl)nicotinamide (<b>13x</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.71 (s, 1H), 9.40 (s, 1H), 9.21 (s, 1H), 8.71 (s, 1H), 8.27 (s, 1H), 8.08 (s, 1H), 7.75 (d, <i>J</i> = 8.2 Hz, 1H), 7.39 (d, <i>J</i> = 8.4 Hz, 1H), 4.74–4.59 (m, 1H), 2.97 (s, 2H), 2.49 (s, 3H), 2.29 (s, 3H), 2.20 (br. s, 4H), 1.92 (s, 2H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>27</sub>H<sub>26</sub>F<sub>3</sub>N<sub>8</sub>O [M + H]<sup>+</sup> 535.2182; found, 535.2174.</div></div><div id="sec5_16_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80">5.16.32 <i>N</i>-(3-((4-Amino-1-(1-methylpiperidin-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide (<b>13y</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.93 (s, 1H), 8.99 (d, <i>J</i> = 4.7 Hz, 1H), 8.41 (s, 1H), 8.26 (s, 2H), 8.11 (s, 1H), 7.79 (d, <i>J</i> = 8.1 Hz, 1H), 7.37 (d, <i>J</i> = 8.3 Hz, 1H), 4.87 (t, <i>J</i> = 10.8 Hz, 1H), 3.36 (d, <i>J</i> = 7.3 Hz, 2H), 2.90 (br. s, 2H), 2.60 (s, 3H), 2.47 (s, 3H), 2.38 (d, <i>J</i> = 11.5 Hz, 2H), 2.07 (d, <i>J</i> = 11.3 Hz, 2H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>27</sub>H<sub>26</sub>F<sub>3</sub>N<sub>8</sub>O [M + H]<sup>+</sup> 535.2182; found, 535.2186.</div></div><div id="sec5_16_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81">5.16.33 <i>N</i>-(3-((4-Amino-1-(1-methylpiperidin-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-5-(<i>tert</i>-butyl)isoxazole-3-carboxamide (<b>13z</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.71 (s, 1H), 8.27 (s, 1H), 8.06 (d, <i>J</i> = 2.1 Hz, 1H), 7.70 (dd, <i>J</i> = 8.4, 2.1 Hz, 1H), 7.34 (d, <i>J</i> = 8.4 Hz, 1H),6.67 (s, 1H), 4.97 (t, <i>J</i> = 11.5 Hz, 1H), 3.51 (br. s, 2H), 3.22 (br. s, 2H), 2.80 (s, 3H), 2.45 (s, 3H), 2.33 (dd, <i>J</i> = 25.3, 10.0 Hz, 2H), 2.16 (d, <i>J</i> = 12.2 Hz, 2H), 1.34 (s, 9H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>28</sub>H<sub>33</sub>N<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup> 513.2726; found, 513.2726.</div></div><div id="sec5_16_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82">5.16.34 <i>N</i>-(3-((4-Amino-1-(1-methylpiperidin-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-2-(<i>tert</i>-butyl)thiazole-5-carboxamide (<b>13aa</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.00 (s, 1H), 8.30 (d, <i>J</i> = 7.6 Hz, 2H), 8.14 (s, 1H), 7.82 (d, <i>J</i> = 7.6 Hz, 1H), 7.36 (d, <i>J</i> = 7.9 Hz, 1H), 5.08–4.92 (m, 1H), 3.54 (d, <i>J</i> = 7.9 Hz, 2H), 3.30–3.15 (m, 2H), 2.82 (s, 3H), 2.47 (s, 3H), 2.43 (d, <i>J</i> = 11.2 Hz, 2H), 2.19 (d, <i>J</i> = 11.5 Hz, 2H), 1.47 (s, 9H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>28</sub>H<sub>33</sub>N<sub>8</sub>OS [M + H]<sup>+</sup> 529.2498; found, 529.2495.</div></div><div id="sec5_16_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83">5.16.35 <i>N</i>-(3-((4-Amino-1-(1-methylpiperidin-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-3-(<i>tert</i>-butyl)-1-methyl-1H-pyrazole-5-carboxamide (<b>13ab</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.19 (s, 1H), 8.26 (s, 1H), 8.04 (d, <i>J</i> = 2.0 Hz, 1H), 7.70 (dd, <i>J</i> = 8.3, 2.0 Hz, 1H), 7.35 (d, <i>J</i> = 8.4 Hz, 1H), 6.97 (s, 1H), 4.74–4.54 (m, 1H), 4.04 (s, 3H), 2.93 (d, <i>J</i> = 9.9 Hz, 2H), 2.47 (s, 3H), 2.24 (s, 3H), 2.22–2.02 (m, 4H), 1.90 (d, <i>J</i> = 10.9 Hz, 2H), 1.29 (s, 9H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>29</sub>H<sub>36</sub>N<sub>9</sub>O [M + H]<sup>+</sup> 526.3043; found, 526.3041.</div></div><div id="sec5_16_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84">5.16.36 <i>N</i>-(3-((4-Amino-1-((1-methylpiperidin-4-yl)methyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-3-(trifluoromethyl)benzamide hydrochloride salt (<b>13ac</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.63 (s, 1H), 10.13 (s, 1H), 8.33 (s, 1H), 8.31 (d, <i>J</i> = 8.2 Hz, 1H), 8.28 (s, 1H), 8.13 (d, <i>J</i> = 2.2 Hz, 1H), 7.99 (d, <i>J</i> = 7.8 Hz, 1H), 7.81 (t, <i>J</i> = 7.8 Hz, 1H), 7.75 (dd, <i>J</i> = 8.3, 2.2 Hz, 1H), 7.37 (d, <i>J</i> = 8.5 Hz, 1H), 4.30 (s, 2H), 3.32–3.25 (m, 2H), 2.87 (s, 2H), 2.67 (s, 3H), 2.48 (s, 3H), 2.20 (s, 1H), 1.70 (d, <i>J</i> = 12.9 Hz, 2H), 1.60–1.52 (m, 2H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>29</sub>H<sub>29</sub>F<sub>3</sub>N<sub>7</sub>O [M + H]<sup>+</sup> 548.2386; found, 548.2384.</div></div><div id="sec5_16_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85">5.16.37 <i>N</i>-(3-((4-Amino-1-((1-methylpyrrolidin-3-yl)methyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (<b>13ad</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.59 (s, 1H), 8.33 (s, 1H), 8.31 (s, 1H), 8.28 (s, 1H), 8.11 (d, <i>J</i> = 2.2 Hz, 1H), 7.99 (d, <i>J</i> = 7.8 Hz, 1H), 7.81 (t, <i>J</i> = 7.8 Hz, 1H), 7.76 (dd, <i>J</i> = 8.3, 2.2 Hz, 1H), 7.37 (d, <i>J</i> = 8.5 Hz, 1H), 4.44–4.30 (m, 2H), 2.92–2.71 (m, 3H), 2.71–2.58 (m, 2H), 2.48 (s, 3H), 2.42 (s, 3H), 2.00–1.85 (m, 1H), 1.70–1.56 (m, 1H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>28</sub>H<sub>27</sub>F<sub>3</sub>N<sub>7</sub>O [M + H]<sup>+</sup> 534.2229; found, 534.2231.</div></div><div id="sec5_16_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86">5.16.38 (<i>R</i>)-<i>N</i>-(3-((4-amino-1-(1-methylpyrrolidin-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (<b>13ae</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.55 (s, 1H), 8.32 (s, 1H), 8.29 (s, 1H), 8.27 (s, 1H), 8.10 (d, <i>J</i> = 2.2 Hz, 1H), 7.99 (d, <i>J</i> = 7.8 Hz, 1H), 7.81 (t, <i>J</i> = 7.8 Hz, 1H), 7.75 (dd, <i>J</i> = 8.3, 2.2 Hz, 1H), 7.37 (d, <i>J</i> = 8.5 Hz, 1H), 5.47–5.34 (m, 1H), 3.08 (t, <i>J</i> = 8.6 Hz, 1H), 2.85–2.69 (m, 3H), 2.49 (s, 3H), 2.36 (s, 3H), 2.34–2.22 (m, 2H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>27</sub>H<sub>25</sub>F<sub>3</sub>N<sub>7</sub>O [M + H]<sup>+</sup> 520.2073; found, 520.2071.</div></div><div id="sec5_16_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87">5.16.39 (<i>R</i>)-<i>N</i>-(3-((4-Amino-1-(3-hydroxy-2-methylpropyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (<b>13af</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.55 (s, 1H), 8.32 (s, 1H), 8.29 (s, 1H), 8.27 (s, 1H), 8.08 (d, <i>J</i> = 2.2 Hz, 1H), 7.99 (d, <i>J</i> = 7.8 Hz, 1H), 7.81 (t, <i>J</i> = 7.8 Hz, 1H), 7.76 (dd, <i>J</i> = 8.3, 2.2 Hz, 1H), 7.37 (d, <i>J</i> = 8.5 Hz, 1H), 4.67 (s, 1H), 4.36 (dd, <i>J</i> = 13.7, 6.1 Hz, 1H), 4.18 (dd, <i>J</i> = 13.7, 8.1 Hz, 1H), 3.34 (s, 2H), 2.48 (s, 3H), 2.28–2.20 (m, 1H), 0.79 (d, <i>J</i> = 6.8 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.00, 157.90, 156.47, 153.51, 136.67, 135.64, 135.54, 131.85, 130.02, 129.79, 129.22 (d, <i>J</i> = 32.0 Hz), 128.24 (d, <i>J</i> = 3.0 Hz), 125.32, 124.22 (d, <i>J</i> = 3.8 Hz), 123.87, 122.62, 121.84, 121.32, 100.44, 91.90, 84.65, 63.67, 49.92, 36.37, 19.86, 14.48. HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>26</sub>H<sub>24</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup> 509.1913; found, 509.1912.</div></div><div id="sec5_16_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88">5.16.40 (<i>S</i>)-<i>N</i>-(3-((4-Amino-1-(3-hydroxy-2-methylpropyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (<b>13ag</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.55 (s, 1H), 8.32 (s, 1H), 8.29 (s, 1H), 8.27 (s, 1H), 8.08 (d, <i>J</i> = 2.2 Hz, 1H), 7.99 (d, <i>J</i> = 7.8 Hz, 1H), 7.81 (t, <i>J</i> = 7.8 Hz, 1H), 7.76 (dd, <i>J</i> = 8.3, 2.2 Hz, 1H), 7.37 (d, <i>J</i> = 8.5 Hz, 1H), 4.67 (t, <i>J</i> = 5.3 Hz, 1H), 4.36 (dd, <i>J</i> = 13.7, 6.1 Hz, 1H), 4.18 (dd, <i>J</i> = 13.7, 8.1 Hz, 1H), 3.35 (d, <i>J</i> = 5.6 Hz, 2H), 2.48 (s, 3H), 2.28–2.20 (m, 1H), 0.79 (d, <i>J</i> = 6.8 Hz, 3H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>26</sub>H<sub>24</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup> 509.1913; found, 509.1906.</div></div><div id="sec5_16_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89">5.16.41 <i>N</i>-(3-((4-Amino-1-(<i>cis</i>-4-hydroxycyclohexyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (<b>13ah</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.55 (s, 1H), 8.36–8.22 (m, 3H), 8.08 (d, <i>J</i> = 1.9 Hz, 1H), 7.99 (d, <i>J</i> = 7.7 Hz, 1H), 7.81 (t, <i>J</i> = 7.8 Hz, 1H), 7.76 (dd, <i>J</i> = 8.3, 1.9 Hz, 1H), 7.37 (d, <i>J</i> = 8.4 Hz, 1H), 4.75–4.61 (m, 1H), 4.51 (d, <i>J</i> = 2.5 Hz, 1H), 3.90 (s, 1H), 2.42–2.26 (m, 2H), 1.82 (d, <i>J</i> = 11.7 Hz, 2H), 1.64 (t, <i>J</i> = 12.8 Hz, 4H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>28</sub>H<sub>26</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup> 535.2069; found, 535.2070.</div></div><div id="sec5_16_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90">5.16.42 <i>N</i>-(3-((4-Amino-1-(<i>trans</i>-4-hydroxycyclohexyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (<b>13ai</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.55 (s, 1H), 8.32–8.26 (M, 3H), 8.08 (s, 1H), 7.99 (d, <i>J</i> = 7.6 Hz, 1H), 7.80 (t, <i>J</i> = 7.8 Hz, 1H), 7.75 (d, <i>J</i> = 8.2 Hz, 1H), 7.36 (d, <i>J</i> = 8.4 Hz, 1H), 4.73 (d, <i>J</i> = 4.0 Hz, 1H), 4.64 (t, <i>J</i> = 11.1 Hz, 1H), 3.61–3.47 (m, 1H), 2.47 (s, 3H), 2.09–1.83 (m, 6H), 1.49–1.31 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 164.01, 157.87, 156.24, 152.51, 136.67, 135.61, 135.54, 131.86, 130.02, 129.80, 129.21 (d, <i>J</i> = 32.0 Hz), 128.25 (d, <i>J</i> = 4.0 Hz), 125.33, 125.03, 124.22 (d, <i>J</i> = 3.9 Hz), 123.86, 122.62, 121.81, 121.32, 100.74, 91.79, 84.70, 67.87, 55.42, 34.08, 29.81, 19.88. HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>28</sub>H<sub>26</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup> 535.2069; found, 535.2067.</div></div><div id="sec5_16_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91">5.16.43 (<i>R</i>)-<i>N</i>-(3-((4-Amino-1-(3-hydroxy-2-methylpropyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-2-(<i>tert</i>-butyl)thiazole-5-carboxamide (<b>13aj</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.01 (s, 1H), 8.32 (s, 1H), 8.27 (s, 1H), 8.12 (d, <i>J</i> = 1.5 Hz, 1H), 7.84 (d, <i>J</i> = 8.3 Hz, 1H), 7.36 (d, <i>J</i> = 8.4 Hz, 1H), 4.69 (s, 1H), 4.36 (dd, <i>J</i> = 13.6, 5.9 Hz, 1H), 4.18 (dd, <i>J</i> = 13.6, 8.2 Hz, 1H), 3.49–3.39 (m, 2H), 2.48 (s, 3H), 2.28–2.20 (m, 1H), 1.47 (s, 9H), 0.79 (d, <i>J</i> = 6.8 Hz, 3H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>26</sub>H<sub>30</sub>N<sub>7</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 504.2182; found, 504.2184.</div></div><div id="sec5_16_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92">5.16.44 <i>N</i>-(3-((4-Amino-1-(<i>trans</i>-4-hydroxycyclohexyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-3-(<i>tert</i>-butyl)benzamide (<b>13ak</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.28 (s, 1H), 8.26 (s, 1H), 8.07 (d, <i>J</i> = 2.1 Hz, 1H), 7.95 (s, 1H), 7.79 (d, <i>J</i> = 7.7 Hz, 1H), 7.75 (dd, <i>J</i> = 8.4, 2.1 Hz, 1H), 7.64 (d, <i>J</i> = 7.9 Hz, 1H), 7.47 (t, <i>J</i> = 7.7 Hz, 1H), 7.34 (d, <i>J</i> = 8.5 Hz, 1H), 4.80–4.56 (m, 2H), 3.55 (t, <i>J</i> = 10.4 Hz, 1H), 2.47 (s, 3H), 2.11–1.83 (m, 6H), 1.51–1.37 (m, 2H), 1.35 (s, 9H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>31</sub>H<sub>35</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup> 523.2821; found, 523.2844.</div></div><div id="sec5_16_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93">5.16.45 (<i>R</i>)-<i>N</i>-(3-((4-Amino-1-(3-hydroxy-2-methylpropyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-4-methyl-3-(trifluoromethyl)benzamide (<b>13al</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.48 (s, 1H), 8.27 (s, 2H), 8.18 (d, <i>J</i> = 7.9 Hz, 1H), 8.08 (d, <i>J</i> = 2.2 Hz, 1H), 7.75 (dd, <i>J</i> = 8.3, 2.2 Hz, 1H), 7.64 (d, <i>J</i> = 8.0 Hz, 1H), 7.36 (d, <i>J</i> = 8.5 Hz, 1H), 4.68 (s, 1H), 4.36 (dd, <i>J</i> = 13.7, 6.1 Hz, 1H), 4.18 (dd, <i>J</i> = 13.7, 8.1 Hz, 1H), 3.34 (s, 2H), 2.54 (s, 3H), 2.48 (s, 3H), 2.28–2.20 (m, 1H), 0.79 (d, <i>J</i> = 6.8 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.95, 157.91, 156.47, 153.51, 139.97, 136.74, 135.50, 132.61, 132.50, 131.54, 129.99, 127.48 (d, <i>J</i> = 30.0 Hz), 125.48 (d, <i>J</i> = 30.0 Hz), 124.91 (q, <i>J</i> = 5.5 Hz), 123.84, 122.92, 121.82, 121.28, 100.46, 91.92, 84.62, 63.67, 49.92, 36.37, 19.85, 18.82, 14.47. HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>27</sub>H<sub>26</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup> 523.2069; found, 523.2066.</div></div><div id="sec5_16_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94">5.16.46 (<i>S</i>)-<i>N</i>-(3-((4-Amino-1-(3-hydroxy-2-methylpropyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-4-methyl-3-(trifluoromethyl)benzamide (<b>13am</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.48 (s, 1H), 8.27 (s, 2H), 8.18 (d, <i>J</i> = 7.9 Hz, 1H), 8.07 (d, <i>J</i> = 2.2 Hz, 1H), 7.75 (dd, <i>J</i> = 8.3, 2.2 Hz, 1H), 7.64 (d, <i>J</i> = 8.0 Hz, 1H), 7.36 (d, <i>J</i> = 8.5 Hz, 1H), 4.67 (t, <i>J</i> = 5.3 Hz, 1H), 4.36 (dd, <i>J</i> = 13.7, 6.0 Hz, 1H), 4.18 (dd, <i>J</i> = 13.7, 8.1 Hz, 1H), 3.35 (d, <i>J</i> = 5.6 Hz, 2H), 2.54 (s, 3H), 2.48 (s, 3H), 2.28–2.20 (m, 1H), 0.79 (d, <i>J</i> = 6.8 Hz, 3H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>27</sub>H<sub>26</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup> 523.2069; found, 523.2076.</div></div><div id="sec5_16_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95">5.16.47 <i>N</i>-(3-((4-Amino-1-(<i>trans</i>-4-hydroxycyclohexyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-4-methyl-3-(trifluoromethyl)benzamide (<b>13an</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.48 (s, 1H), 8.27 (s, 1H), 8.26 (s, 1H), 8.18 (d, <i>J</i> = 8.0 Hz, 1H), 8.07 (d, <i>J</i> = 2.2 Hz, 1H), 7.74 (dd, <i>J</i> = 8.3, 2.2 Hz, 1H), 7.64 (d, <i>J</i> = 8.0 Hz, 1H), 7.36 (d, <i>J</i> = 8.5 Hz, 1H), 4.71 (s, 1H), 4.69–4.56 (m, 1H), 3.63–3.47 (m, 1H), 2.54 (s, 3H), 2.47 (s, 3H), 2.10–1.83 (m, 6H), 1.46–1.36 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.95, 157.67, 155.96, 152.43, 139.98, 136.76, 135.47, 132.61, 132.49, 131.54, 129.97, 127.48 (d, <i>J</i> = 30.0 Hz), 125.39 (d, <i>J</i> = 50.0 Hz), 124.92 (q, <i>J</i> = 5.7 Hz), 123.83, 122.92, 121.80, 121.27, 100.73, 91.90, 84.61, 67.87, 55.45, 34.08, 29.82, 19.86, 18.80. HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>29</sub>H<sub>28</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup> 549.2226; found, 549.2229.</div></div><div id="sec5_16_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96">5.16.48 (<i>R</i>)-<i>N</i>-(3-((4-Amino-1-(3-hydroxy-2-methylpropyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-4-chloro-3-(trifluoromethyl)benzamide (<b>13ao</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.59 (s, 1H), 8.41 (s, 1H), 8.31 (s, 1H), 8.28 (d, <i>J</i> = 8.4 Hz, 1H), 8.06 (d, <i>J</i> = 1.8 Hz, 1H), 7.94 (d, <i>J</i> = 8.4 Hz, 1H), 7.74 (dd, <i>J</i> = 8.4, 1.8 Hz, 1H), 7.37 (d, <i>J</i> = 8.4 Hz, 1H), 4.67 (t, <i>J</i> = 5.3 Hz, 1H), 4.36 (dd, <i>J</i> = 13.7, 6.0 Hz, 1H), 4.18 (dd, <i>J</i> = 13.6, 8.1 Hz, 1H), 3.35 (d, <i>J</i> = 5.6 Hz, 2H), 2.48 (s, 3H), 2.24 (dq, <i>J</i> = 12.9, 6.4 Hz, 1H), 0.79 (d, <i>J</i> = 6.8 Hz, 3H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>26</sub>H<sub>23</sub>ClF<sub>3</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup> 543.1523; found, 543.1522.</div></div><div id="sec5_16_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97">5.16.49 (<i>S</i>)-<i>N</i>-(3-((4-Amino-1-(3-hydroxy-2-methylpropyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-4-chloro-3-(trifluoromethyl)benzamide (<b>13ap</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.59 (s, 1H), 8.41 (d, <i>J</i> = 1.5 Hz, 1H), 8.28 (d, <i>J</i> = 8.4 Hz, 2H), 8.06 (d, <i>J</i> = 2.0 Hz, 1H), 7.94 (d, <i>J</i> = 8.4 Hz, 1H), 7.74 (dd, <i>J</i> = 8.4, 2.0 Hz, 1H), 7.37 (d, <i>J</i> = 8.4 Hz, 1H), 4.67 (t, <i>J</i> = 5.3 Hz, 1H), 4.36 (dd, <i>J</i> = 13.7, 6.1 Hz, 1H), 4.18 (dd, <i>J</i> = 13.7, 8.1 Hz, 1H), 3.35 (d, <i>J</i> = 5.8 Hz, 2H), 2.48 (s, 3H), 2.24 (dq, <i>J</i> = 13.1, 6.4 Hz, 1H), 0.79 (d, <i>J</i> = 6.8 Hz, 3H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>26</sub>H<sub>23</sub>ClF<sub>3</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup> 543.1523; found, 543.1524.</div></div><div id="sec5_16_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98">5.16.50 <i>N</i>-(3-((4-Amino-1-(<i>trans</i>-4-hydroxycyclohexyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-4-chloro-3-(trifluoromethyl)benzamide (<b>13aq</b>)</h4><div class="NLM_p"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.59 (s, 1H), 8.41 (s, 1H), 8.28 (d, <i>J</i> = 5.9 Hz, 2H), 8.06 (s, 1H), 7.94 (d, <i>J</i> = 7.9 Hz, 1H), 7.73 (d, <i>J</i> = 7.7 Hz, 1H), 7.37 (d, <i>J</i> = 7.9 Hz, 1H),4.70 (s, 1H), 4.64 (d, <i>J</i> = 9.9 Hz, 1H), 3.56 (s, 1H), 2.14–1.81 (m, 6H), 1.53–1.31 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.09, 157.85, 156.21, 152.50, 136.52, 135.73, 134.01, 133.89, 133.38, 132.00, 130.03, 127.03 (d, <i>J</i> = 5.0 Hz), 126.69 (d, <i>J</i> = 31.0 Hz), 125.02, 123.96 (d, <i>J</i> = 17.0 Hz), 121.79, 121.32 (d, <i>J</i> = 6.0 Hz), 100.74, 91.74, 84.74, 67.87, 55.42, 34.08, 29.81, 19.88. HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>28</sub>H<sub>25</sub>ClF<sub>3</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup> 569.1680; found, 569.1679.</div><div class="NLM_p last">Compounds <b>17a</b>–<b>c</b> were prepared in a manner similar to that described for <b>8c</b> from <b>7i</b> and <b>16a</b>–<b>c</b>; yield 47.9–55.0%.</div></div><div id="sec5_16_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99">5.16.51 1-(3-((4-Amino-1-(1-methylpiperidin-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea (<b>17a</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.45 (s, 1H), 9.25 (s, 1H), 8.26 (s, 1H), 8.04 (s, 1H), 7.87 (s, 1H), 7.60 (d, <i>J</i> = 8.0 Hz, 1H), 7.58–7.47 (m, 2H), 7.38 (d, <i>J</i> = 7.1 Hz, 2H), 7.33 (d, <i>J</i> = 7.5 Hz, 1H), 4.89–4.65 (m, 1H), 3.42 (br. s, 2H), 3.12 (d, <i>J</i> = 7.1 Hz, 2H), 2.43 (s, 3H), 2.25 (dd, <i>J</i> = 22.2, 11.0 Hz, 2H), 1.99 (d, <i>J</i> = 10.7 Hz, 2H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>27</sub>H<sub>26</sub>F<sub>3</sub>N<sub>8</sub>O [M + H]<sup>+</sup> 535.2182; found, 535.2200.</div></div><div id="sec5_16_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100">5.16.52 1-(3-((4-Amino-1-(1-methylpiperidin-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-3-(3-(trifluoromethyl)phenyl)urea (<b>17b</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.19 (s, 1H), 8.93 (s, 1H), 8.26 (s, 1H), 8.03 (s, 1H), 7.81 (d, <i>J</i> = 2.2 Hz, 1H), 7.59 (d, <i>J</i> = 8.3 Hz, 1H), 7.52 (t, <i>J</i> = 7.9 Hz, 1H), 7.43 (dd, <i>J</i> = 8.3, 2.2 Hz, 1H), 7.32 (d, <i>J</i> = 7.5 Hz, 1H), 7.28 (d, <i>J</i> = 8.4 Hz, 1H), 4.79–4.49 (m, 1H), 2.99 (br. s, 2H), 2.44 (s, 3H), 2.31 (s, 3H), 2.20 (dd, <i>J</i> = 18.5, 7.4 Hz, 4H), 1.93 (d, <i>J</i> = 11.4 Hz, 2H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>28</sub>H<sub>28</sub>F<sub>3</sub>N<sub>8</sub>O [M + H]<sup>+</sup> 549.2338; found, 549.2357.</div></div><div id="sec5_16_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101">5.16.53 1-(3-((4-Amino-1-(1-methylpiperidin-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-3-yl)ethynyl)-4-chlorophenyl)-3-(3-(trifluoromethyl)phenyl)urea (<b>17c</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.59 (s, 1H), 9.51 (s, 1H), 8.29 (s, 1H), 8.02 (s, 1H), 7.98 (t, <i>J</i> = 1.4 Hz, 1H), 7.60 (d, <i>J</i> = 8.5 Hz, 1H), 7.55 (d, <i>J</i> = 1.4 Hz, 2H), 7.52 (d, <i>J</i> = 8.1 Hz, 1H), 7.33 (d, <i>J</i> = 7.6 Hz, 1H), 4.83 (t, <i>J</i> = 11.2 Hz, 1H), 3.24 (d, <i>J</i> = 10.6 Hz, 2H), 2.70 (br. s, 2H), 2.52 (s, 3H), 2.31 (dd, <i>J</i> = 22.7, 10.7 Hz, 2H), 2.06 (d, <i>J</i> = 12.1 Hz, 2H). HRMS <i>m</i>/<i>z</i> (ESI) calcd for C<sub>27</sub>H<sub>25</sub>ClF<sub>3</sub>N<sub>8</sub>O [M + H]<sup>+</sup> 569.1792; found, 569.1805.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i102"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00943">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25422" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25422" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b00943" class="ext-link">10.1021/acs.jmedchem.6b00943</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Chemical data of key intermediates, acute toxicity evaluation of compound <b>1</b> and <b>13an</b>, mappings of <b>13b</b> and <b>13ai</b> with the pharmacophore hypothesis of hERG blockers, and kinase profiling results of <b>13an</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00943/suppl_file/jm6b00943_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">SMILES data (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00943/suppl_file/jm6b00943_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00943/suppl_file/jm6b00943_si_001.pdf">jm6b00943_si_001.pdf (1.38 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00943/suppl_file/jm6b00943_si_002.csv">jm6b00943_si_002.csv (6.47 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b00943" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54764" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54764" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sheng-Yong Yang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center, West China Hospital,
and Collaborative Innovation Center for Biotherapy, Sichuan University, Sichuan 610041, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#f68f979891858fb6859583d8939283d89598"><span class="__cf_email__" data-cfemail="fe879f90998d87be8d9d8bd09b9a8bd09d90">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chun-Hui Zhang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center, West China Hospital,
and Collaborative Innovation Center for Biotherapy, Sichuan University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kai Chen</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center, West China Hospital,
and Collaborative Innovation Center for Biotherapy, Sichuan University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yan Jiao</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center, West China Hospital,
and Collaborative Innovation Center for Biotherapy, Sichuan University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lin-Li Li</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Drug Targeting and Drug Delivery System of Ministry
of Education, West China School of Pharmacy, Sichuan University, Chengdu, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ya-Ping Li</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center, West China Hospital,
and Collaborative Innovation Center for Biotherapy, Sichuan University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rong-Jie Zhang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center, West China Hospital,
and Collaborative Innovation Center for Biotherapy, Sichuan University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ming-Wu Zheng</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center, West China Hospital,
and Collaborative Innovation Center for Biotherapy, Sichuan University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lei Zhong</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center, West China Hospital,
and Collaborative Innovation Center for Biotherapy, Sichuan University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shen-Zhen Huang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center, West China Hospital,
and Collaborative Innovation Center for Biotherapy, Sichuan University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chun-Li Song</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Drug Targeting and Drug Delivery System of Ministry
of Education, West China School of Pharmacy, Sichuan University, Chengdu, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wan-Ting Lin</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center, West China Hospital,
and Collaborative Innovation Center for Biotherapy, Sichuan University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jiao Yang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center, West China Hospital,
and Collaborative Innovation Center for Biotherapy, Sichuan University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rong Xiang</span> - <span class="hlFld-Affiliation affiliation">Department
of Clinical Medicine, School of Medicine, Nankai University, Tianjin 300071, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bing Peng</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center, West China Hospital,
and Collaborative Innovation Center for Biotherapy, Sichuan University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jun-Hong Han</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center, West China Hospital,
and Collaborative Innovation Center for Biotherapy, Sichuan University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guang-Wen Lu</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center, West China Hospital,
and Collaborative Innovation Center for Biotherapy, Sichuan University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yu-Quan Wei</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Biotherapy and Cancer Center, West China Hospital,
and Collaborative Innovation Center for Biotherapy, Sichuan University, Sichuan 610041, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>C.-H.Z., K.C., Y.J., and L.-L.L. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d86e7954-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i104">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02170" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02170" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by the 973 Program (2013CB967204), the National Natural Science Foundation of China (81325021, 81473140, and 81573349), and the Program for Changjiang Scholars and Innovative Research Team in University (IRT13031).</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i105" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i105"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i106" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i106"> Abbreviations Used</h2><tr><td class="NLM_term">TNBC</td><td class="NLM_def"><p class="first last">triple-negative breast cancer</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human Ether-a-go-go Related Gene</p></td></tr><tr><td class="NLM_term">FAK</td><td class="NLM_def"><p class="first last">focal adhesion kinase</p></td></tr><tr><td class="NLM_term">ERK</td><td class="NLM_def"><p class="first last">extracellular regulated protein kinases</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">Fra1</td><td class="NLM_def"><p class="first last">fos-related antigen 1</p></td></tr><tr><td class="NLM_term">SFKs</td><td class="NLM_def"><p class="first last">Src family kinases</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">Ar</td><td class="NLM_def"><p class="first last">aromatic</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">EA</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i107">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62165" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62165" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 44 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Foulkes, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reis-Filho, J. S.</span><span> </span><span class="NLM_article-title">Triple-negative breast cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">1938</span><span class="NLM_x">–</span> <span class="NLM_lpage">1948</span><span class="refDoi"> DOI: 10.1056/NEJMra1001389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1056%2FNEJMra1001389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=21067385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVCltr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1938-1948&author=W.+D.+Foulkesauthor=I.+E.+Smithauthor=J.+S.+Reis-Filho&title=Triple-negative+breast+cancer&doi=10.1056%2FNEJMra1001389"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Triple-negative breast cancer</span></div><div class="casAuthors">Foulkes, William D.; Smith, Ian E.; Reis-Filho, Jorge S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1938-1948</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiN8P8IsovvLVg90H21EOLACvtfcHk0liQDmwNdHtC6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVCltr7P&md5=641fe4726e6a7118208aa6b3502c9df6</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1001389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1001389%26sid%3Dliteratum%253Aachs%26aulast%3DFoulkes%26aufirst%3DW.%2BD.%26aulast%3DSmith%26aufirst%3DI.%2BE.%26aulast%3DReis-Filho%26aufirst%3DJ.%2BS.%26atitle%3DTriple-negative%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1938%26epage%3D1948%26doi%3D10.1056%2FNEJMra1001389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Schmadeka, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmon, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, M.</span><span> </span><span class="NLM_article-title">Triple-negative breast carcinoma: current and emerging concepts</span> <span class="citation_source-journal">Am. J. Clin. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">141</span><span class="NLM_x">, </span> <span class="NLM_fpage">462</span><span class="NLM_x">–</span> <span class="NLM_lpage">477</span><span class="refDoi"> DOI: 10.1309/AJCPQN8GZ8SILKGN</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1309%2FAJCPQN8GZ8SILKGN" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=24619745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosVyks7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2014&pages=462-477&author=R.+Schmadekaauthor=B.+E.+Harmonauthor=M.+Singh&title=Triple-negative+breast+carcinoma%3A+current+and+emerging+concepts&doi=10.1309%2FAJCPQN8GZ8SILKGN"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Triple-negative breast carcinoma current and emerging concepts</span></div><div class="casAuthors">Schmadeka, Robert; Harmon, Bryan E.; Singh, Meenakshi</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Clinical Pathology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">462-477</span>CODEN:
                <span class="NLM_cas:coden">AJCPAI</span>;
        ISSN:<span class="NLM_cas:issn">0002-9173</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Pathology</span>)
        </div><div class="casAbstract">A review.  Objectives: Triple-neg. breast cancer is regarded as an aggressive disease that affects a young patient population and for which effective targeted therapy is not yet available.  Methods: Intense efforts have been made to gain a better understanding of this heterogeneous group of tumors from the histol. to the genomic and mol. levels.  Results: Progress has been made, including the ability to subtype these tumors and the discovery of biomarkers toward which current therapeutic efforts are focused.  Many novel targets under exploration have the potential to affect the clin. course of this disease.  Conclusions This article reviews the current concepts regarding the clinicopathol. features of triple-neg. breast carcinoma, its histol. subtypes, mol. classification, the prognostic and therapeutic potential of biomarkers, and emerging targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPAq8FdcryxrVg90H21EOLACvtfcHk0liQDmwNdHtC6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosVyks7s%253D&md5=8cae66e043639ea6f8f49383c3772481</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1309%2FAJCPQN8GZ8SILKGN&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1309%252FAJCPQN8GZ8SILKGN%26sid%3Dliteratum%253Aachs%26aulast%3DSchmadeka%26aufirst%3DR.%26aulast%3DHarmon%26aufirst%3DB.%2BE.%26aulast%3DSingh%26aufirst%3DM.%26atitle%3DTriple-negative%2520breast%2520carcinoma%253A%2520current%2520and%2520emerging%2520concepts%26jtitle%3DAm.%2520J.%2520Clin.%2520Pathol.%26date%3D2014%26volume%3D141%26spage%3D462%26epage%3D477%26doi%3D10.1309%2FAJCPQN8GZ8SILKGN" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Prat, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adamo, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheang, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anders, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carey, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perou, C. M.</span><span> </span><span class="NLM_article-title">Molecular characterization of basal-like and non-basal-like triple-negative breast cancer</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">123</span><span class="NLM_x">–</span> <span class="NLM_lpage">133</span><span class="refDoi"> DOI: 10.1634/theoncologist.2012-0397</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1634%2Ftheoncologist.2012-0397" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=23404817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltFChsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=123-133&author=A.+Pratauthor=B.+Adamoauthor=M.+C.+Cheangauthor=C.+K.+Andersauthor=L.+A.+Careyauthor=C.+M.+Perou&title=Molecular+characterization+of+basal-like+and+non-basal-like+triple-negative+breast+cancer&doi=10.1634%2Ftheoncologist.2012-0397"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular characterization of basal-like and non-basal-like triple-negative breast cancer</span></div><div class="casAuthors">Prat, Aleix; Adamo, Barbara; Cheang, Maggie C. U.; Anders, Carey K.; Carey, Lisa A.; Perou, Charles M.</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-133</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">Triple-neg. (TN) and basal-like (BL) breast cancer definitions have been used interchangeably to identify breast cancers that lack expression of the hormone receptors and overexpression and/or amplification of HER2.  However, both classifications show substantial discordance rates when compared to each other.  Here, we molecularly characterize TN tumors and BL tumors, comparing and contrasting the results in terms of common patterns and distinct patterns for each.  In total, when testing 412 TN and 473 BL tumors, 21.4% and 31.5% were identified as non-BL and non-TN, resp.  TN tumors identified as luminal or HER2-enriched (HER2E) showed undistinguishable overall gene expression profiles when compared vs. luminal or HER2E tumors that were not TN.  Similar findings were obsd. within BL tumors regardless of their TN status, which suggests that mol. subtype is preserved regardless of individual marker results.  Interestingly, most TN tumors identified as HER2E showed low HER2 expression and lacked HER2 amplification, despite the similar overall gene expression profiles to HER2E tumors that were clin. HER2-pos.  Lastly, addnl. genomic classifications were examd. within TN and BL cancers, most of which were highly concordant with tumor intrinsic subtype.  These results suggest that future clin. trials focused on TN disease should consider stratifying patients based upon BL vs. non-BL gene expression profiles, which appears to be the main biol. difference seen in patients with TN breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrir3DV-VTCJbVg90H21EOLACvtfcHk0lgQdlBHcIbatQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltFChsLs%253D&md5=015894461c9b3a6008a682e0c9251ac6</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2012-0397&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2012-0397%26sid%3Dliteratum%253Aachs%26aulast%3DPrat%26aufirst%3DA.%26aulast%3DAdamo%26aufirst%3DB.%26aulast%3DCheang%26aufirst%3DM.%2BC.%26aulast%3DAnders%26aufirst%3DC.%2BK.%26aulast%3DCarey%26aufirst%3DL.%2BA.%26aulast%3DPerou%26aufirst%3DC.%2BM.%26atitle%3DMolecular%2520characterization%2520of%2520basal-like%2520and%2520non-basal-like%2520triple-negative%2520breast%2520cancer%26jtitle%3DOncologist%26date%3D2013%26volume%3D18%26spage%3D123%26epage%3D133%26doi%3D10.1634%2Ftheoncologist.2012-0397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Lehmann, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietenpol, J. A.</span><span> </span><span class="NLM_article-title">Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes</span> <span class="citation_source-journal">J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">232</span><span class="NLM_x">, </span> <span class="NLM_fpage">142</span><span class="NLM_x">–</span> <span class="NLM_lpage">150</span><span class="refDoi"> DOI: 10.1002/path.4280</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1002%2Fpath.4280" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=24114677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A280%3ADC%252BC2c%252FktVyjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=232&publication_year=2014&pages=142-150&author=B.+D.+Lehmannauthor=J.+A.+Pietenpol&title=Identification+and+use+of+biomarkers+in+treatment+strategies+for+triple-negative+breast+cancer+subtypes&doi=10.1002%2Fpath.4280"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes</span></div><div class="casAuthors">Lehmann Brian D; Pietenpol Jennifer A</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of pathology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">232</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">142-50</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Triple-negative breast cancer (TNBC) is a heterogeneous disease with distinct molecular subtypes that respond differentially to chemotherapy and targeted agents.  The absence of high-frequency molecular alterations and a limited number of known biomarkers have limited the development of therapeutic strategies for the disease.  Herein, we summarize the results of the first round of targeted therapy approaches in TNBC and discuss new preclinical strategies.  Common themes emerge from the proposed strategies, such as the use of biomarkers to identify tumours with genomic instability, targeting adapted molecular states resulting from tumour suppressor loss, and targeting altered metabolic pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTtCSjtyCVZVynGiHuhFGv8fW6udTcc2eYRPMOMbbuBT7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c%252FktVyjsA%253D%253D&md5=a7a8e781d659aa5f0cf41feefaf8682c</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1002%2Fpath.4280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.4280%26sid%3Dliteratum%253Aachs%26aulast%3DLehmann%26aufirst%3DB.%2BD.%26aulast%3DPietenpol%26aufirst%3DJ.%2BA.%26atitle%3DIdentification%2520and%2520use%2520of%2520biomarkers%2520in%2520treatment%2520strategies%2520for%2520triple-negative%2520breast%2520cancer%2520subtypes%26jtitle%3DJ.%2520Pathol.%26date%3D2014%26volume%3D232%26spage%3D142%26epage%3D150%26doi%3D10.1002%2Fpath.4280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">von Minckwitz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M.</span><span> </span><span class="NLM_article-title">Neoadjuvant treatments for triple-negative breast cancer (TNBC)</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl 6</span><span class="NLM_x">) </span> <span class="NLM_fpage">vi35</span><span class="NLM_x">–</span> <span class="NLM_lpage">vi39</span><span class="refDoi"> DOI: 10.1093/annonc/mds193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1093%2Fannonc%2Fmds193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=23012300" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=vi35-vi39&issue=Suppl+6&author=G.+von+Minckwitzauthor=M.+Martin&title=Neoadjuvant+treatments+for+triple-negative+breast+cancer+%28TNBC%29&doi=10.1093%2Fannonc%2Fmds193"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmds193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmds193%26sid%3Dliteratum%253Aachs%26aulast%3Dvon%2BMinckwitz%26aufirst%3DG.%26aulast%3DMartin%26aufirst%3DM.%26atitle%3DNeoadjuvant%2520treatments%2520for%2520triple-negative%2520breast%2520cancer%2520%2528TNBC%2529%26jtitle%3DAnn.%2520Oncol.%26date%3D2012%26volume%3D23%26issue%3DSuppl%25206%26spage%3Dvi35%26epage%3Dvi39%26doi%3D10.1093%2Fannonc%2Fmds193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Masuda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baggerly, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez-Angulo, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meric-Bernstam, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valero, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehmann, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietenpol, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hortobagyi, G. N.</span><span> </span><span class="NLM_article-title">Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">5533</span><span class="NLM_x">–</span> <span class="NLM_lpage">5540</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-0799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1158%2F1078-0432.CCR-13-0799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=23948975" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFynsL7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=5533-5540&author=H.+Masudaauthor=K.+A.+Baggerlyauthor=Y.+Wangauthor=Y.+Zhangauthor=A.+M.+Gonzalez-Anguloauthor=F.+Meric-Bernstamauthor=V.+Valeroauthor=B.+D.+Lehmannauthor=J.+A.+Pietenpolauthor=G.+N.+Hortobagyi&title=Differential+response+to+neoadjuvant+chemotherapy+among+7+triple-negative+breast+cancer+molecular+subtypes&doi=10.1158%2F1078-0432.CCR-13-0799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes</span></div><div class="casAuthors">Masuda, Hiroko; Baggerly, Keith A.; Wang, Ying; Zhang, Ya; Gonzalez-Angulo, Ana Maria; Meric-Bernstam, Funda; Valero, Vicente; Lehmann, Brian D.; Pietenpol, Jennifer A.; Hortobagyi, Gabriel N.; Symmans, W. Fraser; Ueno, Naoto T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5533-5540</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The clin. relevancy of the 7-subtype classification of triple-neg. breast cancer (TNBC) reported by Lehmann and colleagues is unknown.  We investigated the clin. relevancy of TNBC heterogeneity by detg. pathol. complete response (pCR) rates after neoadjuvant chemotherapy, based on TNBC subtypes.  Exptl. Design: We revalidated the Lehmann and colleagues expts. using Affymetrix CEL files from public datasets.  We applied these methods to 146 patients with TNBC with gene expression microarrays obtained from June 2000 to March 2010 at our institution.  Of those, 130 had received std. neoadjuvant chemotherapy and had evaluable pathol. response data.  We classified the TNBC samples by subtype and then correlated subtype and pCR status using Fisher exact test and a logistic regression model.  We also assessed survival and compared the subtypes with PAM50 intrinsic subtypes and residual cancer burden (RCB) index.  Results: TNBC subtype and pCR status were significantly assocd. (P = 0.04379).  The basal-like 1 (BL1) subtype had the highest pCR rate (52%); basal-like 2 (BL2) and luminal androgen receptor had the lowest (0% and 10%, resp.).  TNBC subtype was an independent predictor of pCR status (P = 0.022) by a likelihood ratio test.  The subtypes better predicted pCR status than did the PAM50 intrinsic subtypes (basal-like vs. non basal-like).  Conclusions: Classifying TNBC by 7 subtypes predicts high vs. low pCR rate.  We confirm the clin. relevancy of the 7 subtypes of TNBC.  We need to prospectively validate whether the pCR rate differences translate into long-term outcome differences.  The 7-subtype classification may spur innovative personalized medicine strategies for patients with TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqWCdcnpnUTrVg90H21EOLACvtfcHk0lgQdlBHcIbatQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFynsL7P&md5=a98409bc9f49e7948b21cde4c39df3ea</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0799%26sid%3Dliteratum%253Aachs%26aulast%3DMasuda%26aufirst%3DH.%26aulast%3DBaggerly%26aufirst%3DK.%2BA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DGonzalez-Angulo%26aufirst%3DA.%2BM.%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26aulast%3DValero%26aufirst%3DV.%26aulast%3DLehmann%26aufirst%3DB.%2BD.%26aulast%3DPietenpol%26aufirst%3DJ.%2BA.%26aulast%3DHortobagyi%26aufirst%3DG.%2BN.%26atitle%3DDifferential%2520response%2520to%2520neoadjuvant%2520chemotherapy%2520among%25207%2520triple-negative%2520breast%2520cancer%2520molecular%2520subtypes%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D5533%26epage%3D5540%26doi%3D10.1158%2F1078-0432.CCR-13-0799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Bayraktar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glück, S.</span><span> </span><span class="NLM_article-title">Molecularly targeted therapies for metastatic triple-negative breast cancer</span> <span class="citation_source-journal">Breast Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">138</span><span class="NLM_x">, </span> <span class="NLM_fpage">21</span><span class="NLM_x">–</span> <span class="NLM_lpage">35</span><span class="refDoi"> DOI: 10.1007/s10549-013-2421-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1007%2Fs10549-013-2421-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=23358903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsFOht7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2013&pages=21-35&author=S.+Bayraktarauthor=S.+Gl%C3%BCck&title=Molecularly+targeted+therapies+for+metastatic+triple-negative+breast+cancer&doi=10.1007%2Fs10549-013-2421-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Molecularly targeted therapies for metastatic triple-negative breast cancer</span></div><div class="casAuthors">Bayraktar, Soley; Glueck, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-35</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Triple-neg. breast cancer (TNBC) refers to a heterogeneous group of tumors that do not express the estrogen/progesterone-receptor (ER/PR), and human epidermal growth factor receptor-2 (HER2).  TNBC is an aggressive histol. subtype with limited treatment options and very poor prognosis following progression after std. chemotherapy regimens.  There have been significant improvements in the outcome of other subtypes of breast cancer, including ER-pos./HER2 overexpressed tumors, attributed to the addn. of targeted therapy, including hormonal agents and trastuzumab.  However, no specific targeted agents are currently available for the treatment of TNBC.  This review aims to collate and describe the most recent data on targeted therapies that have demonstrated efficacy in the management of metastatic TNBC.  Targeted agents that have been investigated in the treatment of metastatic TNBC include inhibitors of poly(ADP-ribose) polymerase, angiogenesis, mammalian target of rapamycin, epidermal growth factor receptor, HDAC, Jak2, and Src.  Several of these agents have shown considerable promise.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOoaRuEc8USbVg90H21EOLACvtfcHk0ljH9yAQftEwYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsFOht7Y%253D&md5=45c8c03991e456036dd3f2f34a2713eb</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2Fs10549-013-2421-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-013-2421-5%26sid%3Dliteratum%253Aachs%26aulast%3DBayraktar%26aufirst%3DS.%26aulast%3DGl%25C3%25BCck%26aufirst%3DS.%26atitle%3DMolecularly%2520targeted%2520therapies%2520for%2520metastatic%2520triple-negative%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2013%26volume%3D138%26spage%3D21%26epage%3D35%26doi%3D10.1007%2Fs10549-013-2421-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Finn, R. S.</span><span> </span><span class="NLM_article-title">Targeting Src in breast cancer</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1379</span><span class="NLM_x">–</span> <span class="NLM_lpage">1386</span><span class="refDoi"> DOI: 10.1093/annonc/mdn291</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1093%2Fannonc%2Fmdn291" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=18487549" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A280%3ADC%252BD1cvotV2rsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2008&pages=1379-1386&author=R.+S.+Finn&title=Targeting+Src+in+breast+cancer&doi=10.1093%2Fannonc%2Fmdn291"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Src in breast cancer</span></div><div class="casAuthors">Finn R S</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1379-86</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The clinical benefit of blocking oncogenic pathways in breast cancer and other malignancies has validated this approach and ushered in the era of molecularly targeted therapeutics.  Src and its family members make up the largest group of nonreceptor tyrosine kinases.  In laboratory models, these proteins have been shown to play a critical role in cellular growth and proliferation, angiogenesis, and invasion and metastasis.  In addition, Src plays an important role in osteoclast activation and bone resorption, which are often aberrantly activated in the setting of bone metastases.  Given its role in these functions, blocking Src kinase would be predicted to have a broad therapeutic benefit in patients with Src-dependent cancers.  In this review, we highlight the rationale for targeting Src in breast cancer, including laboratory and clinical data implicating it in these signaling pathways, and review small-molecule tyrosine kinase inhibitors currently in clinical development.  Identifying which patients should be selected for Src-directed therapies will be important to the clinical success of these agents.  Importantly, recent preclinical data support a role for this class of inhibitors in basal-type/triple-negative breast cancer, which represents a group of patients with limited effective treatment options.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSq3-Zi9cm6LUNHe_gFldTbfW6udTcc2eZOW1avLQZK9bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cvotV2rsw%253D%253D&md5=b4f29b2ada4dcb6c89c0301a8440c617</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdn291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdn291%26sid%3Dliteratum%253Aachs%26aulast%3DFinn%26aufirst%3DR.%2BS.%26atitle%3DTargeting%2520Src%2520in%2520breast%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2008%26volume%3D19%26spage%3D1379%26epage%3D1386%26doi%3D10.1093%2Fannonc%2Fmdn291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Kim, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haura, E. B.</span><span> </span><span class="NLM_article-title">Src kinases as therapeutic targets for cancer</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">587</span><span class="NLM_x">–</span> <span class="NLM_lpage">595</span><span class="refDoi"> DOI: 10.1038/nrclinonc.2009.129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1038%2Fnrclinonc.2009.129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=19787002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFyntbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2009&pages=587-595&author=L.+C.+Kimauthor=L.+Songauthor=E.+B.+Haura&title=Src+kinases+as+therapeutic+targets+for+cancer&doi=10.1038%2Fnrclinonc.2009.129"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Src kinases as therapeutic targets for cancer</span></div><div class="casAuthors">Kim, Lori C.; Song, Lanxi; Haura, Eric B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">587-595</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Src family kinases have been extensively studied and found to be central mediators in multiple signaling pathways that are important in oncogenesis.  Preclin. studies have shown that SFK inhibitors can suppress tumor growth and metastases.  The authors of this Review discuss the potential use of these agents to target cancer in humans.  Src family kinases (SFKs) have a crit. role in cell adhesion, invasion, proliferation, survival, and angiogenesis during tumor development.  SFKs comprise nine family members that share similar structure and function.  Overexpression or high activation of SFKs occurs frequently in tumor tissues and they are central mediators in multiple signaling pathways that are important in oncogenesis.  SFKs can interact with tyrosine kinase receptors, such as EGFR and the VEGF receptor.  SFKs can affect cell proliferation via the Ras/ERK/MAPK pathway and can regulate gene expression via transcription factors such as STAT mols.  SFKs can also affect cell adhesion and migration via interaction with integrins, actins, GTPase-activating proteins, scaffold proteins, such as p130CAS and paxillin, and kinases such as focal adhesion kinases.  Furthermore, SFKs can regulate angiogenesis via gene expression of angiogenic growth factors, such as fibroblast growth factor, VEGF, and interleukin 8.  On the basis of these important findings, small-mol. SFK inhibitors have been developed and are undergoing early phase clin. testing.  In preclin. studies these agents can suppress tumor growth and metastases.  The agents seem to be safe in humans and could add to the therapeutic arsenal against subsets of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7mbcbDFh577Vg90H21EOLACvtfcHk0ljH9yAQftEwYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFyntbbP&md5=5e9e587e835265d1c83857be11411dba</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2009.129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2009.129%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DL.%2BC.%26aulast%3DSong%26aufirst%3DL.%26aulast%3DHaura%26aufirst%3DE.%2BB.%26atitle%3DSrc%2520kinases%2520as%2520therapeutic%2520targets%2520for%2520cancer%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D6%26spage%3D587%26epage%3D595%26doi%3D10.1038%2Fnrclinonc.2009.129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowery, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sahin, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aldape, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steeg, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, D.</span><span> </span><span class="NLM_article-title">SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">5764</span><span class="NLM_x">–</span> <span class="NLM_lpage">5774</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-12-1803</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1158%2F0008-5472.CAN-12-1803" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=5764-5774&author=S.+Zhangauthor=W.+C.+Huangauthor=L.+Zhangauthor=C.+Zhangauthor=F.+J.+Loweryauthor=Z.+Dingauthor=H.+Guoauthor=H.+Wangauthor=S.+Huangauthor=A.+A.+Sahinauthor=K.+D.+Aldapeauthor=P.+S.+Steegauthor=D.+Yu&title=SRC+family+kinases+as+novel+therapeutic+targets+to+treat+breast+cancer+brain+metastases&doi=10.1158%2F0008-5472.CAN-12-1803"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-12-1803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-12-1803%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DW.%2BC.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLowery%26aufirst%3DF.%2BJ.%26aulast%3DDing%26aufirst%3DZ.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DSahin%26aufirst%3DA.%2BA.%26aulast%3DAldape%26aufirst%3DK.%2BD.%26aulast%3DSteeg%26aufirst%3DP.%2BS.%26aulast%3DYu%26aufirst%3DD.%26atitle%3DSRC%2520family%2520kinases%2520as%2520novel%2520therapeutic%2520targets%2520to%2520treat%2520breast%2520cancer%2520brain%2520metastases%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26spage%3D5764%26epage%3D5774%26doi%3D10.1158%2F0008-5472.CAN-12-1803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Shields, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiede, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurzov, E. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauser, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molloy, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Toole, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daly, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherland, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLean, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiganis, T.</span><span> </span><span class="NLM_article-title">TCPTP regulates SFK and STAT3 signaling and is lost in triple-negative breast cancers</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">557</span><span class="NLM_x">–</span> <span class="NLM_lpage">570</span><span class="refDoi"> DOI: 10.1128/MCB.01016-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1128%2FMCB.01016-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=23166300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVOitL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2013&pages=557-570&author=B.+J.+Shieldsauthor=F.+Wiedeauthor=E.+N.+Gurzovauthor=K.+Weeauthor=C.+Hauserauthor=H.+J.+Zhuauthor=T.+J.+Molloyauthor=S.+A.+O%E2%80%99Tooleauthor=R.+J.+Dalyauthor=R.+L.+Sutherlandauthor=C.+A.+Mitchellauthor=C.+A.+McLeanauthor=T.+Tiganis&title=TCPTP+regulates+SFK+and+STAT3+signaling+and+is+lost+in+triple-negative+breast+cancers&doi=10.1128%2FMCB.01016-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">TCPTP regulates SFK and STAT3 signaling and is lost in triple-negative breast cancers</span></div><div class="casAuthors">Shields, Benjamin J.; Wiede, Florian; Gurzov, Esteban N.; Wee, Kenneth; Hauser, Christine; Zhu, Hong-Jian; Molloy, Timothy J.; O'Toole, Sandra A.; Daly, Roger J.; Sutherland, Robert L.; Mitchell, Christina A.; McLean, Catriona A.; Tiganis, Tony</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">557-570</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Tyrosine phosphorylation-dependent signaling, as mediated by members of the epidermal growth factor receptor (EGFR) family (ErbB1 to -4) of protein tyrosine kinases (PTKs), Src family PTKs (SFKs), and cytokines such as interleukin-6 (IL-6) that signal via signal transducer and activator of transcription 3 (STAT3), is crit. to the development and progression of many human breast cancers.  EGFR, SFKs, and STAT3 can serve as substrates for the protein tyrosine phosphatase TCPTP (PTPN2).  Here we report that TCPTP protein levels are decreased in a subset of breast cancer cell lines in vitro and that TCPTP protein is absent in a large proportion of "triple-neg." primary human breast cancers.  Homozygous TCPTP deficiency in murine mammary fat pads in vivo is assocd. with elevated SFK and STAT3 signaling, whereas TCPTP deficiency in human breast cancer cell lines enhances SFK and STAT3 signaling.  On the other hand, TCPTP reconstitution in human breast cancer cell lines severely impaired cell proliferation and suppressed anchorage-independent growth in vitro and xenograft growth in vivo.  These studies establish TCPTP's potential to serve as a tumor suppressor in human breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYKrzpgI9BYrVg90H21EOLACvtfcHk0ljsX39ymaRIiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVOitL0%253D&md5=82593972a2f8ee8979199c2d10903114</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1128%2FMCB.01016-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.01016-12%26sid%3Dliteratum%253Aachs%26aulast%3DShields%26aufirst%3DB.%2BJ.%26aulast%3DWiede%26aufirst%3DF.%26aulast%3DGurzov%26aufirst%3DE.%2BN.%26aulast%3DWee%26aufirst%3DK.%26aulast%3DHauser%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DH.%2BJ.%26aulast%3DMolloy%26aufirst%3DT.%2BJ.%26aulast%3DO%25E2%2580%2599Toole%26aufirst%3DS.%2BA.%26aulast%3DDaly%26aufirst%3DR.%2BJ.%26aulast%3DSutherland%26aufirst%3DR.%2BL.%26aulast%3DMitchell%26aufirst%3DC.%2BA.%26aulast%3DMcLean%26aufirst%3DC.%2BA.%26aulast%3DTiganis%26aufirst%3DT.%26atitle%3DTCPTP%2520regulates%2520SFK%2520and%2520STAT3%2520signaling%2520and%2520is%2520lost%2520in%2520triple-negative%2520breast%2520cancers%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2013%26volume%3D33%26spage%3D557%26epage%3D570%26doi%3D10.1128%2FMCB.01016-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Tryfonopoulos, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corkery, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDermott, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evoy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierce, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donovan, N.</span><span> </span><span class="NLM_article-title">Src: a potential target for the treatment of triple-negative breast cancer</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">2234</span><span class="NLM_x">–</span> <span class="NLM_lpage">2240</span><span class="refDoi"> DOI: 10.1093/annonc/mdq757</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1093%2Fannonc%2Fmdq757" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=21357651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A280%3ADC%252BC3MflvFCqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=2234-2240&author=D.+Tryfonopoulosauthor=S.+Walshauthor=D.+Collinsauthor=L.+Flanaganauthor=C.+Quinnauthor=B.+Corkeryauthor=E.+McDermottauthor=D.+Evoyauthor=A.+Pierceauthor=N.+O%E2%80%99Donovan&title=Src%3A+a+potential+target+for+the+treatment+of+triple-negative+breast+cancer&doi=10.1093%2Fannonc%2Fmdq757"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Src: a potential target for the treatment of triple-negative breast cancer</span></div><div class="casAuthors">Tryfonopoulos D; Walsh S; Collins D M; Flanagan L; Quinn C; Corkery B; McDermott E W; Evoy D; Pierce A; O'Donovan N; Crown J; Duffy M J</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2234-40</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Triple-negative breast cancers lack expression of estrogen and progesterone receptors and overexpression of human epidermal growth factor receptor 2 (HER2).  Unlike other subgroups of patients with breast cancer, targeted therapy is currently unavailable for these patients.  The aim of this study was to investigate v-src sarcoma viral oncogene homolog (Src) as a potential target for the treatment of triple-negative breast cancer.  METHODS:  Expression of Src was measured in 87 triple-negative and 93 non-triple-negative breast cancers.  Dasatinib (an inhibitor of Src) was tested in a panel of breast cancer cell lines.  RESULTS:  Cytoplasmic expression of Src was detected in 83 (95%) triple-negative samples versus 78 (84%) non-triple-negative samples (P = 0.012), while membrane Src was detected in 78% triple-negative compared with 38% of non-triple-negative specimens (P < 0.0001).  Dasatinib inhibited growth in three of five triple-negative cell lines (IC(50) < 1 μM).  Dasatinib combined with cisplatin was synergistic in the three dasatinib-sensitive cell lines (combination index < 0.9).  Dasatinib, in combination with 5'-deoxy-5'-fluoruridine, displayed synergy or additivity.  Moderate synergy was observed with docetaxel (Taxotere) in two cell lines but the combination was antagonistic in HCC-1143 cells.  CONCLUSIONS:  We conclude that dasatinib with cisplatin is a rational drug combination for testing in triple-negative breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQRLX-5M5TiggxyojvcjibhfW6udTcc2eZ5wF8uu5z6vrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MflvFCqsQ%253D%253D&md5=f91860cdb5da0f86ff6e0ef46eb3ff2f</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdq757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdq757%26sid%3Dliteratum%253Aachs%26aulast%3DTryfonopoulos%26aufirst%3DD.%26aulast%3DWalsh%26aufirst%3DS.%26aulast%3DCollins%26aufirst%3DD.%26aulast%3DFlanagan%26aufirst%3DL.%26aulast%3DQuinn%26aufirst%3DC.%26aulast%3DCorkery%26aufirst%3DB.%26aulast%3DMcDermott%26aufirst%3DE.%26aulast%3DEvoy%26aufirst%3DD.%26aulast%3DPierce%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Donovan%26aufirst%3DN.%26atitle%3DSrc%253A%2520a%2520potential%2520target%2520for%2520the%2520treatment%2520of%2520triple-negative%2520breast%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2011%26volume%3D22%26spage%3D2234%26epage%3D2240%26doi%3D10.1093%2Fannonc%2Fmdq757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Finn, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dering, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ginther, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glaspy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tchekmedyian, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slamon, D. J.</span><span> </span><span class="NLM_article-title">Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/″triple-negative″ breast cancer cell lines growing in vitro</span> <span class="citation_source-journal">Breast Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">319</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span><span class="refDoi"> DOI: 10.1007/s10549-006-9463-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1007%2Fs10549-006-9463-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=17268817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFSlsr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2007&pages=319-326&author=R.+S.+Finnauthor=J.+Deringauthor=C.+Gintherauthor=C.+A.+Wilsonauthor=P.+Glaspyauthor=N.+Tchekmedyianauthor=D.+J.+Slamon&title=Dasatinib%2C+an+orally+active+small+molecule+inhibitor+of+both+the+src+and+abl+kinases%2C+selectively+inhibits+growth+of+basal-type%2F%E2%80%B3triple-negative%E2%80%B3+breast+cancer+cell+lines+growing+in+vitro&doi=10.1007%2Fs10549-006-9463-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro</span></div><div class="casAuthors">Finn, Richard S.; Dering, Judy; Ginther, Charles; Wilson, Cindy A.; Glaspy, Padraic; Tchekmedyian, Nishan; Slamon, Dennis J.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">319-326</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Dasatinib is an orally active small mol. kinase inhibitor of both the src and abl proteins.  To evaluate the potential role of dasatinib in breast cancer we used 39 human breast cancer cell lines that have been mol. profiled using Agilent Microarrays.  They represent both luminal and basal breast cancer subtypes based on the relative gene expression of cytokeratin (CK) 8/CK18 and CK5/CK17, resp., and those that have undergone an epithelial-to-mesenchymal transition (post-EMT) based on their expression of vimentin and the loss of CKs.  When treated with 1 μM dasatinib in vitro 8 of them were highly sensitive (>60% growth inhibition), 10 of them were moderately sensitive (40-59% growth inhibition), and 21 were resistant to dasatinib.  A highly significant relationship between breast cancer subtype and sensitivity to dasatinib was obsd. (χ2 = 9.66 and P = 0.008).  Specifically, basal-type and post-EMT breast cancer cell lines were most sensitive to growth inhibition by dasatinib.  In an attempt to identify potential predictive markers of dasatinib response other than breast cancer subtype we analyzed the baseline gene expression profiles for differentially expressed genes.  We identified a set of three biol. relevant genes whose elevated expression is assocd. with dasatinib inhibition including moesin, caveolin-1, and yes-assocd. protein-1 with a sensitivity and specificity of 88 and 86%, resp.  Importantly, these data provide scientific rationale for the clin. development of dasatinib in the treatment of women with "triple-neg." breast cancer, a subtype that is categorized as being aggressive and lacking effective treatments (i.e. hormonal manipulation or trastuzumab).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuiY_J2m5UELVg90H21EOLACvtfcHk0ljsX39ymaRIiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFSlsr3N&md5=82beaf55532a0440f64e215ec57df02e</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1007%2Fs10549-006-9463-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-006-9463-x%26sid%3Dliteratum%253Aachs%26aulast%3DFinn%26aufirst%3DR.%2BS.%26aulast%3DDering%26aufirst%3DJ.%26aulast%3DGinther%26aufirst%3DC.%26aulast%3DWilson%26aufirst%3DC.%2BA.%26aulast%3DGlaspy%26aufirst%3DP.%26aulast%3DTchekmedyian%26aufirst%3DN.%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26atitle%3DDasatinib%252C%2520an%2520orally%2520active%2520small%2520molecule%2520inhibitor%2520of%2520both%2520the%2520src%2520and%2520abl%2520kinases%252C%2520selectively%2520inhibits%2520growth%2520of%2520basal-type%252F%25E2%2580%25B3triple-negative%25E2%2580%25B3%2520breast%2520cancer%2520cell%2520lines%2520growing%2520in%2520vitro%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2007%26volume%3D105%26spage%3D319%26epage%3D326%26doi%3D10.1007%2Fs10549-006-9463-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Finn, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bengala, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roche, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sparano, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strauss, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairchild, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sy, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, L. J.</span><span> </span><span class="NLM_article-title">Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">6905</span><span class="NLM_x">–</span> <span class="NLM_lpage">6913</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-0288</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1158%2F1078-0432.CCR-11-0288" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=22028489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVWlsrzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=6905-6913&author=R.+S.+Finnauthor=C.+Bengalaauthor=N.+Ibrahimauthor=H.+Rocheauthor=J.+Sparanoauthor=L.+C.+Straussauthor=J.+Fairchildauthor=O.+Syauthor=L.+J.+Goldstein&title=Dasatinib+as+a+single+agent+in+triple-negative+breast+cancer%3A+results+of+an+open-label+phase+2+study&doi=10.1158%2F1078-0432.CCR-11-0288"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study</span></div><div class="casAuthors">Finn, Richard S.; Bengala, Carmelo; Ibrahim, Nuhad; Roche, Henri; Sparano, Joseph; Strauss, Lewis C.; Fairchild, Justin; Sy, Oumar; Goldstein, Lori J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6905-6913</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Dasatinib is a potent, oral SRC-family kinase inhibitor with preclin. antiproliferative, antimetastatic, and antiosteoclastic activity suggesting dasatinib sensitivity in triple-neg., or basal-like, breast cancer cell lines.  This phase 2 trial assessed efficacy and safety of single-agent dasatinib in patients with advanced triple-neg. breast cancer (TNBC).  Exptl. Design: Female patients with measurable, locally advanced or metastatic TNBC initially received dasatinib 100 mg twice daily (BID); to improve tolerability, the protocol was amended and subsequent patients received 70 mg BID.  Primary endpoint was Response Evaluation Criteria in Solid Tumors-defined objective response rate (ORR); secondary endpoints included progression-free survival (PFS), disease control rate (DCR), safety, and limited pharmacokinetics.  RESULTS: Of the 44 treated patients, 43 were response evaluable.  ORR was 4.7%: two patients had confirmed partial responses lasting 14 and 58 wk, resp.  Of 11 patients with stable disease, two continued for more than 16 wk, thus protocol-defined DCR was 9.3%.  Median PFS was 8.3 wk (95% CI: 7.3-15.3).  Five patients discontinued before first tumor assessment.  No grade 4 adverse events (AE) were reported; grade 3 AEs occurring in more than 5% of patients were fatigue (9.1%), diarrhea, pleural effusion, and dyspnea (all 6.8%).  Lab. abnormalities were uncommon.  Dasatinib at 100 mg BID was not well tolerated; rates of treatment interruption, dose redn., and serious AEs were lower with dasatinib 70 mg BID.  CONCLUSIONS: Single-agent dasatinib has limited activity in unselected patients with TNBC.  Dasatinib 70 mg BID was better tolerated than 100 mg BID.  Future studies will investigate dasatinib in other breast cancer settings, including chemotherapy combinations.  Clin Cancer Res; 17(21); 6905-13.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1kTbssh-wALVg90H21EOLACvtfcHk0lhVDlPLKfm9qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVWlsrzE&md5=a9133015486c0f5d61a2b6cc33ab7e53</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-0288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-0288%26sid%3Dliteratum%253Aachs%26aulast%3DFinn%26aufirst%3DR.%2BS.%26aulast%3DBengala%26aufirst%3DC.%26aulast%3DIbrahim%26aufirst%3DN.%26aulast%3DRoche%26aufirst%3DH.%26aulast%3DSparano%26aufirst%3DJ.%26aulast%3DStrauss%26aufirst%3DL.%2BC.%26aulast%3DFairchild%26aufirst%3DJ.%26aulast%3DSy%26aufirst%3DO.%26aulast%3DGoldstein%26aufirst%3DL.%2BJ.%26atitle%3DDasatinib%2520as%2520a%2520single%2520agent%2520in%2520triple-negative%2520breast%2520cancer%253A%2520results%2520of%2520an%2520open-label%2520phase%25202%2520study%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D6905%26epage%3D6913%26doi%3D10.1158%2F1078-0432.CCR-11-0288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Das, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padmanabha, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moquin, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doweyko, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Fex, H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuster, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillooly, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behnia, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schieven, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wityak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span> </span><span class="NLM_article-title">2-Aminothiazole as a novel kinase inhibitor template. Structure–activity relationship studies toward the discovery of N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (Dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6819</span><span class="NLM_x">–</span> <span class="NLM_lpage">6832</span><span class="refDoi"> DOI: 10.1021/jm060727j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060727j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6819-6832&author=J.+Dasauthor=P.+Chenauthor=D.+Norrisauthor=R.+Padmanabhaauthor=J.+Linauthor=R.+V.+Moquinauthor=Z.+Shenauthor=L.+S.+Cookauthor=A.+M.+Doweykoauthor=S.+Pittauthor=S.+Pangauthor=D.+R.+Shenauthor=Q.+Fangauthor=H.+F.+de+Fexauthor=K.+W.+McIntyreauthor=D.+J.+Shusterauthor=K.+M.+Gilloolyauthor=K.+Behniaauthor=G.+L.+Schievenauthor=J.+Wityakauthor=J.+C.+Barrish&title=2-Aminothiazole+as+a+novel+kinase+inhibitor+template.+Structure%E2%80%93activity+relationship+studies+toward+the+discovery+of+N-%282-Chloro-6-methylphenyl%29-2-%5B%5B6-%5B4-%282-hydroxyethyl%29-1-+piperazinyl%29%5D-2-methyl-4-pyrimidinyl%5Damino%29%5D-1%2C3-thiazole-5-carboxamide+%28Dasatinib%2C+BMS-354825%29+as+a+potent+pan-Src+kinase+inhibitor&doi=10.1021%2Fjm060727j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm060727j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060727j%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DNorris%26aufirst%3DD.%26aulast%3DPadmanabha%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DMoquin%26aufirst%3DR.%2BV.%26aulast%3DShen%26aufirst%3DZ.%26aulast%3DCook%26aufirst%3DL.%2BS.%26aulast%3DDoweyko%26aufirst%3DA.%2BM.%26aulast%3DPitt%26aufirst%3DS.%26aulast%3DPang%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DD.%2BR.%26aulast%3DFang%26aufirst%3DQ.%26aulast%3Dde%2BFex%26aufirst%3DH.%2BF.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DShuster%26aufirst%3DD.%2BJ.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DBehnia%26aufirst%3DK.%26aulast%3DSchieven%26aufirst%3DG.%2BL.%26aulast%3DWityak%26aufirst%3DJ.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26atitle%3D2-Aminothiazole%2520as%2520a%2520novel%2520kinase%2520inhibitor%2520template.%2520Structure%25E2%2580%2593activity%2520relationship%2520studies%2520toward%2520the%2520discovery%2520of%2520N-%25282-Chloro-6-methylphenyl%2529-2-%255B%255B6-%255B4-%25282-hydroxyethyl%2529-1-%2520piperazinyl%2529%255D-2-methyl-4-pyrimidinyl%255Damino%2529%255D-1%252C3-thiazole-5-carboxamide%2520%2528Dasatinib%252C%2520BMS-354825%2529%2520as%2520a%2520potent%2520pan-Src%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6819%26epage%3D6832%26doi%3D10.1021%2Fjm060727j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Mayer, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abramson, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehmann, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietenpol, J. A.</span><span> </span><span class="NLM_article-title">New strategies for triple-negative breast cancer--deciphering the heterogeneity</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">782</span><span class="NLM_x">–</span> <span class="NLM_lpage">790</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-0583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1158%2F1078-0432.CCR-13-0583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=24536073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivVejsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=782-790&author=I.+A.+Mayerauthor=V.+G.+Abramsonauthor=B.+D.+Lehmannauthor=J.+A.+Pietenpol&title=New+strategies+for+triple-negative+breast+cancer%2D%2Ddeciphering+the+heterogeneity&doi=10.1158%2F1078-0432.CCR-13-0583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">New Strategies for Triple-Negative Breast Cancer-Deciphering the Heterogeneity</span></div><div class="casAuthors">Mayer, Ingrid A.; Abramson, Vandana G.; Lehmann, Brian D.; Pietenpol, Jennifer A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">782-790</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Triple-neg. breast cancer (TNBC) is a heterogeneous disease; gene expression analyses recently identified six distinct TNBC subtypes, each displaying a unique biol.  Exploring novel approaches to treatment of these subtypes is crit. because less than 30% of women with metastatic breast cancer survive five years and virtually all women with metastatic TNBC will ultimately die of their disease despite systemic therapy.  To date, not a single targeted therapy has been approved for the treatment of TNBC and cytotoxic chemotherapy remains the std. treatment.  We discuss the current and upcoming therapeutic strategies being explored in an attempt to "target" TNBC.  Clin Cancer Res; 20(4); 782-90. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdvsR_JjXMyLVg90H21EOLACvtfcHk0lib1FtXSqvYwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivVejsb0%253D&md5=4ce0876cb914096f913a7a637d7b63d5</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0583%26sid%3Dliteratum%253Aachs%26aulast%3DMayer%26aufirst%3DI.%2BA.%26aulast%3DAbramson%26aufirst%3DV.%2BG.%26aulast%3DLehmann%26aufirst%3DB.%2BD.%26aulast%3DPietenpol%26aufirst%3DJ.%2BA.%26atitle%3DNew%2520strategies%2520for%2520triple-negative%2520breast%2520cancer--deciphering%2520the%2520heterogeneity%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D782%26epage%3D790%26doi%3D10.1158%2F1078-0432.CCR-13-0583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Kalimutho, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mittal, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">López, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srihari, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khanna, K. K.</span><span> </span><span class="NLM_article-title">Targeted therapies for triple-negative breast cancer: combating a stubborn disease</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">822</span><span class="NLM_x">–</span> <span class="NLM_lpage">846</span><span class="refDoi"> DOI: 10.1016/j.tips.2015.08.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1016%2Fj.tips.2015.08.009" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=822-846&author=M.+Kalimuthoauthor=K.+Parsonsauthor=D.+Mittalauthor=J.+A.+L%C3%B3pezauthor=S.+Srihariauthor=K.+K.+Khanna&title=Targeted+therapies+for+triple-negative+breast+cancer%3A+combating+a+stubborn+disease&doi=10.1016%2Fj.tips.2015.08.009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2015.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2015.08.009%26sid%3Dliteratum%253Aachs%26aulast%3DKalimutho%26aufirst%3DM.%26aulast%3DParsons%26aufirst%3DK.%26aulast%3DMittal%26aufirst%3DD.%26aulast%3DL%25C3%25B3pez%26aufirst%3DJ.%2BA.%26aulast%3DSrihari%26aufirst%3DS.%26aulast%3DKhanna%26aufirst%3DK.%2BK.%26atitle%3DTargeted%2520therapies%2520for%2520triple-negative%2520breast%2520cancer%253A%2520combating%2520a%2520stubborn%2520disease%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2015%26volume%3D36%26spage%3D822%26epage%3D846%26doi%3D10.1016%2Fj.tips.2015.08.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Giltnane, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balko, J. M.</span><span> </span><span class="NLM_article-title">Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancer</span> <span class="citation_source-journal">Discovery Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">275</span><span class="NLM_x">–</span> <span class="NLM_lpage">283</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=24882719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A280%3ADC%252BC2cjot1Khsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2014&pages=275-283&author=J.+M.+Giltnaneauthor=J.+M.+Balko&title=Rationale+for+targeting+the+Ras%2FMAPK+pathway+in+triple-negative+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancer</span></div><div class="casAuthors">Giltnane Jennifer M; Balko Justin M</div><div class="citationInfo"><span class="NLM_cas:title">Discovery medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">95</span>),
    <span class="NLM_cas:pages">275-83</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">"Triple negative" breast cancer (TNBC) is the most aggressive and least common clinical subtype of breast cancer.  As its nomenclature implies, TNBC lacks specific biomarker expression marking response to an effective targeted therapy.  The incidence of TNBC is higher in young minority women who suffer from high rates of early recurrence and death from their disease.  Mounting preclinical evidence supports targeting the Ras/MAPK cell signaling pathway in the TNBC subtype, despite large genomic surveys such as The Cancer Genome Atlas demonstrating infrequent canonical mutations in this pathway.  Due to the early spread of TNBC, targeted treatment in the neoadjuvant setting may offer the effective therapeutic punch needed to eliminate micro-metastatic disease and reduce mortality.  Herein, we will review the evidence supporting clinical trials of targeted inhibitors of the Ras/MAPK pathway in TNBC, and discuss the obstacles and opportunities of this approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRuQgkh0x-AT-kdrW1FkXG-fW6udTcc2eYoro5e5IlqPbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cjot1Khsg%253D%253D&md5=b9ce19b319c945165e53f77dcc6e290b</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGiltnane%26aufirst%3DJ.%2BM.%26aulast%3DBalko%26aufirst%3DJ.%2BM.%26atitle%3DRationale%2520for%2520targeting%2520the%2520Ras%252FMAPK%2520pathway%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DDiscovery%2520Med.%26date%3D2014%26volume%3D17%26spage%3D275%26epage%3D283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Bianchi-Smiraglia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paesante, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bakin, A. V.</span><span> </span><span class="NLM_article-title">Integrin β5 contributes to the tumorigenic potential of breast cancer cells through the Src-FAK and MEK-ERK signaling pathways</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">3049</span><span class="NLM_x">–</span> <span class="NLM_lpage">3058</span><span class="refDoi"> DOI: 10.1038/onc.2012.320</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1038%2Fonc.2012.320" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=22824793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOisrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=3049-3058&author=A.+Bianchi-Smiragliaauthor=S.+Paesanteauthor=A.+V.+Bakin&title=Integrin+%CE%B25+contributes+to+the+tumorigenic+potential+of+breast+cancer+cells+through+the+Src-FAK+and+MEK-ERK+signaling+pathways&doi=10.1038%2Fonc.2012.320"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Integrin β5 contributes to the tumorigenic potential of breast cancer cells through the Src-FAK and MEK-ERK signaling pathways</span></div><div class="casAuthors">Bianchi-Smiraglia, A.; Paesante, S.; Bakin, A. V.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">3049-3058</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancer progression, response to therapy and metastasis depend on tumor microenvironment.  Integrins are cell-adhesion receptors that mediate interactions of cells with extracellular matrix.  The αv-β-family of integrins contributes to tumorigenesis, response to therapy and cancer stem cell biol.  Thus, understanding the function of specific integrins in cancer is crit. for the development of therapeutic approaches targeting integrins.  The study investigated the role of integrin β5 in breast carcinomas by depleting integrin β5 using RNA interference and reexpression of integrin β5.  Depletion of integrin β5 in triple-neg. breast carcinoma cells markedly reduced tumor take, growth and tumor angiogenesis, whereas reexpression of integrin β5 rescued this phenotype.  Redn. in tumor angiogenesis is assocd. with lower expression of vascular endothelial growth factor-A in integrin β5-depleted tumors.  Tumor cells deficient in integrin β5 have lower migration and proliferative capacities.  Biochem. assays revealed that integrin β5 mediates the Src-focal adhesion kinase and MEK-extracellular signal-regulated kinase signaling events that operate independently, and inhibition of these pathways phenocopies integrin β5 deficiency.  Breast carcinoma cells express high levels of integrin β5, whereas expression of integrin β3 is limited to stromal compartments and integrin β6 is lost in metastatic cells.  Together, these findings show a crit. role for integrin β5 in the tumorigenic potential of breast carcinoma cells and therapeutic targeting of integrin β5 is esp. attractive for triple-neg. breast carcinomas, which are refractory to most of the current therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtxbA3BTsodrVg90H21EOLACvtfcHk0lib1FtXSqvYwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOisrnF&md5=c11d07878b3158c26f34574e94f6865c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fonc.2012.320&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2012.320%26sid%3Dliteratum%253Aachs%26aulast%3DBianchi-Smiraglia%26aufirst%3DA.%26aulast%3DPaesante%26aufirst%3DS.%26aulast%3DBakin%26aufirst%3DA.%2BV.%26atitle%3DIntegrin%2520%25CE%25B25%2520contributes%2520to%2520the%2520tumorigenic%2520potential%2520of%2520breast%2520cancer%2520cells%2520through%2520the%2520Src-FAK%2520and%2520MEK-ERK%2520signaling%2520pathways%26jtitle%3DOncogene%26date%3D2013%26volume%3D32%26spage%3D3049%26epage%3D3058%26doi%3D10.1038%2Fonc.2012.320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">El Touny, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vieira, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendoza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khanna, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoenerhoff, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, J. E.</span><span> </span><span class="NLM_article-title">Combined SFK/MEK inhibition prevents metastatic outgrowth of dormant tumor cells</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">124</span><span class="NLM_x">, </span> <span class="NLM_fpage">156</span><span class="NLM_x">–</span> <span class="NLM_lpage">168</span><span class="refDoi"> DOI: 10.1172/JCI70259</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1172%2FJCI70259" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=156-168&author=L.+H.+El+Tounyauthor=A.+Vieiraauthor=A.+Mendozaauthor=C.+Khannaauthor=M.+J.+Hoenerhoffauthor=J.+E.+Green&title=Combined+SFK%2FMEK+inhibition+prevents+metastatic+outgrowth+of+dormant+tumor+cells&doi=10.1172%2FJCI70259"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1172%2FJCI70259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI70259%26sid%3Dliteratum%253Aachs%26aulast%3DEl%2BTouny%26aufirst%3DL.%2BH.%26aulast%3DVieira%26aufirst%3DA.%26aulast%3DMendoza%26aufirst%3DA.%26aulast%3DKhanna%26aufirst%3DC.%26aulast%3DHoenerhoff%26aufirst%3DM.%2BJ.%26aulast%3DGreen%26aufirst%3DJ.%2BE.%26atitle%3DCombined%2520SFK%252FMEK%2520inhibition%2520prevents%2520metastatic%2520outgrowth%2520of%2520dormant%2520tumor%2520cells%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2014%26volume%3D124%26spage%3D156%26epage%3D168%26doi%3D10.1172%2FJCI70259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Zhang, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, X. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, X. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S. Y.</span><span> </span><span class="NLM_article-title">Design, synthesis, and structure-activity relationship studies of 3-(phenylethynyl)-1H-pyrazolo 3,4-d pyrimidin-4-amine derivatives as a new class of Src inhibitors with potent activities in models of triple negative breast cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">3957</span><span class="NLM_x">–</span> <span class="NLM_lpage">3974</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00270</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00270" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3957-3974&author=C.+H.+Zhangauthor=M.+W.+Zhengauthor=Y.+P.+Liauthor=X.+D.+Linauthor=M.+Huangauthor=L.+Zhongauthor=G.+B.+Liauthor=R.+J.+Zhangauthor=W.+T.+Linauthor=Y.+Jiaoauthor=X.+A.+Wuauthor=J.+Yangauthor=R.+Xiangauthor=L.+J.+Chenauthor=Y.+L.+Zhaoauthor=W.+Chengauthor=Y.+Q.+Weiauthor=S.+Y.+Yang&title=Design%2C+synthesis%2C+and+structure-activity+relationship+studies+of+3-%28phenylethynyl%29-1H-pyrazolo+3%2C4-d+pyrimidin-4-amine+derivatives+as+a+new+class+of+Src+inhibitors+with+potent+activities+in+models+of+triple+negative+breast+cancer&doi=10.1021%2Facs.jmedchem.5b00270"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00270%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%2BH.%26aulast%3DZheng%26aufirst%3DM.%2BW.%26aulast%3DLi%26aufirst%3DY.%2BP.%26aulast%3DLin%26aufirst%3DX.%2BD.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DZhong%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DG.%2BB.%26aulast%3DZhang%26aufirst%3DR.%2BJ.%26aulast%3DLin%26aufirst%3DW.%2BT.%26aulast%3DJiao%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DX.%2BA.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DXiang%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DL.%2BJ.%26aulast%3DZhao%26aufirst%3DY.%2BL.%26aulast%3DCheng%26aufirst%3DW.%26aulast%3DWei%26aufirst%3DY.%2BQ.%26aulast%3DYang%26aufirst%3DS.%2BY.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520structure-activity%2520relationship%2520studies%2520of%25203-%2528phenylethynyl%2529-1H-pyrazolo%25203%252C4-d%2520pyrimidin-4-amine%2520derivatives%2520as%2520a%2520new%2520class%2520of%2520Src%2520inhibitors%2520with%2520potent%2520activities%2520in%2520models%2520of%2520triple%2520negative%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3957%26epage%3D3974%26doi%3D10.1021%2Facs.jmedchem.5b00270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Sanguinetti, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tristani-Firouzi, M.</span><span> </span><span class="NLM_article-title">hERG potassium channels and cardiac arrhythmia</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">440</span><span class="NLM_x">, </span> <span class="NLM_fpage">463</span><span class="NLM_x">–</span> <span class="NLM_lpage">469</span><span class="refDoi"> DOI: 10.1038/nature04710</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1038%2Fnature04710" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=16554806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BD28Xis1OlsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=440&publication_year=2006&pages=463-469&author=M.+C.+Sanguinettiauthor=M.+Tristani-Firouzi&title=hERG+potassium+channels+and+cardiac+arrhythmia&doi=10.1038%2Fnature04710"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">hERG potassium channels and cardiac arrhythmia</span></div><div class="casAuthors">Sanguinetti, Michael C.; Tristani-Firouzi, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">440</span>
        (<span class="NLM_cas:issue">7083</span>),
    <span class="NLM_cas:pages">463-469</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  HERG potassium channels are essential for normal elec. activity in the heart.  Inherited mutations in the HERG gene cause long QT syndrome, a disorder that predisposes individuals to life-threatening arrhythmias.  Arrhythmia can also be induced by a blockage of hERG channels by a surprisingly diverse group of drugs.  This side effect is a common reason for drug failure in preclin. safety trials.  Insights gained from the crystal structures of other potassium channels have helped our understanding of the block of hERG channels and the mechanisms of gating.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopS3WBEpuAUrVg90H21EOLACvtfcHk0li8rouyW34IiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xis1OlsLs%253D&md5=3f355dcd51da3488d73c7c91cbe8d3b8</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnature04710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature04710%26sid%3Dliteratum%253Aachs%26aulast%3DSanguinetti%26aufirst%3DM.%2BC.%26aulast%3DTristani-Firouzi%26aufirst%3DM.%26atitle%3DhERG%2520potassium%2520channels%2520and%2520cardiac%2520arrhythmia%26jtitle%3DNature%26date%3D2006%26volume%3D440%26spage%3D463%26epage%3D469%26doi%3D10.1038%2Fnature04710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Knight, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">Targeting the cancer kinome through polypharmacology</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">130</span><span class="NLM_x">–</span> <span class="NLM_lpage">137</span><span class="refDoi"> DOI: 10.1038/nrc2787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1038%2Fnrc2787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=20094047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=130-137&author=Z.+A.+Knightauthor=H.+Linauthor=K.+M.+Shokat&title=Targeting+the+cancer+kinome+through+polypharmacology&doi=10.1038%2Fnrc2787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the cancer kinome through polypharmacology</span></div><div class="casAuthors">Knight, Zachary A.; Lin, Henry; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-137</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Kinase inhibitors are the largest class of new cancer drugs.  However, it is already apparent that most tumors can escape from the inhibition of any single kinase.  If it is necessary to inhibit multiple kinases, how do we choose which ones.  In this Opinion article, we discuss some of the strategies that are currently being used to identify new therapeutic combinations of kinase targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkDv2FeeH58rVg90H21EOLACvtfcHk0li8rouyW34IiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D&md5=9aaa314e54b43889e147a9f11ac77072</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnrc2787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2787%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DTargeting%2520the%2520cancer%2520kinome%2520through%2520polypharmacology%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D130%26epage%3D137%26doi%3D10.1038%2Fnrc2787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Davis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hocker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">Comprehensive analysis of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1046</span><span class="NLM_x">–</span> <span class="NLM_lpage">1051</span><span class="refDoi"> DOI: 10.1038/nbt.1990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1038%2Fnbt.1990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=22037378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1046-1051&author=M.+I.+Davisauthor=J.+P.+Huntauthor=S.+Herrgardauthor=P.+Ciceriauthor=L.+M.+Wodickaauthor=G.+Pallaresauthor=M.+Hockerauthor=D.+K.+Treiberauthor=P.+P.+Zarrinkar&title=Comprehensive+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt.1990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Davis, Mindy I.; Hunt, Jeremy P.; Herrgard, Sanna; Ciceri, Pietro; Wodicka, Lisa M.; Pallares, Gabriel; Hocker, Michael; Treiber, Daniel K.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1046-1051</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We tested the interaction of 72 kinase inhibitors with 442 kinases covering >80% of the human catalytic protein kinome.  Our data show that, as a class, type II inhibitors are more selective than type I inhibitors, but that there are important exceptions to this trend.  The data further illustrate that selective inhibitors have been developed against the majority of kinases targeted by the compds. tested.  Anal. of the interaction patterns reveals a class of 'group-selective' inhibitors broadly active against a single subfamily of kinases, but selective outside that subfamily.  The data set suggests compds. to use as tools to study kinases for which no dedicated inhibitors exist.  It also provides a foundation for further exploring kinase inhibitor biol. and toxicity, as well as for studying the structural basis of the obsd. interaction patterns.  Our findings will help to realize the direct enabling potential of genomics for drug development and basic research about cellular signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEZnKVs6Xt5rVg90H21EOLACvtfcHk0liExcRjWV24qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK&md5=67639f702cb48ffb2c60e9a250f0df5e</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1990%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DHocker%26aufirst%3DM.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DComprehensive%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D1046%26epage%3D1051%26doi%3D10.1038%2Fnbt.1990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Sánchez-Bailón, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calcabrini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gómez-Domínguez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morte, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martín-Forero, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gómez-López, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molinari, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, K.-U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martín-Pérez, J.</span><span> </span><span class="NLM_article-title">Src kinases catalytic activity regulates proliferation, migration and invasiveness of MDA-MB-231 breast cancer cells</span> <span class="citation_source-journal">Cell. Signalling</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1276</span><span class="NLM_x">–</span> <span class="NLM_lpage">1286</span><span class="refDoi"> DOI: 10.1016/j.cellsig.2012.02.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1016%2Fj.cellsig.2012.02.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=22570868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvF2itrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2012&pages=1276-1286&author=M.+P.+S%C3%A1nchez-Bail%C3%B3nauthor=A.+Calcabriniauthor=D.+G%C3%B3mez-Dom%C3%ADnguezauthor=B.+Morteauthor=E.+Mart%C3%ADn-Foreroauthor=G.+G%C3%B3mez-L%C3%B3pezauthor=A.+Molinariauthor=K.-U.+Wagnerauthor=J.+Mart%C3%ADn-P%C3%A9rez&title=Src+kinases+catalytic+activity+regulates+proliferation%2C+migration+and+invasiveness+of+MDA-MB-231+breast+cancer+cells&doi=10.1016%2Fj.cellsig.2012.02.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Src kinases catalytic activity regulates proliferation, migration and invasiveness of MDA-MB-231 breast cancer cells</span></div><div class="casAuthors">Sanchez-Bailon, Maria Pilar; Calcabrini, Annarica; Gomez-Dominguez, Daniel; Morte, Beatriz; Martin-Forero, Esther; Gomez-Lopez, Gonzalo; Molinari, Agnese; Wagner, Kay-Uwe; Martin-Perez, Jorge</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1276-1286</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">SFKs are frequently deregulated in cancer where they control cellular proliferation, migration, survival and metastasis.  Here we study the role of SFKs catalytic activity in triple-neg./basal-like and metastatic human breast cancer MDA-MB-231 cells employing three well-established inhibitors: Dasatinib, PP2 and SU6656.  These compds. inhibited migration and invasion.  Concomitantly, they reduced Fak, paxillin, p130CAS, caveolin-1 phosphorylation and altered cytoskeletal structures.  They also inhibited cell proliferation, but in different manners.  Dasatinib and PP2 increased p27Kip1 expression and reduced c-Myc levels, restraining G1-S transition.  In contrast, SU6656 did not modify p27Kip1 expression, slightly altered c-Myc levels and generated polyploid multinucleated cells, indicating inhibition of cytokinesis.  These later effects were also obsd. in SYF fibroblasts, suggesting a SFKs-independent action.  ZM447439, an Aurora B kinase inhibitor, produced similar cell cycle and morphol. alterations in MDA-MB-231 cells, indicating that SU6656 blocked Aurora B kinase.  This was confirmed by inhibition of histone H3 phosphorylation, the canonical Aurora B kinase substrate.  Furthermore, hierarchical clustering anal. of gene expression profiles showed that SU6656 defined a set of genes that differed from Dasatinib and PP2.  Addnl., Gene Set Enrichment Analyses revealed that SU6656 significantly reduces the Src pathway.  Together, these results show the importance of SFKs catalytic activity for MDA-MB-231 proliferation, migration and invasiveness.  They also illustrate that SU6656 acts as dual SFKs and Aurora B kinase inhibitor, suggesting its possible use as a therapeutic agent in breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxhZ62Ycaq7bVg90H21EOLACvtfcHk0liExcRjWV24qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvF2itrw%253D&md5=527ed67289deb9acc1ab9a6fe15b527d</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2012.02.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2012.02.011%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25A1nchez-Bail%25C3%25B3n%26aufirst%3DM.%2BP.%26aulast%3DCalcabrini%26aufirst%3DA.%26aulast%3DG%25C3%25B3mez-Dom%25C3%25ADnguez%26aufirst%3DD.%26aulast%3DMorte%26aufirst%3DB.%26aulast%3DMart%25C3%25ADn-Forero%26aufirst%3DE.%26aulast%3DG%25C3%25B3mez-L%25C3%25B3pez%26aufirst%3DG.%26aulast%3DMolinari%26aufirst%3DA.%26aulast%3DWagner%26aufirst%3DK.-U.%26aulast%3DMart%25C3%25ADn-P%25C3%25A9rez%26aufirst%3DJ.%26atitle%3DSrc%2520kinases%2520catalytic%2520activity%2520regulates%2520proliferation%252C%2520migration%2520and%2520invasiveness%2520of%2520MDA-MB-231%2520breast%2520cancer%2520cells%26jtitle%3DCell.%2520Signalling%26date%3D2012%26volume%3D24%26spage%3D1276%26epage%3D1286%26doi%3D10.1016%2Fj.cellsig.2012.02.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Egan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durda, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujita, D. J.</span><span> </span><span class="NLM_article-title">Activation of Src in human breast tumor cell lines: elevated levels of phosphotyrosine phosphatase activity that preferentially recognizes the Src carboxy terminal negative regulatory tyrosine 530</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1227</span><span class="NLM_x">–</span> <span class="NLM_lpage">1237</span><span class="refDoi"> DOI: 10.1038/sj.onc.1202233</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1038%2Fsj.onc.1202233" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1999&pages=1227-1237&author=C.+Eganauthor=A.+Pangauthor=D.+Durdaauthor=H.+C.+Chengauthor=J.+H.+Wangauthor=D.+J.+Fujita&title=Activation+of+Src+in+human+breast+tumor+cell+lines%3A+elevated+levels+of+phosphotyrosine+phosphatase+activity+that+preferentially+recognizes+the+Src+carboxy+terminal+negative+regulatory+tyrosine+530&doi=10.1038%2Fsj.onc.1202233"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1202233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1202233%26sid%3Dliteratum%253Aachs%26aulast%3DEgan%26aufirst%3DC.%26aulast%3DPang%26aufirst%3DA.%26aulast%3DDurda%26aufirst%3DD.%26aulast%3DCheng%26aufirst%3DH.%2BC.%26aulast%3DWang%26aufirst%3DJ.%2BH.%26aulast%3DFujita%26aufirst%3DD.%2BJ.%26atitle%3DActivation%2520of%2520Src%2520in%2520human%2520breast%2520tumor%2520cell%2520lines%253A%2520elevated%2520levels%2520of%2520phosphotyrosine%2520phosphatase%2520activity%2520that%2520preferentially%2520recognizes%2520the%2520Src%2520carboxy%2520terminal%2520negative%2520regulatory%2520tyrosine%2520530%26jtitle%3DOncogene%26date%3D1999%26volume%3D18%26spage%3D1227%26epage%3D1237%26doi%3D10.1038%2Fsj.onc.1202233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Stonans, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stonane, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rußwurm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deigner, H.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Böhm, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiederhold, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jäger, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reinhart, K.</span><span> </span><span class="NLM_article-title">HepG2 human hepatoma cells express multiple cytokine genes</span> <span class="citation_source-journal">Cytokine</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">151</span><span class="NLM_x">–</span> <span class="NLM_lpage">156</span><span class="refDoi"> DOI: 10.1006/cyto.1998.0366</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1006%2Fcyto.1998.0366" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1999&pages=151-156&author=I.+Stonansauthor=E.+Stonaneauthor=S.+Ru%C3%9Fwurmauthor=H.-P.+Deignerauthor=K.+J.+B%C3%B6hmauthor=M.+Wiederholdauthor=L.+J%C3%A4gerauthor=K.+Reinhart&title=HepG2+human+hepatoma+cells+express+multiple+cytokine+genes&doi=10.1006%2Fcyto.1998.0366"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1006%2Fcyto.1998.0366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fcyto.1998.0366%26sid%3Dliteratum%253Aachs%26aulast%3DStonans%26aufirst%3DI.%26aulast%3DStonane%26aufirst%3DE.%26aulast%3DRu%25C3%259Fwurm%26aufirst%3DS.%26aulast%3DDeigner%26aufirst%3DH.-P.%26aulast%3DB%25C3%25B6hm%26aufirst%3DK.%2BJ.%26aulast%3DWiederhold%26aufirst%3DM.%26aulast%3DJ%25C3%25A4ger%26aufirst%3DL.%26aulast%3DReinhart%26aufirst%3DK.%26atitle%3DHepG2%2520human%2520hepatoma%2520cells%2520express%2520multiple%2520cytokine%2520genes%26jtitle%3DCytokine%26date%3D1999%26volume%3D11%26spage%3D151%26epage%3D156%26doi%3D10.1006%2Fcyto.1998.0366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Rational design of inhibitors that bind to inactive kinase conformations</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">358</span><span class="NLM_x">–</span> <span class="NLM_lpage">364</span><span class="refDoi"> DOI: 10.1038/nchembio799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1038%2Fnchembio799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=16783341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=358-364&author=Y.+Liuauthor=N.+S.+Gray&title=Rational+design+of+inhibitors+that+bind+to+inactive+kinase+conformations&doi=10.1038%2Fnchembio799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of inhibitors that bind to inactive kinase conformations</span></div><div class="casAuthors">Liu, Yi; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">358-364</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The majority of kinase inhibitors, known as type I inhibitors that have been developed so far target the ATP binding site of the kinase in its active conformation, in which the activation loop is phosphorylated.  Recently, crystal structures of inhibitors such as imatinib, BIRB796, and sorafenib (BAY43-9006), known as type II inhibitors, have revealed a new binding mode that exploits an addnl. binding site immediately adjacent to the region occupied by ATP.  This pocket is made accessible by an activation-loop rearrangement that is characteristic of kinases in an inactive conformation.  The examn. of binding features of known type II inhibitors is discussed and a pharmacophore model currently used in the design of a new generation of structurally diverse type II inhibitors is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxahsMPlhgDbVg90H21EOLACvtfcHk0ljdbcj6QTGZLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D&md5=4a9347a44a2cf4a412c9741fdcc5696b</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fnchembio799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio799%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DRational%2520design%2520of%2520inhibitors%2520that%2520bind%2520to%2520inactive%2520kinase%2520conformations%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2006%26volume%3D2%26spage%3D358%26epage%3D364%26doi%3D10.1038%2Fnchembio799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span> </span><span class="NLM_article-title">Discovery and optimization of 3-(2-(pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">3281</span><span class="NLM_x">–</span> <span class="NLM_lpage">3295</span><span class="refDoi"> DOI: 10.1021/jm301824k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301824k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksFSktLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=3281-3295&author=M.+Gaoauthor=L.+Duanauthor=J.+Luoauthor=L.+Zhangauthor=X.+Luauthor=Y.+Zhangauthor=Z.+Zhangauthor=Z.+Tuauthor=Y.+Xuauthor=X.+Renauthor=K.+Ding&title=Discovery+and+optimization+of+3-%282-%28pyrazolo%5B1%2C5-a%5Dpyrimidin-6-yl%29ethynyl%29benzamides+as+novel+selective+and+orally+bioavailable+discoidin+domain+receptor+1+%28DDR1%29+inhibitors&doi=10.1021%2Fjm301824k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as Novel Selective and Orally Bioavailable Discoidin Domain Receptor 1 (DDR1) Inhibitors</span></div><div class="casAuthors">Gao, Mingshan; Duan, Lei; Luo, Jinfeng; Zhang, Lianwen; Lu, Xiaoyun; Zhang, Yan; Zhang, Zhang; Tu, Zhengchao; Xu, Yong; Ren, Xiaomei; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3281-3295</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Discoidin domain receptor 1 (DDR1) is an emerging potential mol. target for new anticancer drug discovery.  The authors have discovered a series of 3-(2-(pyrazolo[1,5-a]pyrimidin-6-yl) ethynyl)benzamides that are selective and orally bioavailable DDR1 inhibitors.  The two most promising compds. (I and II) inhibited the enzymic activity of DDR1, with IC50 values of 6.8 and 7.0 nM, resp., but were significantly less potent in suppressing the kinase activities of DDR2, Bcr-Abl, and c-Kit.  Further study revealed that I bound with DDR1 with a Kd value of 0.6 nM, while it was significantly less potent to the other 455 kinases tested.  The S(35) and S(10) selectivity scores of I were 0.035 and 0.008, resp.  The compds. also potently inhibited the proliferation of cancer cells expressing high levels of DDR1 and strongly suppressed cancer cell invasion, adhesion, and tumorigenicity.  Preliminary pharmacokinetic studies suggested that they possessed good PK profiles, with oral bioavailabilities of 67.4% and 56.2%, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoP2AZAoE5zU7Vg90H21EOLACvtfcHk0ljdbcj6QTGZLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksFSktLo%253D&md5=7b3adcc8175907627727c4653b93be2c</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm301824k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301824k%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DM.%26aulast%3DDuan%26aufirst%3DL.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDiscovery%2520and%2520optimization%2520of%25203-%25282-%2528pyrazolo%255B1%252C5-a%255Dpyrimidin-6-yl%2529ethynyl%2529benzamides%2520as%2520novel%2520selective%2520and%2520orally%2520bioavailable%2520discoidin%2520domain%2520receptor%25201%2520%2528DDR1%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D3281%26epage%3D3295%26doi%3D10.1021%2Fjm301824k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Tan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomanbhoy, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurbani, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patricelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herhaus, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauls, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ham, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buhrlage, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sim, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sapkota, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westover, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Discovery of type II inhibitors of TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">183</span><span class="NLM_x">–</span> <span class="NLM_lpage">196</span><span class="refDoi"> DOI: 10.1021/jm500480k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500480k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFyiurrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=183-196&author=L.+Tanauthor=T.+Nomanbhoyauthor=D.+Gurbaniauthor=M.+Patricelliauthor=J.+Hunterauthor=J.+Gengauthor=L.+Herhausauthor=J.+Zhangauthor=E.+Paulsauthor=Y.+Hamauthor=H.+G.+Choiauthor=T.+Xieauthor=X.+Dengauthor=S.+J.+Buhrlageauthor=T.+Simauthor=P.+Cohenauthor=G.+Sapkotaauthor=K.+D.+Westoverauthor=N.+S.+Gray&title=Discovery+of+type+II+inhibitors+of+TGF%CE%B2-activated+kinase+1+%28TAK1%29+and+mitogen-activated+protein+kinase+kinase+kinase+kinase+2+%28MAP4K2%29&doi=10.1021%2Fjm500480k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Type II Inhibitors of TGFβ-Activated Kinase 1 (TAK1) and Mitogen-Activated Protein Kinase Kinase Kinase Kinase 2 (MAP4K2)</span></div><div class="casAuthors">Tan, Li; Nomanbhoy, Tyzoon; Gurbani, Deepak; Patricelli, Matthew; Hunter, John; Geng, Jiefei; Herhaus, Lina; Zhang, Jianming; Pauls, Eduardo; Ham, Youngjin; Choi, Hwan Geun; Xie, Ting; Deng, Xianming; Buhrlage, Sara J.; Sim, Taebo; Cohen, Philip; Sapkota, Gopal; Westover, Kenneth D.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">183-196</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors developed a pharmacophore model for type II inhibitors that was used to guide the construction of a library of kinase inhibitors.  Kinome-wide selectivity profiling of the library resulted in the identification of a series of 4-substituted 1H-pyrrolo[2,3-b]pyridines that exhibited potent inhibitory activity against two mitogen-activated protein kinases (MAPKs), TAK1 (MAP3K7) and MAP4K2, as well as pharmacol. well interrogated kinases such as p38α (MAPK14) and ABL.  Further investigation of the structure-activity relationship (SAR) resulted in the identification effect two potent dual TAK1 and MAP4K2 inhibitors such as I as well as two MAP4K2 selective inhibitors such as II.  Some of these inhibitors possess good pharmacokinetic properties that will enable their use in pharmacol. studies in vivo.  A 2.4 Å cocrystal structure of TAK1 in complex with 1 confirms that the activation loop of TAK1 assumes the DFG-out conformation characteristic of type II inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzjzVF_V_qSLVg90H21EOLACvtfcHk0ljdbcj6QTGZLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFyiurrJ&md5=288a6be4b9b4a5a6a5b925673cadd47a</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm500480k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500480k%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DL.%26aulast%3DNomanbhoy%26aufirst%3DT.%26aulast%3DGurbani%26aufirst%3DD.%26aulast%3DPatricelli%26aufirst%3DM.%26aulast%3DHunter%26aufirst%3DJ.%26aulast%3DGeng%26aufirst%3DJ.%26aulast%3DHerhaus%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DPauls%26aufirst%3DE.%26aulast%3DHam%26aufirst%3DY.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DXie%26aufirst%3DT.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DBuhrlage%26aufirst%3DS.%2BJ.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DSapkota%26aufirst%3DG.%26aulast%3DWestover%26aufirst%3DK.%2BD.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520type%2520II%2520inhibitors%2520of%2520TGF%25CE%25B2-activated%2520kinase%25201%2520%2528TAK1%2529%2520and%2520mitogen-activated%2520protein%2520kinase%2520kinase%2520kinase%2520kinase%25202%2520%2528MAP4K2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D183%26epage%3D196%26doi%3D10.1021%2Fjm500480k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poluzzi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Ponti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Recanatini, M.</span><span> </span><span class="NLM_article-title">Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K+ channel blockers</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">3844</span><span class="NLM_x">–</span> <span class="NLM_lpage">3853</span><span class="refDoi"> DOI: 10.1021/jm0208875</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0208875" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BD38XlsFalsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=3844-3853&author=A.+Cavalliauthor=E.+Poluzziauthor=F.+De+Pontiauthor=M.+Recanatini&title=Toward+a+pharmacophore+for+drugs+inducing+the+long+QT+syndrome%3A+insights+from+a+CoMFA+study+of+HERG+K%2B+channel+blockers&doi=10.1021%2Fjm0208875"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K+ channel blockers</span></div><div class="casAuthors">Cavalli, Andrea; Poluzzi, Elisabetta; De Ponti, Fabrizio; Recanatini, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3844-3853</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this paper, we present a pharmacophore for QT-prolonging drugs, along with a 3D QSAR (CoMFA) study for a series of very structurally variegate HERG K+ channel blockers.  The blockade of HERG K+ channels is one of the most important mol. mechanisms through which QT-prolonging drugs increase cardiac action potential duration.  Since QT prolongation is one of the most undesirable side effects of drugs, we first tried to identify the min. set of mol. features responsible for this action and then we attempted to develop a quant. model correlating the 3D stereoelectronic characteristics of the mols. with their HERG blocking potency.  Having considered an initial set of 31 QT-prolonging drugs for which the HERG K+ channel blocking activity was measured on mammalian transfected cells, we started the construction of a theor. screening tool able to predict whether a new mol. can interact with the HERG channel and eventually induce the long QT syndrome.  This in silico tool might be useful in the design of new drug candidates devoid of the physicochem. features likely to cause the above-mentioned side effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7WFt3kf6ZVLVg90H21EOLACvtfcHk0lh9NwucAzavHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlsFalsrk%253D&md5=5e980476ccc9a8a6244aaab230eeb701</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm0208875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0208875%26sid%3Dliteratum%253Aachs%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DPoluzzi%26aufirst%3DE.%26aulast%3DDe%2BPonti%26aufirst%3DF.%26aulast%3DRecanatini%26aufirst%3DM.%26atitle%3DToward%2520a%2520pharmacophore%2520for%2520drugs%2520inducing%2520the%2520long%2520QT%2520syndrome%253A%2520insights%2520from%2520a%2520CoMFA%2520study%2520of%2520HERG%2520K%252B%2520channel%2520blockers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D3844%26epage%3D3853%26doi%3D10.1021%2Fjm0208875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Aronov, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, B. B.</span><span> </span><span class="NLM_article-title">A model for identifying HERG K+ channel blockers</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">2307</span><span class="NLM_x">–</span> <span class="NLM_lpage">2315</span><span class="refDoi"> DOI: 10.1016/j.bmc.2004.02.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1016%2Fj.bmc.2004.02.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=15080928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjtVKqu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2004&pages=2307-2315&author=A.+M.+Aronovauthor=B.+B.+Goldman&title=A+model+for+identifying+HERG+K%2B+channel+blockers&doi=10.1016%2Fj.bmc.2004.02.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">A model for identifying HERG K+ channel blockers</span></div><div class="casAuthors">Aronov, Alex M.; Goldman, Brian B.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2307-2315</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Acquired long QT syndrome (LQTS) occurs frequently as a side effect of blockade of cardiac HERG K+ channels by commonly used medications.  A large no. of structurally diverse compds. have been shown to inhibit K+ current through HERG.  There is considerable interest in developing in silico tools to filter out potential HERG blockers early in the drug discovery process.  We describe a binary classification model that combines a 2D topol. similarity filter with a 3D pharmacophore ensemble procedure to discriminate between HERG actives and inactives with an overall accuracy of 82%, with false neg. and false pos. rates of 29% and 15%, resp.  This model should be generally applicable in virtual library counterscreening against HERG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK7a2-P1CNkLVg90H21EOLACvtfcHk0lh9NwucAzavHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjtVKqu7g%253D&md5=acfa27de5815ccbe7cb1ebbefefc99e2</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2004.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2004.02.003%26sid%3Dliteratum%253Aachs%26aulast%3DAronov%26aufirst%3DA.%2BM.%26aulast%3DGoldman%26aufirst%3DB.%2BB.%26atitle%3DA%2520model%2520for%2520identifying%2520HERG%2520K%252B%2520channel%2520blockers%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2004%26volume%3D12%26spage%3D2307%26epage%3D2315%26doi%3D10.1016%2Fj.bmc.2004.02.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Kim, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, E.-J.</span><span> </span><span class="NLM_article-title">Pathological roles of MAPK signaling pathways in human diseases</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Mol. Basis Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1802</span><span class="NLM_x">, </span> <span class="NLM_fpage">396</span><span class="NLM_x">–</span> <span class="NLM_lpage">405</span><span class="refDoi"> DOI: 10.1016/j.bbadis.2009.12.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1016%2Fj.bbadis.2009.12.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=20079433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitlSntLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1802&publication_year=2010&pages=396-405&author=E.+K.+Kimauthor=E.-J.+Choi&title=Pathological+roles+of+MAPK+signaling+pathways+in+human+diseases&doi=10.1016%2Fj.bbadis.2009.12.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Pathological roles of MAPK signaling pathways in human diseases</span></div><div class="casAuthors">Kim, Eun Kyung; Choi, Eui-Ju</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Basis of Disease</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1802</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">396-405</span>CODEN:
                <span class="NLM_cas:coden">BBADEX</span>;
        ISSN:<span class="NLM_cas:issn">0925-4439</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  The mammalian family of mitogen-activated protein kinases (MAPKs) includes extracellular signal-regulated kinase (ERK), p38, and c-Jun N-terminal kinase (JNK), with each MAPK signaling pathway consisting of at least three components, a MAPK kinase kinase (MAP3K), a MAPK kinase (MAP2K), and a MAPK.  The MAPK pathways are activated by diverse extracellular and intracellular stimuli including peptide growth factors, cytokines, hormones, and various cellular stressors such as oxidative stress and endoplasmic reticulum stress.  These signaling pathways regulate a variety of cellular activities including proliferation, differentiation, survival, and death.  Deviation from the strict control of MAPK signaling pathways has been implicated in the development of many human diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and various types of cancers.  Persistent activation of the JNK or p38 signaling pathways has been suggested to mediate neuronal apoptosis in AD, PD, and ALS, whereas the ERK signaling pathway plays a key role in several steps of tumorigenesis including cancer cell proliferation, migration, and invasion.  In this review, we summarize recent findings on the roles of MAPK signaling pathways in human disorders, focusing on cancer and neurodegenerative diseases including AD, PD, and ALS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH-o9cqFzUgLVg90H21EOLACvtfcHk0lh9NwucAzavHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitlSntLY%253D&md5=dff0ef076a287270ae2dd59c21cef333</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.bbadis.2009.12.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbadis.2009.12.009%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DE.%2BK.%26aulast%3DChoi%26aufirst%3DE.-J.%26atitle%3DPathological%2520roles%2520of%2520MAPK%2520signaling%2520pathways%2520in%2520human%2520diseases%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Basis%2520Dis.%26date%3D2010%26volume%3D1802%26spage%3D396%26epage%3D405%26doi%3D10.1016%2Fj.bbadis.2009.12.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Ongusaha, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. i.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yancopoulos, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aaronson, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. W.</span><span> </span><span class="NLM_article-title">p53 induction and activation of DDR1 kinase counteract p53 - mediated apoptosis and influence p53 regulation through a positive feedback loop</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1289</span><span class="NLM_x">–</span> <span class="NLM_lpage">1301</span><span class="refDoi"> DOI: 10.1093/emboj/cdg129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1093%2Femboj%2Fcdg129" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2003&pages=1289-1301&author=P.+P.+Ongusahaauthor=J.+i.+Kimauthor=L.+Fangauthor=T.+W.+Wongauthor=G.+D.+Yancopoulosauthor=S.+A.+Aaronsonauthor=S.+W.+Lee&title=p53+induction+and+activation+of+DDR1+kinase+counteract+p53+-+mediated+apoptosis+and+influence+p53+regulation+through+a+positive+feedback+loop&doi=10.1093%2Femboj%2Fcdg129"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1093%2Femboj%2Fcdg129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252Fcdg129%26sid%3Dliteratum%253Aachs%26aulast%3DOngusaha%26aufirst%3DP.%2BP.%26aulast%3DKim%26aufirst%3DJ.%2Bi.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DWong%26aufirst%3DT.%2BW.%26aulast%3DYancopoulos%26aufirst%3DG.%2BD.%26aulast%3DAaronson%26aufirst%3DS.%2BA.%26aulast%3DLee%26aufirst%3DS.%2BW.%26atitle%3Dp53%2520induction%2520and%2520activation%2520of%2520DDR1%2520kinase%2520counteract%2520p53%2520-%2520mediated%2520apoptosis%2520and%2520influence%2520p53%2520regulation%2520through%2520a%2520positive%2520feedback%2520loop%26jtitle%3DEMBO%2520J.%26date%3D2003%26volume%3D22%26spage%3D1289%26epage%3D1301%26doi%3D10.1093%2Femboj%2Fcdg129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Pennati, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sbarra, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Cesare, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopergolo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Locatelli, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daidone, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlo-Stella, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gianni, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaffaroni, N.</span><span> </span><span class="NLM_article-title">YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">136</span><span class="NLM_x">, </span> <span class="NLM_fpage">299</span><span class="NLM_x">–</span> <span class="NLM_lpage">309</span><span class="refDoi"> DOI: 10.1002/ijc.28993</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1002%2Fijc.28993" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=24866585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptlKrtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2015&pages=299-309&author=M.+Pennatiauthor=S.+Sbarraauthor=M.+De+Cesareauthor=A.+Lopergoloauthor=S.+L.+Locatelliauthor=E.+Campiauthor=M.+G.+Daidoneauthor=C.+Carlo-Stellaauthor=A.+M.+Gianniauthor=N.+Zaffaroni&title=YM155+sensitizes+triple-negative+breast+cancer+to+membrane-bound+TRAIL+through+p38+MAPK-+and+CHOP-mediated+DR5+upregulation&doi=10.1002%2Fijc.28993"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation</span></div><div class="casAuthors">Pennati, Marzia; Sbarra, Stefania; De Cesare, Michelandrea; Lopergolo, Alessia; Locatelli, Silvia L.; Campi, Elisa; Daidone, Maria Grazia; Carlo-Stella, Carmelo; Gianni, Alessandro M.; Zaffaroni, Nadia</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">299-309</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Because available treatments have limited efficacy in triple-neg. breast cancer (TNBC), the identification of new therapeutic strategies to improve patients' outcome is urgently needed.  In our study, we investigated the effects of the administration of the small mol. selective survivin suppressant YM155, alone or in assocn. with CD34+ cells transduced with a replication-deficient adenovirus encoding the human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene (CD34-TRAIL+ cells), in three TNBC cell models.  YM155 exposure significantly impaired TNBC cell growth and selectively modulated survivin expression at both mRNA and protein level.  In addn., co-culturing YM155-treated TNBC cells with CD34-TRAIL+ cells resulted in markedly increased cytotoxic effect and apoptotic response in comparison with single treatments.  Such a chemosensitizing effect was obsd. only in TNBC cells inherently expressing DR5 and relied on the ability of YM155 to upregulate DR5 expression through a p38 MAPK- and CHOP-dependent mechanism.  YM155/CD34-TRAIL+ combination also showed a significant inhibitory effect on the growth of DR5-expressing TNBC cells following xenotransplantation into NOD/SCID mice, in the absence of toxicity.  Overall, our data (i) provide, for the first time, evidence that YM155 sensitizes TNBC cells to CD34-TRAIL+ cells-induced apoptosis by a mechanism involving the downregulation of survivin and the simultaneous p38 MAPK- and CHOP-mediated upregulation of DR5, and (ii) suggest the combination of YM155 with TRAIL-armed CD34+ progenitor cells as a promising therapeutic option for patients with TNBC expressing DR5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvyPRRqGE5aLVg90H21EOLACvtfcHk0liyUYVnpP3m7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptlKrtr8%253D&md5=0eb641407663c2b843a2519d8bef8d1e</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fijc.28993&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.28993%26sid%3Dliteratum%253Aachs%26aulast%3DPennati%26aufirst%3DM.%26aulast%3DSbarra%26aufirst%3DS.%26aulast%3DDe%2BCesare%26aufirst%3DM.%26aulast%3DLopergolo%26aufirst%3DA.%26aulast%3DLocatelli%26aufirst%3DS.%2BL.%26aulast%3DCampi%26aufirst%3DE.%26aulast%3DDaidone%26aufirst%3DM.%2BG.%26aulast%3DCarlo-Stella%26aufirst%3DC.%26aulast%3DGianni%26aufirst%3DA.%2BM.%26aulast%3DZaffaroni%26aufirst%3DN.%26atitle%3DYM155%2520sensitizes%2520triple-negative%2520breast%2520cancer%2520to%2520membrane-bound%2520TRAIL%2520through%2520p38%2520MAPK-%2520and%2520CHOP-mediated%2520DR5%2520upregulation%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2015%26volume%3D136%26spage%3D299%26epage%3D309%26doi%3D10.1002%2Fijc.28993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Qi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lepp, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jing, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dwinell, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chitambar, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, G.</span><span> </span><span class="NLM_article-title">p38γ MAPK is a therapeutic target for triple-negative breast cancer by stimulation of cancer stem-like cell expansion</span> <span class="citation_source-journal">Stem Cells</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">2738</span><span class="NLM_x">–</span> <span class="NLM_lpage">2747</span><span class="refDoi"> DOI: 10.1002/stem.2068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1002%2Fstem.2068" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=2738-2747&author=X.+Qiauthor=N.+Yinauthor=S.+Maauthor=A.+Leppauthor=J.+Tangauthor=W.+Jingauthor=B.+Johnsonauthor=M.+B.+Dwinellauthor=C.+R.+Chitambarauthor=G.+Chen&title=p38%CE%B3+MAPK+is+a+therapeutic+target+for+triple-negative+breast+cancer+by+stimulation+of+cancer+stem-like+cell+expansion&doi=10.1002%2Fstem.2068"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1002%2Fstem.2068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fstem.2068%26sid%3Dliteratum%253Aachs%26aulast%3DQi%26aufirst%3DX.%26aulast%3DYin%26aufirst%3DN.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DLepp%26aufirst%3DA.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DJing%26aufirst%3DW.%26aulast%3DJohnson%26aufirst%3DB.%26aulast%3DDwinell%26aufirst%3DM.%2BB.%26aulast%3DChitambar%26aufirst%3DC.%2BR.%26aulast%3DChen%26aufirst%3DG.%26atitle%3Dp38%25CE%25B3%2520MAPK%2520is%2520a%2520therapeutic%2520target%2520for%2520triple-negative%2520breast%2520cancer%2520by%2520stimulation%2520of%2520cancer%2520stem-like%2520cell%2520expansion%26jtitle%3DStem%2520Cells%26date%3D2015%26volume%3D33%26spage%3D2738%26epage%3D2747%26doi%3D10.1002%2Fstem.2068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Shin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blenis, J.</span><span> </span><span class="NLM_article-title">ERK2/Fra1/ZEB pathway induces epithelial-to-mesenchymal transition</span> <span class="citation_source-journal">Cell Cycle</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">2483</span><span class="NLM_x">–</span> <span class="NLM_lpage">2484</span><span class="refDoi"> DOI: 10.4161/cc.9.13.12270</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.4161%2Fcc.9.13.12270" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=2483-2484&author=S.+Shinauthor=J.+Blenis&title=ERK2%2FFra1%2FZEB+pathway+induces+epithelial-to-mesenchymal+transition&doi=10.4161%2Fcc.9.13.12270"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.4161%2Fcc.9.13.12270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.9.13.12270%26sid%3Dliteratum%253Aachs%26aulast%3DShin%26aufirst%3DS.%26aulast%3DBlenis%26aufirst%3DJ.%26atitle%3DERK2%252FFra1%252FZEB%2520pathway%2520induces%2520epithelial-to-mesenchymal%2520transition%26jtitle%3DCell%2520Cycle%26date%3D2010%26volume%3D9%26spage%3D2483%26epage%3D2484%26doi%3D10.4161%2Fcc.9.13.12270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Porter, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janicke, R. U.</span><span> </span><span class="NLM_article-title">Emerging roles of caspase-3 in apoptosis</span> <span class="citation_source-journal">Cell Death Differ.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">99</span><span class="NLM_x">–</span> <span class="NLM_lpage">104</span><span class="refDoi"> DOI: 10.1038/sj.cdd.4400476</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1038%2Fsj.cdd.4400476" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10200555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADyaK1MXhs1Cgu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1999&pages=99-104&author=A.+G.+Porterauthor=R.+U.+Janicke&title=Emerging+roles+of+caspase-3+in+apoptosis&doi=10.1038%2Fsj.cdd.4400476"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging roles of caspase-3 in apoptosis</span></div><div class="casAuthors">Porter, Alan G.; Janicke, Reiner U.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death and Differentiation</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">99-104</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Stockton Press</span>)
        </div><div class="casAbstract">A review with 41 refs.  Caspases are crucial mediators of programmed cell death (apoptosis).  Among them, caspase-3 is a frequently activated death protease, catalyzing the specific cleavage of many key cellular proteins.  However, the specific requirements of this (or any other) caspase in apoptosis have remained largely unknown until now.  Pathways to caspase-3 activation have been identified that are either dependent on or independent of mitochondrial cytochrome c release and caspase-9 function.  Caspase-3 is essential for normal brain development and is important or essential in other apoptotic scenarios in a remarkable tissue-, cell type- or death stimulus-specific manner.  Caspase-3 is also required for some typical hallmarks of apoptosis, and is indispensable for apoptotic chromatin condensation and DNA fragmentation in all cell types examd.  Thus, caspase-3 is essential for certain processes assocd. with the dismantling of the cell and the formation of apoptotic bodies, but it may also function before or at the stage when commitment to loss of cell viability is made.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvEdRSRLukZbVg90H21EOLACvtfcHk0liyUYVnpP3m7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhs1Cgu7c%253D&md5=8d45a2f52ffed84897d36061c3dca019</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fsj.cdd.4400476&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.cdd.4400476%26sid%3Dliteratum%253Aachs%26aulast%3DPorter%26aufirst%3DA.%2BG.%26aulast%3DJanicke%26aufirst%3DR.%2BU.%26atitle%3DEmerging%2520roles%2520of%2520caspase-3%2520in%2520apoptosis%26jtitle%3DCell%2520Death%2520Differ.%26date%3D1999%26volume%3D6%26spage%3D99%26epage%3D104%26doi%3D10.1038%2Fsj.cdd.4400476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Delano, W. L.</span> <span class="citation_source-book">The PyMOL Molecular Graphics System</span>, version 1.7; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=W.+L.+Delano&title=The+PyMOL+Molecular+Graphics+System"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DDelano%26aufirst%3DW.%2BL.%26btitle%3DThe%2520PyMOL%2520Molecular%2520Graphics%2520System%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Yang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span> </span><span class="NLM_article-title">Discovery of a teraryl oxazolidinone compound (S)-N-((3-(3-fluoro-4-(4-(pyridin-2-yl)-1H-pyrazol-1-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)acetamide phosphate as a novel antimicrobial agent with enhanced safety profile and efficacies</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">6389</span><span class="NLM_x">–</span> <span class="NLM_lpage">6409</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00152</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00152" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1altb7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6389-6409&author=T.+Yangauthor=G.+Chenauthor=Z.+Sangauthor=Y.+Liuauthor=X.+Yangauthor=Y.+Changauthor=H.+Longauthor=W.+Angauthor=J.+Tangauthor=Z.+Wangauthor=G.+Liauthor=S.+Yangauthor=J.+Zhangauthor=Y.+Weiauthor=Y.+Luo&title=Discovery+of+a+teraryl+oxazolidinone+compound+%28S%29-N-%28%283-%283-fluoro-4-%284-%28pyridin-2-yl%29-1H-pyrazol-1-yl%29phenyl%29-2-oxooxazolidin-5-yl%29methyl%29acetamide+phosphate+as+a+novel+antimicrobial+agent+with+enhanced+safety+profile+and+efficacies&doi=10.1021%2Facs.jmedchem.5b00152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Teraryl Oxazolidinone Compound (S)-N-((3-(3-Fluoro-4-(4-(pyridin-2-yl)-1H-pyrazol-1-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)acetamide Phosphate as a Novel Antimicrobial Agent with Enhanced Safety Profile and Efficacies</span></div><div class="casAuthors">Yang, Tao; Chen, Gong; Sang, Zitai; Liu, Yuanyuan; Yang, Xiaoyan; Chang, Ying; Long, Haiyue; Wei, Ang; Tang, Jianying; Wang, Zhenling; Li, Guobo; Yang, Shengyong; Zhang, Jingren; Wei, Yuquan; Luo, Youfu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6389-6409</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel teraryl oxazolidinone compds. was designed, synthesized, and evaluated for their antimicrobial activity and toxicities.  The compds. with arom. N-heterocyclic substituents at the 4-position of pyrazolyl ring showed better antibacterial activity against the tested bacteria than other compds. with different patterns of substitution.  Among all potent compds., I exhibited promising safety profile in MTT assays and in hERG K+ channel inhibition test.  Furthermore, its phosphate was found to be highly sol. in water (47.1 mg/mL), which is beneficial for the subsequent in vivo test.  In MRSA systemic infection mice models, I phosphate exerted significantly improved survival protection compared with linezolid.  The compd. also demonstrated high oral bioavailability (F = 99.1%).  Moreover, from the results of in vivo toxicol. expts., I phosphate would be predicted to have less bone marrow suppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2zOHxUIAO2bVg90H21EOLACvtfcHk0liqecuULf547A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1altb7E&md5=69b436025095d8fc3fcd25c2c7530a94</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00152%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DSang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DChang%26aufirst%3DY.%26aulast%3DLong%26aufirst%3DH.%26aulast%3DAng%26aufirst%3DW.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520a%2520teraryl%2520oxazolidinone%2520compound%2520%2528S%2529-N-%2528%25283-%25283-fluoro-4-%25284-%2528pyridin-2-yl%2529-1H-pyrazol-1-yl%2529phenyl%2529-2-oxooxazolidin-5-yl%2529methyl%2529acetamide%2520phosphate%2520as%2520a%2520novel%2520antimicrobial%2520agent%2520with%2520enhanced%2520safety%2520profile%2520and%2520efficacies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6389%26epage%3D6409%26doi%3D10.1021%2Facs.jmedchem.5b00152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Chartier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chenard, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Najmanovich, R.</span><span> </span><span class="NLM_article-title">Kinome Render: a stand-alone and web-accessible tool to annotate the human protein kinome tree</span> <span class="citation_source-journal">PeerJ</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">e126</span><span class="refDoi"> DOI: 10.7717/peerj.126</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.7717%2Fpeerj.126" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=23940838" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2013&pages=e126&author=M.+Chartierauthor=T.+Chenardauthor=J.+Barkerauthor=R.+Najmanovich&title=Kinome+Render%3A+a+stand-alone+and+web-accessible+tool+to+annotate+the+human+protein+kinome+tree&doi=10.7717%2Fpeerj.126"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.7717%2Fpeerj.126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7717%252Fpeerj.126%26sid%3Dliteratum%253Aachs%26aulast%3DChartier%26aufirst%3DM.%26aulast%3DChenard%26aufirst%3DT.%26aulast%3DBarker%26aufirst%3DJ.%26aulast%3DNajmanovich%26aufirst%3DR.%26atitle%3DKinome%2520Render%253A%2520a%2520stand-alone%2520and%2520web-accessible%2520tool%2520to%2520annotate%2520the%2520human%2520protein%2520kinome%2520tree%26jtitle%3DPeerJ%26date%3D2013%26volume%3D1%26spage%3De126%26doi%3D10.7717%2Fpeerj.126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Shen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hao, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, R.</span><span> </span><span class="NLM_article-title">TIFA suppresses hepatocellular carcinoma progression via MALT1-dependent and -independent signaling pathways</span> <span class="citation_source-journal">Signal Transduct. Target. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">16013</span><span class="refDoi"> DOI: 10.1038/sigtrans.2016.13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1038%2Fsigtrans.2016.13" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2016&pages=16013&author=W.+Shenauthor=R.+Duauthor=J.+Liauthor=X.+Luoauthor=S.+Zhaoauthor=A.+Changauthor=W.+Zhouauthor=R.+Gaoauthor=D.+Luoauthor=J.+Wangauthor=N.+Haoauthor=Y.+Liuauthor=Y.+Chenauthor=Y.+Luoauthor=P.+Sunauthor=S.+Yangauthor=N.+Luoauthor=R.+Xiang&title=TIFA+suppresses+hepatocellular+carcinoma+progression+via+MALT1-dependent+and+-independent+signaling+pathways&doi=10.1038%2Fsigtrans.2016.13"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2Fsigtrans.2016.13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsigtrans.2016.13%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DW.%26aulast%3DDu%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DGao%26aufirst%3DR.%26aulast%3DLuo%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DHao%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DN.%26aulast%3DXiang%26aufirst%3DR.%26atitle%3DTIFA%2520suppresses%2520hepatocellular%2520carcinoma%2520progression%2520via%2520MALT1-dependent%2520and%2520-independent%2520signaling%2520pathways%26jtitle%3DSignal%2520Transduct.%2520Target.%2520Ther.%26date%3D2016%26volume%3D1%26spage%3D16013%26doi%3D10.1038%2Fsigtrans.2016.13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Wert, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahajan, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tosi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagasaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janisch, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grant, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahajan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bassuk, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsang, S. H.</span><span> </span><span class="NLM_article-title">Neuroretinal hypoxic signaling in a new preclinical murine model for proliferative diabetic retinopathy</span> <span class="citation_source-journal">Signal Transduct. Target. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">16005</span><span class="refDoi"> DOI: 10.1038/sigtrans.2016.5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1038%2Fsigtrans.2016.5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=27195131" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2016&pages=16005&author=K.+J.+Wertauthor=V.+B.+Mahajanauthor=L.+Zhangauthor=Y.+Yanauthor=Y.+Liauthor=J.+Tosiauthor=C.+W.+Hsuauthor=T.+Nagasakiauthor=K.+M.+Janischauthor=M.+B.+Grantauthor=M.+Mahajanauthor=A.+G.+Bassukauthor=S.+H.+Tsang&title=Neuroretinal+hypoxic+signaling+in+a+new+preclinical+murine+model+for+proliferative+diabetic+retinopathy&doi=10.1038%2Fsigtrans.2016.5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fsigtrans.2016.5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsigtrans.2016.5%26sid%3Dliteratum%253Aachs%26aulast%3DWert%26aufirst%3DK.%2BJ.%26aulast%3DMahajan%26aufirst%3DV.%2BB.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DTosi%26aufirst%3DJ.%26aulast%3DHsu%26aufirst%3DC.%2BW.%26aulast%3DNagasaki%26aufirst%3DT.%26aulast%3DJanisch%26aufirst%3DK.%2BM.%26aulast%3DGrant%26aufirst%3DM.%2BB.%26aulast%3DMahajan%26aufirst%3DM.%26aulast%3DBassuk%26aufirst%3DA.%2BG.%26aulast%3DTsang%26aufirst%3DS.%2BH.%26atitle%3DNeuroretinal%2520hypoxic%2520signaling%2520in%2520a%2520new%2520preclinical%2520murine%2520model%2520for%2520proliferative%2520diabetic%2520retinopathy%26jtitle%3DSignal%2520Transduct.%2520Target.%2520Ther.%26date%3D2016%26volume%3D1%26spage%3D16005%26doi%3D10.1038%2Fsigtrans.2016.5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">He, Z.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, M.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, S.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">But, P. P.-H.</span><span> </span><span class="NLM_article-title">Anti-angiogenic effects of rhubarb and its anthraquinone derivatives</span> <span class="citation_source-journal">J. Ethnopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">121</span><span class="NLM_x">, </span> <span class="NLM_fpage">313</span><span class="NLM_x">–</span> <span class="NLM_lpage">317</span><span class="refDoi"> DOI: 10.1016/j.jep.2008.11.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1016%2Fj.jep.2008.11.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=19061946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVGnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2009&pages=313-317&author=Z.-H.+Heauthor=M.-F.+Heauthor=S.-C.+Maauthor=P.+P.-H.+But&title=Anti-angiogenic+effects+of+rhubarb+and+its+anthraquinone+derivatives&doi=10.1016%2Fj.jep.2008.11.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-angiogenic effects of rhubarb and its anthraquinone derivatives</span></div><div class="casAuthors">He, Zhi-Heng; He, Ming-Fang; Ma, Shuang-Cheng; But, Paul Pui-Hay</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Ethnopharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">313-317</span>CODEN:
                <span class="NLM_cas:coden">JOETD7</span>;
        ISSN:<span class="NLM_cas:issn">0378-8741</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Ethnopharmacol. relevance: Rhubarb root (Dahuang) is often included as an ingredient in traditional Chinese compd. prescriptions for the treatment of inflammatory diseases.  This application may possibly be mediated through anti-angiogensis and thus would shed light on its potential value in cancer therapy.  Aim of the study: To elucidate the anti-angiogenic properties of rhubarb root, we tested the inhibitory effects of different fractions and a series of anthraquinone derivs. against vessel formation in zebrafish embryos.  Materials and methods: The 95% ethanol ext. and four subsequent fractions (n-hexane, Et acetate, n-butanol and aq. fractions) of rhubarb root and five anthraquinone derivs. were investigated on zebrafish model by quant. endogenous alk. phosphatase assay and staining assay.  Results: Et acetate fraction showed the strongest inhibition of vessel formation by 52%.  Three anthraquinones (aloe-emodin, emodin and rhein) displayed potent anti-angiogenic activities.  Conclusions: The angiogenic properties of rhubarb root may partly account for its use in inflammatory diseases.  The anthraquinones with acidic or polar, hydrophilic substitution at C-6 or C-3 positions played a substantial role in inhibiting angiogenesis.  The value of the zebrafish angiogenic model is further supported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrNorUWMZNArVg90H21EOLACvtfcHk0lgYtFmjyof2nQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVGnsw%253D%253D&md5=d0a7ab359f9c9cbeff33ee80f5ad4e45</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.jep.2008.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jep.2008.11.008%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DZ.-H.%26aulast%3DHe%26aufirst%3DM.-F.%26aulast%3DMa%26aufirst%3DS.-C.%26aulast%3DBut%26aufirst%3DP.%2BP.-H.%26atitle%3DAnti-angiogenic%2520effects%2520of%2520rhubarb%2520and%2520its%2520anthraquinone%2520derivatives%26jtitle%3DJ.%2520Ethnopharmacol.%26date%3D2009%26volume%3D121%26spage%3D313%26epage%3D317%26doi%3D10.1016%2Fj.jep.2008.11.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 12 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Minru Liao, Jin Zhang, Guan Wang, Leiming Wang, Jie Liu, Liang Ouyang, <span class="NLM_string-name hlFld-ContribAuthor">Bo Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule Drug Discovery in Triple Negative Breast Cancer: Current Situation and Future Directions. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (5)
                                     , 2382-2418. <a href="https://doi.org/10.1021/acs.jmedchem.0c01180" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01180</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01180%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall-Molecule%252BDrug%252BDiscovery%252Bin%252BTriple%252BNegative%252BBreast%252BCancer%25253A%252BCurrent%252BSituation%252Band%252BFuture%252BDirections%26aulast%3DLiao%26aufirst%3DMinru%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D07072020%26date%3D02032021%26volume%3D64%26issue%3D5%26spage%3D2382%26epage%3D2418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Steven Cassar, Isaac Adatto, Jennifer L. Freeman, Joshua T. Gamse, Iñaki Iturria, Christian Lawrence, Arantza Muriana, Randall T. Peterson, Steven Van Cruchten, <span class="NLM_string-name hlFld-ContribAuthor">Leonard I. Zon</span>. </span><span class="cited-content_cbyCitation_article-title">Use of Zebrafish in Drug Discovery Toxicology. </span><span class="cited-content_cbyCitation_journal-name">Chemical Research in Toxicology</span><span> <strong>2020,</strong> <em>33 </em>
                                    (1)
                                     , 95-118. <a href="https://doi.org/10.1021/acs.chemrestox.9b00335" title="DOI URL">https://doi.org/10.1021/acs.chemrestox.9b00335</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrestox.9b00335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrestox.9b00335%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Research%2520in%2520Toxicology%26atitle%3DUse%252Bof%252BZebrafish%252Bin%252BDrug%252BDiscovery%252BToxicology%26aulast%3DCassar%26aufirst%3DSteven%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D13082019%26date%3D16112019%26date%3D18102019%26volume%3D33%26issue%3D1%26spage%3D95%26epage%3D118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yueshan Li, Yu Xiong, Guo Zhang, Liting Zhang, Wei Yang, Jiao Yang, Luyi Huang, Zeen Qiao, Zhuang Miao, Guifeng Lin, Qiu Sun, Ting Niu, Lijuan Chen, Dawen Niu, Linli Li, <span class="NLM_string-name hlFld-ContribAuthor">Shengyong Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of 5-(2,3-Dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine Derivatives as a New Class of Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors, Which Showed Potent Activity in a Tumor Metastasis Model. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (24)
                                     , 11398-11414. <a href="https://doi.org/10.1021/acs.jmedchem.8b01652" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01652</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01652%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252B5-%2525282%25252C3-Dihydro-1H-indol-5-yl%252529-7H-pyrrolo%25255B2%25252C3-d%25255Dpyrimidin-4-amine%252BDerivatives%252Bas%252Ba%252BNew%252BClass%252Bof%252BReceptor-Interacting%252BProtein%252BKinase%252B1%252B%252528RIPK1%252529%252BInhibitors%25252C%252BWhich%252BShowed%252BPotent%252BActivity%252Bin%252Ba%252BTumor%252BMetastasis%252BModel%26aulast%3DLi%26aufirst%3DYueshan%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D24102018%26date%3D10122018%26date%3D27112018%26volume%3D61%26issue%3D24%26spage%3D11398%26epage%3D11414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ting  Guo</span>, <span class="hlFld-ContribAuthor ">Shutao  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in the Discovery of Multitargeted Tyrosine Kinase Inhibitors as Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>16 </em>
                                    (4)
                                     , 600-620. <a href="https://doi.org/10.1002/cmdc.202000658" title="DOI URL">https://doi.org/10.1002/cmdc.202000658</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202000658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202000658%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DRecent%252BAdvances%252Bin%252Bthe%252BDiscovery%252Bof%252BMultitargeted%252BTyrosine%252BKinase%252BInhibitors%252Bas%252BAnticancer%252BAgents%26aulast%3DGuo%26aufirst%3DTing%26date%3D2021%26date%3D2020%26volume%3D16%26issue%3D4%26spage%3D600%26epage%3D620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eddie L  Myers</span>. </span><span class="cited-content_cbyCitation_article-title">Bicyclic 5–6 Systems: Other Four Heteroatoms 2:2. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/B978-0-12-818655-8.00056-1" title="DOI URL">https://doi.org/10.1016/B978-0-12-818655-8.00056-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-818655-8.00056-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-818655-8.00056-1%26sid%3Dliteratum%253Aachs%26atitle%3DBicyclic%252B5%2525E2%252580%2525936%252BSystems%25253A%252BOther%252BFour%252BHeteroatoms%252B2%25253A2%26aulast%3DMyers%26aufirst%3DEddie%2BL%26date%3D2021%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2021%26volume%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoyuan  Zhang</span>, <span class="hlFld-ContribAuthor ">Renle  Du</span>, <span class="hlFld-ContribAuthor ">Na  Luo</span>, <span class="hlFld-ContribAuthor ">Rong  Xiang</span>, <span class="hlFld-ContribAuthor ">Wenzhi  Shen</span>. </span><span class="cited-content_cbyCitation_article-title">Aspirin mediates histone methylation that inhibits inflammation-related stemness gene expression to diminish cancer stemness via COX-independent manner. </span><span class="cited-content_cbyCitation_journal-name">Stem Cell Research & Therapy</span><span> <strong>2020,</strong> <em>11 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13287-020-01884-4" title="DOI URL">https://doi.org/10.1186/s13287-020-01884-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13287-020-01884-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13287-020-01884-4%26sid%3Dliteratum%253Aachs%26jtitle%3DStem%2520Cell%2520Research%2520%2526%2520Therapy%26atitle%3DAspirin%252Bmediates%252Bhistone%252Bmethylation%252Bthat%252Binhibits%252Binflammation-related%252Bstemness%252Bgene%252Bexpression%252Bto%252Bdiminish%252Bcancer%252Bstemness%252Bvia%252BCOX-independent%252Bmanner%26aulast%3DZhang%26aufirst%3DXiaoyuan%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rajibul  Islam</span>, <span class="hlFld-ContribAuthor ">Kok Wai  Lam</span>. </span><span class="cited-content_cbyCitation_article-title">Recent progress in small molecule agents for the targeted therapy of triple-negative breast cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>207 </em>, 112812. <a href="https://doi.org/10.1016/j.ejmech.2020.112812" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112812</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112812&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112812%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bprogress%252Bin%252Bsmall%252Bmolecule%252Bagents%252Bfor%252Bthe%252Btargeted%252Btherapy%252Bof%252Btriple-negative%252Bbreast%252Bcancer%26aulast%3DIslam%26aufirst%3DRajibul%26date%3D2020%26volume%3D207%26spage%3D112812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">R. Nishanth  Rao</span>, <span class="hlFld-ContribAuthor ">Kaushik  Chanda</span>. </span><span class="cited-content_cbyCitation_article-title">An assessment study of known pyrazolopyrimidines: Chemical methodology and cellular activity. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>99 </em>, 103801. <a href="https://doi.org/10.1016/j.bioorg.2020.103801" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103801</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103801%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DAn%252Bassessment%252Bstudy%252Bof%252Bknown%252Bpyrazolopyrimidines%25253A%252BChemical%252Bmethodology%252Band%252Bcellular%252Bactivity%26aulast%3DRao%26aufirst%3DR.%2BNishanth%26date%3D2020%26volume%3D99%26spage%3D103801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jun-wei  Wang</span>, <span class="hlFld-ContribAuthor ">Ya-ting  Deng</span>, <span class="hlFld-ContribAuthor ">Han  Chu</span>, <span class="hlFld-ContribAuthor ">Juan  Wang</span>, <span class="hlFld-ContribAuthor ">Yong  Hu</span>, <span class="hlFld-ContribAuthor ">Zhi-hua  Lin</span>. </span><span class="cited-content_cbyCitation_article-title">3D-QSAR, molecular docking, and new compound design of pyrimidine derivatives as Src small molecule inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry Research</span><span> <strong>2019,</strong> <em>28 </em>
                                    (8)
                                     , 1246-1263. <a href="https://doi.org/10.1007/s00044-019-02370-0" title="DOI URL">https://doi.org/10.1007/s00044-019-02370-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00044-019-02370-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00044-019-02370-0%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%2520Research%26atitle%3D3D-QSAR%25252C%252Bmolecular%252Bdocking%25252C%252Band%252Bnew%252Bcompound%252Bdesign%252Bof%252Bpyrimidine%252Bderivatives%252Bas%252BSrc%252Bsmall%252Bmolecule%252Binhibitors%26aulast%3DWang%26aufirst%3DJun-wei%26date%3D2019%26date%3D2019%26volume%3D28%26issue%3D8%26spage%3D1246%26epage%3D1263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei  Yang</span>, <span class="hlFld-ContribAuthor ">Lingwei  Meng</span>, <span class="hlFld-ContribAuthor ">Kai  Chen</span>, <span class="hlFld-ContribAuthor ">Chenyu  Tian</span>, <span class="hlFld-ContribAuthor ">Bing  Peng</span>, <span class="hlFld-ContribAuthor ">Lei  Zhong</span>, <span class="hlFld-ContribAuthor ">Chunhui  Zhang</span>, <span class="hlFld-ContribAuthor ">Xin  Yang</span>, <span class="hlFld-ContribAuthor ">Jun  Zou</span>, <span class="hlFld-ContribAuthor ">Shengyong  Yang</span>, <span class="hlFld-ContribAuthor ">Linli  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Preclinical pharmacodynamic evaluation of a new Src/
              FOSL
              1 inhibitor,
              LY
              ‐1816, in pancreatic ductal adenocarcinoma. </span><span class="cited-content_cbyCitation_journal-name">Cancer Science</span><span> <strong>2019,</strong> <em>110 </em>
                                    (4)
                                     , 1408-1419. <a href="https://doi.org/10.1111/cas.13929" title="DOI URL">https://doi.org/10.1111/cas.13929</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cas.13929&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcas.13929%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Science%26atitle%3DPreclinical%252Bpharmacodynamic%252Bevaluation%252Bof%252Ba%252Bnew%252BSrc%25252F%252BFOSL%252B1%252Binhibitor%25252C%252BLY%252B%2525E2%252580%2525901816%25252C%252Bin%252Bpancreatic%252Bductal%252Badenocarcinoma%26aulast%3DYang%26aufirst%3DWei%26date%3D2019%26date%3D2019%26volume%3D110%26issue%3D4%26spage%3D1408%26epage%3D1419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenzhi  Shen</span>, <span class="hlFld-ContribAuthor ">Junling  Xie</span>, <span class="hlFld-ContribAuthor ">Shuangtao  Zhao</span>, <span class="hlFld-ContribAuthor ">Renle  Du</span>, <span class="hlFld-ContribAuthor ">Xiaohe  Luo</span>, <span class="hlFld-ContribAuthor ">Huiwen  He</span>, <span class="hlFld-ContribAuthor ">Shan  Jiang</span>, <span class="hlFld-ContribAuthor ">Na  Hao</span>, <span class="hlFld-ContribAuthor ">Chong  Chen</span>, <span class="hlFld-ContribAuthor ">Chunlei  Guo</span>, <span class="hlFld-ContribAuthor ">Yanhua  Liu</span>, <span class="hlFld-ContribAuthor ">Yanan  Chen</span>, <span class="hlFld-ContribAuthor ">Peiqing  Sun</span>, <span class="hlFld-ContribAuthor ">Shengyong  Yang</span>, <span class="hlFld-ContribAuthor ">Na  Luo</span>, <span class="hlFld-ContribAuthor ">Rong  Xiang</span>, <span class="hlFld-ContribAuthor ">Yunping  Luo</span>. </span><span class="cited-content_cbyCitation_article-title">ICAM3 mediates inflammatory signaling to promote cancer cell stemness. </span><span class="cited-content_cbyCitation_journal-name">Cancer Letters</span><span> <strong>2018,</strong> <em>422 </em>, 29-43. <a href="https://doi.org/10.1016/j.canlet.2018.02.034" title="DOI URL">https://doi.org/10.1016/j.canlet.2018.02.034</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.canlet.2018.02.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.canlet.2018.02.034%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Letters%26atitle%3DICAM3%252Bmediates%252Binflammatory%252Bsignaling%252Bto%252Bpromote%252Bcancer%252Bcell%252Bstemness%26aulast%3DShen%26aufirst%3DWenzhi%26date%3D2018%26volume%3D422%26spage%3D29%26epage%3D43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhaoping  Pan</span>, <span class="hlFld-ContribAuthor ">Yujuan  Chen</span>, <span class="hlFld-ContribAuthor ">Jingyan  Liu</span>, <span class="hlFld-ContribAuthor ">Qinglin  Jiang</span>, <span class="hlFld-ContribAuthor ">Shengyong  Yang</span>, <span class="hlFld-ContribAuthor ">Li  Guo</span>, <span class="hlFld-ContribAuthor ">Gu  He</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>144 </em>, 517-528. <a href="https://doi.org/10.1016/j.ejmech.2017.12.046" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.12.046</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.12.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.12.046%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252Bpolo-like%252Bkinase%252B1%25252Feukaryotic%252Belongation%252Bfactor%252B2%252Bkinase%252B%252528PLK1%25252FEEF2K%252529%252Bdual%252Binhibitors%252Bfor%252Bregulating%252Bbreast%252Bcancer%252Bcells%252Bapoptosis%252Band%252Bautophagy%26aulast%3DPan%26aufirst%3DZhaoping%26date%3D2018%26volume%3D144%26spage%3D517%26epage%3D528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/medium/jm-2016-00943q_0022.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00943&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/medium/jm-2016-00943q_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Schematic showing the lead optimization process.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00943&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/medium/jm-2016-00943q_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0010.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Routes for Compounds <b>8a</b>–<b>g</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00943&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (i) SOCl<sub>2</sub>, 80 °C, (ii) DIPEA, EA, 0 °C to rt; (b) ethynyltrimethylsilane, CuI, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, DIPEA, THF, rt, N<sub>2</sub>; (c) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt; (d) NIS, DMF, 80 °C, N<sub>2</sub>; (e) R<sub>1</sub>-X(Br, I) or R<sub>1</sub>-OMs, K<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, N<sub>2</sub>; (f) 5 N HCl in 1,4-dioxane, MeOH, 0 °C to rt; (g) formaldehyde, acetic acid, sodium cyanoborohydride, 1,2-dichloroethane/methanol, rt; (h) 1 N HCl, acetone, 70 °C to rt; (i) sodium borohydride, MeOH, 0 °C to rt; (j) (PPh<sub>3</sub>)<sub>2</sub>PdCl<sub>2</sub>, CuI, DIPEA, DMF, 80 °C, N<sub>2</sub>.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/medium/jm-2016-00943q_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0011.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Routes for Compounds <b>1i</b>–<b>r</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00943&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) ethynyltrimethylsilane, CuI, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, triethylamine, THF, rt, N<sub>2</sub>; (b) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt; (c) Fe, NH<sub>4</sub>Cl, 70% EtOH, 80 °C; (d) (i) aromatic carboxylic acid, SOCl<sub>2</sub>, 80 °C, (ii) DIPEA, EA, 0 °C to rt; (e) (PPh<sub>3</sub>)<sub>2</sub>PdCl<sub>2</sub>, CuI, DIPEA, DMF, 80 °C, N<sub>2</sub>.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/medium/jm-2016-00943q_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0012.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthetic Routes for Compounds <b>14a</b>–<b>g</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00943&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) triphosgene, DIPEA, EA, 0 °C to rt; (b) <b>11a</b>–<b>c</b>, EA, 70 °C; (c) (PPh<sub>3</sub>)<sub>2</sub>PdCl<sub>2</sub>, CuI, DIPEA, DMF, 80 °C, N<sub>2</sub>.</p></p></figure><figure data-id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/medium/jm-2016-00943q_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Predicted binding mode of <b>1</b> with Src. The crystal structure of Src was taken from the RCSB Protein Data Bank (PDB entry: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3EL7">3EL7</a>). (B) The structure of compound <b>8c</b>. (C) Schematic showing regions that are the focuses of structural modifications.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00943&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/medium/jm-2016-00943q_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Predicted binding mode of <b>13an</b> with Src. (B) A comparison of the binding modes of <b>13an</b> (dark slate blue) and compound <b>1</b> (cyan) with Src. Hydrogen bonding interactions between the compounds and Src are indicated by dashed yellow lines for compound <b>1</b> and dashed green lines for <b>13an</b>. The crystal structure of Src was taken from the RCSB Protein Data Bank (PDB entry: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3EL7">3EL7</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00943&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/medium/jm-2016-00943q_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0005.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Kinase binding selectivity for <b>13an</b> shown on the human kinome dendrogram. The inhibition rates were determined using the KinaseProfiler of Eurofins. The figure was generated by using an online Kinome Render program (<a href="http://bcb.med.usherbrooke.ca/kinomerenderLig.php" class="extLink">http://bcb.med.usherbrooke.ca/kinomerenderLig.php</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00943&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/medium/jm-2016-00943q_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0006.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) <b>13an</b> inhibited colony formation of MDA-MB-231 cells. MDA-MB-231 cells were seeded in 6-well plates and treated with <b>13an</b> or dasatinib for 12 days. Colonies were stained with crystal violet, and pictures were taken. (B) <b>13an</b> induced apoptosis in MDA-MB-231 cells. MDA-MB-231 cells were harvested after treatment with various concentrations of <b>13an</b> and dasatinib for 24 h. Cells were stained using an Annexin V-FITC Apoptosis Detection Kit. (C) <b>13an</b> inhibited MDA-MB-231 cell migration in a wound healing assay. Cells were wounded by a pipet and then treated with various concentrations of compounds for 20 h. Scale bar, 100 μm.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00943&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/medium/jm-2016-00943q_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0007.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. <b>13an</b> inhibited the activation of multiple signaling pathways in intact cells. MDA-MB-231 cells were treated with <b>13an</b> or dasatinib for 20 h. The cells were lysed, and the proteins were analyzed by Western blot analysis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00943&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/medium/jm-2016-00943q_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0008.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. In vivo antitumor efficacies of <b>13an</b> against MDA-MB-231 (A) and MDA-MB-435 (B) tumor xenograft models, and average body weights for treated mice in the MDA-MB-231 (C) and MDA-MB-435 (D) xenograft models. Mice implanted with MDA-MB-231 or MDA-MB-435 cells were treated when the tumor grew to about 200 mm<sup>3</sup>. Animals (6 per group) were treated with solvent control, <b>13an</b> at oral doses of 10, 20, and 40 mg/kg/d, dasatinib at an oral dose of 40 mg/kg/day, or paclitaxel at a dose of 10 mg/kg/week through a tail vein injection. Points indicate mean tumor volumes (mm<sup>3</sup>) or mean body weights (g); bars indicate SD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00943&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/medium/jm-2016-00943q_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0009.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Mechanisms of action of <b>13an</b> in human tumor xenograft models. Mice bearing a MDA-MB-231 tumor xenograft treated with <b>13an</b> at 40 mg/kg/q.d. were humanely euthanized at the end of the experiment, and the tumor tissues were removed for further immunohistochemistry analysis. Scale bar, 100 μm. (B) 30 hpf zebrafish embryos were treated with a blank control or 1.25, 2.5, or 5 μM <b>13an</b>. ISV budding and outgrowth were completely inhibited by treatment with 1.25 μM <b>13an</b>. Scale bar, 200 μm. (C) The health status of rats in the acute toxicity evaluation. Average body weights of rats were monitored every 3 days after a single dose of <b>13an</b> at 200 mg/kg; <i>n</i> = 3; bars indicate SD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-21/acs.jmedchem.6b00943/20161104/images/large/jm-2016-00943q_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00943&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i107">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57085" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57085" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 44 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Foulkes, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reis-Filho, J. S.</span><span> </span><span class="NLM_article-title">Triple-negative breast cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">1938</span><span class="NLM_x">–</span> <span class="NLM_lpage">1948</span><span class="refDoi"> DOI: 10.1056/NEJMra1001389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1056%2FNEJMra1001389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=21067385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVCltr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1938-1948&author=W.+D.+Foulkesauthor=I.+E.+Smithauthor=J.+S.+Reis-Filho&title=Triple-negative+breast+cancer&doi=10.1056%2FNEJMra1001389"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Triple-negative breast cancer</span></div><div class="casAuthors">Foulkes, William D.; Smith, Ian E.; Reis-Filho, Jorge S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1938-1948</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiN8P8IsovvLVg90H21EOLACvtfcHk0lgKr87rNB_iVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVCltr7P&md5=641fe4726e6a7118208aa6b3502c9df6</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1001389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1001389%26sid%3Dliteratum%253Aachs%26aulast%3DFoulkes%26aufirst%3DW.%2BD.%26aulast%3DSmith%26aufirst%3DI.%2BE.%26aulast%3DReis-Filho%26aufirst%3DJ.%2BS.%26atitle%3DTriple-negative%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1938%26epage%3D1948%26doi%3D10.1056%2FNEJMra1001389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Schmadeka, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmon, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, M.</span><span> </span><span class="NLM_article-title">Triple-negative breast carcinoma: current and emerging concepts</span> <span class="citation_source-journal">Am. J. Clin. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">141</span><span class="NLM_x">, </span> <span class="NLM_fpage">462</span><span class="NLM_x">–</span> <span class="NLM_lpage">477</span><span class="refDoi"> DOI: 10.1309/AJCPQN8GZ8SILKGN</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1309%2FAJCPQN8GZ8SILKGN" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=24619745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosVyks7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2014&pages=462-477&author=R.+Schmadekaauthor=B.+E.+Harmonauthor=M.+Singh&title=Triple-negative+breast+carcinoma%3A+current+and+emerging+concepts&doi=10.1309%2FAJCPQN8GZ8SILKGN"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Triple-negative breast carcinoma current and emerging concepts</span></div><div class="casAuthors">Schmadeka, Robert; Harmon, Bryan E.; Singh, Meenakshi</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Clinical Pathology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">462-477</span>CODEN:
                <span class="NLM_cas:coden">AJCPAI</span>;
        ISSN:<span class="NLM_cas:issn">0002-9173</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Pathology</span>)
        </div><div class="casAbstract">A review.  Objectives: Triple-neg. breast cancer is regarded as an aggressive disease that affects a young patient population and for which effective targeted therapy is not yet available.  Methods: Intense efforts have been made to gain a better understanding of this heterogeneous group of tumors from the histol. to the genomic and mol. levels.  Results: Progress has been made, including the ability to subtype these tumors and the discovery of biomarkers toward which current therapeutic efforts are focused.  Many novel targets under exploration have the potential to affect the clin. course of this disease.  Conclusions This article reviews the current concepts regarding the clinicopathol. features of triple-neg. breast carcinoma, its histol. subtypes, mol. classification, the prognostic and therapeutic potential of biomarkers, and emerging targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPAq8FdcryxrVg90H21EOLACvtfcHk0ljTfL-vReBdQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosVyks7s%253D&md5=8cae66e043639ea6f8f49383c3772481</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1309%2FAJCPQN8GZ8SILKGN&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1309%252FAJCPQN8GZ8SILKGN%26sid%3Dliteratum%253Aachs%26aulast%3DSchmadeka%26aufirst%3DR.%26aulast%3DHarmon%26aufirst%3DB.%2BE.%26aulast%3DSingh%26aufirst%3DM.%26atitle%3DTriple-negative%2520breast%2520carcinoma%253A%2520current%2520and%2520emerging%2520concepts%26jtitle%3DAm.%2520J.%2520Clin.%2520Pathol.%26date%3D2014%26volume%3D141%26spage%3D462%26epage%3D477%26doi%3D10.1309%2FAJCPQN8GZ8SILKGN" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Prat, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adamo, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheang, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anders, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carey, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perou, C. M.</span><span> </span><span class="NLM_article-title">Molecular characterization of basal-like and non-basal-like triple-negative breast cancer</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">123</span><span class="NLM_x">–</span> <span class="NLM_lpage">133</span><span class="refDoi"> DOI: 10.1634/theoncologist.2012-0397</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1634%2Ftheoncologist.2012-0397" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=23404817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltFChsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=123-133&author=A.+Pratauthor=B.+Adamoauthor=M.+C.+Cheangauthor=C.+K.+Andersauthor=L.+A.+Careyauthor=C.+M.+Perou&title=Molecular+characterization+of+basal-like+and+non-basal-like+triple-negative+breast+cancer&doi=10.1634%2Ftheoncologist.2012-0397"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular characterization of basal-like and non-basal-like triple-negative breast cancer</span></div><div class="casAuthors">Prat, Aleix; Adamo, Barbara; Cheang, Maggie C. U.; Anders, Carey K.; Carey, Lisa A.; Perou, Charles M.</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-133</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">Triple-neg. (TN) and basal-like (BL) breast cancer definitions have been used interchangeably to identify breast cancers that lack expression of the hormone receptors and overexpression and/or amplification of HER2.  However, both classifications show substantial discordance rates when compared to each other.  Here, we molecularly characterize TN tumors and BL tumors, comparing and contrasting the results in terms of common patterns and distinct patterns for each.  In total, when testing 412 TN and 473 BL tumors, 21.4% and 31.5% were identified as non-BL and non-TN, resp.  TN tumors identified as luminal or HER2-enriched (HER2E) showed undistinguishable overall gene expression profiles when compared vs. luminal or HER2E tumors that were not TN.  Similar findings were obsd. within BL tumors regardless of their TN status, which suggests that mol. subtype is preserved regardless of individual marker results.  Interestingly, most TN tumors identified as HER2E showed low HER2 expression and lacked HER2 amplification, despite the similar overall gene expression profiles to HER2E tumors that were clin. HER2-pos.  Lastly, addnl. genomic classifications were examd. within TN and BL cancers, most of which were highly concordant with tumor intrinsic subtype.  These results suggest that future clin. trials focused on TN disease should consider stratifying patients based upon BL vs. non-BL gene expression profiles, which appears to be the main biol. difference seen in patients with TN breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrir3DV-VTCJbVg90H21EOLACvtfcHk0ljTfL-vReBdQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltFChsLs%253D&md5=015894461c9b3a6008a682e0c9251ac6</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2012-0397&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2012-0397%26sid%3Dliteratum%253Aachs%26aulast%3DPrat%26aufirst%3DA.%26aulast%3DAdamo%26aufirst%3DB.%26aulast%3DCheang%26aufirst%3DM.%2BC.%26aulast%3DAnders%26aufirst%3DC.%2BK.%26aulast%3DCarey%26aufirst%3DL.%2BA.%26aulast%3DPerou%26aufirst%3DC.%2BM.%26atitle%3DMolecular%2520characterization%2520of%2520basal-like%2520and%2520non-basal-like%2520triple-negative%2520breast%2520cancer%26jtitle%3DOncologist%26date%3D2013%26volume%3D18%26spage%3D123%26epage%3D133%26doi%3D10.1634%2Ftheoncologist.2012-0397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Lehmann, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietenpol, J. A.</span><span> </span><span class="NLM_article-title">Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes</span> <span class="citation_source-journal">J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">232</span><span class="NLM_x">, </span> <span class="NLM_fpage">142</span><span class="NLM_x">–</span> <span class="NLM_lpage">150</span><span class="refDoi"> DOI: 10.1002/path.4280</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1002%2Fpath.4280" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=24114677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A280%3ADC%252BC2c%252FktVyjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=232&publication_year=2014&pages=142-150&author=B.+D.+Lehmannauthor=J.+A.+Pietenpol&title=Identification+and+use+of+biomarkers+in+treatment+strategies+for+triple-negative+breast+cancer+subtypes&doi=10.1002%2Fpath.4280"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes</span></div><div class="casAuthors">Lehmann Brian D; Pietenpol Jennifer A</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of pathology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">232</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">142-50</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Triple-negative breast cancer (TNBC) is a heterogeneous disease with distinct molecular subtypes that respond differentially to chemotherapy and targeted agents.  The absence of high-frequency molecular alterations and a limited number of known biomarkers have limited the development of therapeutic strategies for the disease.  Herein, we summarize the results of the first round of targeted therapy approaches in TNBC and discuss new preclinical strategies.  Common themes emerge from the proposed strategies, such as the use of biomarkers to identify tumours with genomic instability, targeting adapted molecular states resulting from tumour suppressor loss, and targeting altered metabolic pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTtCSjtyCVZVynGiHuhFGv8fW6udTcc2ea0KvbwmxtfgLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c%252FktVyjsA%253D%253D&md5=a7a8e781d659aa5f0cf41feefaf8682c</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1002%2Fpath.4280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.4280%26sid%3Dliteratum%253Aachs%26aulast%3DLehmann%26aufirst%3DB.%2BD.%26aulast%3DPietenpol%26aufirst%3DJ.%2BA.%26atitle%3DIdentification%2520and%2520use%2520of%2520biomarkers%2520in%2520treatment%2520strategies%2520for%2520triple-negative%2520breast%2520cancer%2520subtypes%26jtitle%3DJ.%2520Pathol.%26date%3D2014%26volume%3D232%26spage%3D142%26epage%3D150%26doi%3D10.1002%2Fpath.4280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">von Minckwitz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M.</span><span> </span><span class="NLM_article-title">Neoadjuvant treatments for triple-negative breast cancer (TNBC)</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl 6</span><span class="NLM_x">) </span> <span class="NLM_fpage">vi35</span><span class="NLM_x">–</span> <span class="NLM_lpage">vi39</span><span class="refDoi"> DOI: 10.1093/annonc/mds193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1093%2Fannonc%2Fmds193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=23012300" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=vi35-vi39&issue=Suppl+6&author=G.+von+Minckwitzauthor=M.+Martin&title=Neoadjuvant+treatments+for+triple-negative+breast+cancer+%28TNBC%29&doi=10.1093%2Fannonc%2Fmds193"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmds193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmds193%26sid%3Dliteratum%253Aachs%26aulast%3Dvon%2BMinckwitz%26aufirst%3DG.%26aulast%3DMartin%26aufirst%3DM.%26atitle%3DNeoadjuvant%2520treatments%2520for%2520triple-negative%2520breast%2520cancer%2520%2528TNBC%2529%26jtitle%3DAnn.%2520Oncol.%26date%3D2012%26volume%3D23%26issue%3DSuppl%25206%26spage%3Dvi35%26epage%3Dvi39%26doi%3D10.1093%2Fannonc%2Fmds193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Masuda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baggerly, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez-Angulo, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meric-Bernstam, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valero, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehmann, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietenpol, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hortobagyi, G. N.</span><span> </span><span class="NLM_article-title">Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">5533</span><span class="NLM_x">–</span> <span class="NLM_lpage">5540</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-0799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1158%2F1078-0432.CCR-13-0799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=23948975" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFynsL7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=5533-5540&author=H.+Masudaauthor=K.+A.+Baggerlyauthor=Y.+Wangauthor=Y.+Zhangauthor=A.+M.+Gonzalez-Anguloauthor=F.+Meric-Bernstamauthor=V.+Valeroauthor=B.+D.+Lehmannauthor=J.+A.+Pietenpolauthor=G.+N.+Hortobagyi&title=Differential+response+to+neoadjuvant+chemotherapy+among+7+triple-negative+breast+cancer+molecular+subtypes&doi=10.1158%2F1078-0432.CCR-13-0799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes</span></div><div class="casAuthors">Masuda, Hiroko; Baggerly, Keith A.; Wang, Ying; Zhang, Ya; Gonzalez-Angulo, Ana Maria; Meric-Bernstam, Funda; Valero, Vicente; Lehmann, Brian D.; Pietenpol, Jennifer A.; Hortobagyi, Gabriel N.; Symmans, W. Fraser; Ueno, Naoto T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5533-5540</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The clin. relevancy of the 7-subtype classification of triple-neg. breast cancer (TNBC) reported by Lehmann and colleagues is unknown.  We investigated the clin. relevancy of TNBC heterogeneity by detg. pathol. complete response (pCR) rates after neoadjuvant chemotherapy, based on TNBC subtypes.  Exptl. Design: We revalidated the Lehmann and colleagues expts. using Affymetrix CEL files from public datasets.  We applied these methods to 146 patients with TNBC with gene expression microarrays obtained from June 2000 to March 2010 at our institution.  Of those, 130 had received std. neoadjuvant chemotherapy and had evaluable pathol. response data.  We classified the TNBC samples by subtype and then correlated subtype and pCR status using Fisher exact test and a logistic regression model.  We also assessed survival and compared the subtypes with PAM50 intrinsic subtypes and residual cancer burden (RCB) index.  Results: TNBC subtype and pCR status were significantly assocd. (P = 0.04379).  The basal-like 1 (BL1) subtype had the highest pCR rate (52%); basal-like 2 (BL2) and luminal androgen receptor had the lowest (0% and 10%, resp.).  TNBC subtype was an independent predictor of pCR status (P = 0.022) by a likelihood ratio test.  The subtypes better predicted pCR status than did the PAM50 intrinsic subtypes (basal-like vs. non basal-like).  Conclusions: Classifying TNBC by 7 subtypes predicts high vs. low pCR rate.  We confirm the clin. relevancy of the 7 subtypes of TNBC.  We need to prospectively validate whether the pCR rate differences translate into long-term outcome differences.  The 7-subtype classification may spur innovative personalized medicine strategies for patients with TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqWCdcnpnUTrVg90H21EOLACvtfcHk0ljRePlAfmXWVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFynsL7P&md5=a98409bc9f49e7948b21cde4c39df3ea</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0799%26sid%3Dliteratum%253Aachs%26aulast%3DMasuda%26aufirst%3DH.%26aulast%3DBaggerly%26aufirst%3DK.%2BA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DGonzalez-Angulo%26aufirst%3DA.%2BM.%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26aulast%3DValero%26aufirst%3DV.%26aulast%3DLehmann%26aufirst%3DB.%2BD.%26aulast%3DPietenpol%26aufirst%3DJ.%2BA.%26aulast%3DHortobagyi%26aufirst%3DG.%2BN.%26atitle%3DDifferential%2520response%2520to%2520neoadjuvant%2520chemotherapy%2520among%25207%2520triple-negative%2520breast%2520cancer%2520molecular%2520subtypes%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D5533%26epage%3D5540%26doi%3D10.1158%2F1078-0432.CCR-13-0799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Bayraktar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glück, S.</span><span> </span><span class="NLM_article-title">Molecularly targeted therapies for metastatic triple-negative breast cancer</span> <span class="citation_source-journal">Breast Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">138</span><span class="NLM_x">, </span> <span class="NLM_fpage">21</span><span class="NLM_x">–</span> <span class="NLM_lpage">35</span><span class="refDoi"> DOI: 10.1007/s10549-013-2421-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1007%2Fs10549-013-2421-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=23358903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsFOht7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2013&pages=21-35&author=S.+Bayraktarauthor=S.+Gl%C3%BCck&title=Molecularly+targeted+therapies+for+metastatic+triple-negative+breast+cancer&doi=10.1007%2Fs10549-013-2421-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Molecularly targeted therapies for metastatic triple-negative breast cancer</span></div><div class="casAuthors">Bayraktar, Soley; Glueck, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-35</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Triple-neg. breast cancer (TNBC) refers to a heterogeneous group of tumors that do not express the estrogen/progesterone-receptor (ER/PR), and human epidermal growth factor receptor-2 (HER2).  TNBC is an aggressive histol. subtype with limited treatment options and very poor prognosis following progression after std. chemotherapy regimens.  There have been significant improvements in the outcome of other subtypes of breast cancer, including ER-pos./HER2 overexpressed tumors, attributed to the addn. of targeted therapy, including hormonal agents and trastuzumab.  However, no specific targeted agents are currently available for the treatment of TNBC.  This review aims to collate and describe the most recent data on targeted therapies that have demonstrated efficacy in the management of metastatic TNBC.  Targeted agents that have been investigated in the treatment of metastatic TNBC include inhibitors of poly(ADP-ribose) polymerase, angiogenesis, mammalian target of rapamycin, epidermal growth factor receptor, HDAC, Jak2, and Src.  Several of these agents have shown considerable promise.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOoaRuEc8USbVg90H21EOLACvtfcHk0ljRePlAfmXWVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsFOht7Y%253D&md5=45c8c03991e456036dd3f2f34a2713eb</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2Fs10549-013-2421-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-013-2421-5%26sid%3Dliteratum%253Aachs%26aulast%3DBayraktar%26aufirst%3DS.%26aulast%3DGl%25C3%25BCck%26aufirst%3DS.%26atitle%3DMolecularly%2520targeted%2520therapies%2520for%2520metastatic%2520triple-negative%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2013%26volume%3D138%26spage%3D21%26epage%3D35%26doi%3D10.1007%2Fs10549-013-2421-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Finn, R. S.</span><span> </span><span class="NLM_article-title">Targeting Src in breast cancer</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1379</span><span class="NLM_x">–</span> <span class="NLM_lpage">1386</span><span class="refDoi"> DOI: 10.1093/annonc/mdn291</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1093%2Fannonc%2Fmdn291" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=18487549" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A280%3ADC%252BD1cvotV2rsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2008&pages=1379-1386&author=R.+S.+Finn&title=Targeting+Src+in+breast+cancer&doi=10.1093%2Fannonc%2Fmdn291"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Src in breast cancer</span></div><div class="casAuthors">Finn R S</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1379-86</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The clinical benefit of blocking oncogenic pathways in breast cancer and other malignancies has validated this approach and ushered in the era of molecularly targeted therapeutics.  Src and its family members make up the largest group of nonreceptor tyrosine kinases.  In laboratory models, these proteins have been shown to play a critical role in cellular growth and proliferation, angiogenesis, and invasion and metastasis.  In addition, Src plays an important role in osteoclast activation and bone resorption, which are often aberrantly activated in the setting of bone metastases.  Given its role in these functions, blocking Src kinase would be predicted to have a broad therapeutic benefit in patients with Src-dependent cancers.  In this review, we highlight the rationale for targeting Src in breast cancer, including laboratory and clinical data implicating it in these signaling pathways, and review small-molecule tyrosine kinase inhibitors currently in clinical development.  Identifying which patients should be selected for Src-directed therapies will be important to the clinical success of these agents.  Importantly, recent preclinical data support a role for this class of inhibitors in basal-type/triple-negative breast cancer, which represents a group of patients with limited effective treatment options.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSq3-Zi9cm6LUNHe_gFldTbfW6udTcc2eYw9mDyxbkq2bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cvotV2rsw%253D%253D&md5=b4f29b2ada4dcb6c89c0301a8440c617</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdn291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdn291%26sid%3Dliteratum%253Aachs%26aulast%3DFinn%26aufirst%3DR.%2BS.%26atitle%3DTargeting%2520Src%2520in%2520breast%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2008%26volume%3D19%26spage%3D1379%26epage%3D1386%26doi%3D10.1093%2Fannonc%2Fmdn291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Kim, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haura, E. B.</span><span> </span><span class="NLM_article-title">Src kinases as therapeutic targets for cancer</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">587</span><span class="NLM_x">–</span> <span class="NLM_lpage">595</span><span class="refDoi"> DOI: 10.1038/nrclinonc.2009.129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1038%2Fnrclinonc.2009.129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=19787002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFyntbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2009&pages=587-595&author=L.+C.+Kimauthor=L.+Songauthor=E.+B.+Haura&title=Src+kinases+as+therapeutic+targets+for+cancer&doi=10.1038%2Fnrclinonc.2009.129"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Src kinases as therapeutic targets for cancer</span></div><div class="casAuthors">Kim, Lori C.; Song, Lanxi; Haura, Eric B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">587-595</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Src family kinases have been extensively studied and found to be central mediators in multiple signaling pathways that are important in oncogenesis.  Preclin. studies have shown that SFK inhibitors can suppress tumor growth and metastases.  The authors of this Review discuss the potential use of these agents to target cancer in humans.  Src family kinases (SFKs) have a crit. role in cell adhesion, invasion, proliferation, survival, and angiogenesis during tumor development.  SFKs comprise nine family members that share similar structure and function.  Overexpression or high activation of SFKs occurs frequently in tumor tissues and they are central mediators in multiple signaling pathways that are important in oncogenesis.  SFKs can interact with tyrosine kinase receptors, such as EGFR and the VEGF receptor.  SFKs can affect cell proliferation via the Ras/ERK/MAPK pathway and can regulate gene expression via transcription factors such as STAT mols.  SFKs can also affect cell adhesion and migration via interaction with integrins, actins, GTPase-activating proteins, scaffold proteins, such as p130CAS and paxillin, and kinases such as focal adhesion kinases.  Furthermore, SFKs can regulate angiogenesis via gene expression of angiogenic growth factors, such as fibroblast growth factor, VEGF, and interleukin 8.  On the basis of these important findings, small-mol. SFK inhibitors have been developed and are undergoing early phase clin. testing.  In preclin. studies these agents can suppress tumor growth and metastases.  The agents seem to be safe in humans and could add to the therapeutic arsenal against subsets of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7mbcbDFh577Vg90H21EOLACvtfcHk0lh3G5hvDwSMQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFyntbbP&md5=5e9e587e835265d1c83857be11411dba</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2009.129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2009.129%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DL.%2BC.%26aulast%3DSong%26aufirst%3DL.%26aulast%3DHaura%26aufirst%3DE.%2BB.%26atitle%3DSrc%2520kinases%2520as%2520therapeutic%2520targets%2520for%2520cancer%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D6%26spage%3D587%26epage%3D595%26doi%3D10.1038%2Fnrclinonc.2009.129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowery, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sahin, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aldape, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steeg, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, D.</span><span> </span><span class="NLM_article-title">SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">5764</span><span class="NLM_x">–</span> <span class="NLM_lpage">5774</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-12-1803</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1158%2F0008-5472.CAN-12-1803" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=5764-5774&author=S.+Zhangauthor=W.+C.+Huangauthor=L.+Zhangauthor=C.+Zhangauthor=F.+J.+Loweryauthor=Z.+Dingauthor=H.+Guoauthor=H.+Wangauthor=S.+Huangauthor=A.+A.+Sahinauthor=K.+D.+Aldapeauthor=P.+S.+Steegauthor=D.+Yu&title=SRC+family+kinases+as+novel+therapeutic+targets+to+treat+breast+cancer+brain+metastases&doi=10.1158%2F0008-5472.CAN-12-1803"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-12-1803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-12-1803%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DW.%2BC.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLowery%26aufirst%3DF.%2BJ.%26aulast%3DDing%26aufirst%3DZ.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DSahin%26aufirst%3DA.%2BA.%26aulast%3DAldape%26aufirst%3DK.%2BD.%26aulast%3DSteeg%26aufirst%3DP.%2BS.%26aulast%3DYu%26aufirst%3DD.%26atitle%3DSRC%2520family%2520kinases%2520as%2520novel%2520therapeutic%2520targets%2520to%2520treat%2520breast%2520cancer%2520brain%2520metastases%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26spage%3D5764%26epage%3D5774%26doi%3D10.1158%2F0008-5472.CAN-12-1803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Shields, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiede, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurzov, E. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauser, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molloy, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Toole, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daly, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherland, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLean, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiganis, T.</span><span> </span><span class="NLM_article-title">TCPTP regulates SFK and STAT3 signaling and is lost in triple-negative breast cancers</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">557</span><span class="NLM_x">–</span> <span class="NLM_lpage">570</span><span class="refDoi"> DOI: 10.1128/MCB.01016-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1128%2FMCB.01016-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=23166300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVOitL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2013&pages=557-570&author=B.+J.+Shieldsauthor=F.+Wiedeauthor=E.+N.+Gurzovauthor=K.+Weeauthor=C.+Hauserauthor=H.+J.+Zhuauthor=T.+J.+Molloyauthor=S.+A.+O%E2%80%99Tooleauthor=R.+J.+Dalyauthor=R.+L.+Sutherlandauthor=C.+A.+Mitchellauthor=C.+A.+McLeanauthor=T.+Tiganis&title=TCPTP+regulates+SFK+and+STAT3+signaling+and+is+lost+in+triple-negative+breast+cancers&doi=10.1128%2FMCB.01016-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">TCPTP regulates SFK and STAT3 signaling and is lost in triple-negative breast cancers</span></div><div class="casAuthors">Shields, Benjamin J.; Wiede, Florian; Gurzov, Esteban N.; Wee, Kenneth; Hauser, Christine; Zhu, Hong-Jian; Molloy, Timothy J.; O'Toole, Sandra A.; Daly, Roger J.; Sutherland, Robert L.; Mitchell, Christina A.; McLean, Catriona A.; Tiganis, Tony</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">557-570</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Tyrosine phosphorylation-dependent signaling, as mediated by members of the epidermal growth factor receptor (EGFR) family (ErbB1 to -4) of protein tyrosine kinases (PTKs), Src family PTKs (SFKs), and cytokines such as interleukin-6 (IL-6) that signal via signal transducer and activator of transcription 3 (STAT3), is crit. to the development and progression of many human breast cancers.  EGFR, SFKs, and STAT3 can serve as substrates for the protein tyrosine phosphatase TCPTP (PTPN2).  Here we report that TCPTP protein levels are decreased in a subset of breast cancer cell lines in vitro and that TCPTP protein is absent in a large proportion of "triple-neg." primary human breast cancers.  Homozygous TCPTP deficiency in murine mammary fat pads in vivo is assocd. with elevated SFK and STAT3 signaling, whereas TCPTP deficiency in human breast cancer cell lines enhances SFK and STAT3 signaling.  On the other hand, TCPTP reconstitution in human breast cancer cell lines severely impaired cell proliferation and suppressed anchorage-independent growth in vitro and xenograft growth in vivo.  These studies establish TCPTP's potential to serve as a tumor suppressor in human breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYKrzpgI9BYrVg90H21EOLACvtfcHk0lh3G5hvDwSMQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVOitL0%253D&md5=82593972a2f8ee8979199c2d10903114</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1128%2FMCB.01016-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.01016-12%26sid%3Dliteratum%253Aachs%26aulast%3DShields%26aufirst%3DB.%2BJ.%26aulast%3DWiede%26aufirst%3DF.%26aulast%3DGurzov%26aufirst%3DE.%2BN.%26aulast%3DWee%26aufirst%3DK.%26aulast%3DHauser%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DH.%2BJ.%26aulast%3DMolloy%26aufirst%3DT.%2BJ.%26aulast%3DO%25E2%2580%2599Toole%26aufirst%3DS.%2BA.%26aulast%3DDaly%26aufirst%3DR.%2BJ.%26aulast%3DSutherland%26aufirst%3DR.%2BL.%26aulast%3DMitchell%26aufirst%3DC.%2BA.%26aulast%3DMcLean%26aufirst%3DC.%2BA.%26aulast%3DTiganis%26aufirst%3DT.%26atitle%3DTCPTP%2520regulates%2520SFK%2520and%2520STAT3%2520signaling%2520and%2520is%2520lost%2520in%2520triple-negative%2520breast%2520cancers%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2013%26volume%3D33%26spage%3D557%26epage%3D570%26doi%3D10.1128%2FMCB.01016-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Tryfonopoulos, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corkery, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDermott, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evoy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierce, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donovan, N.</span><span> </span><span class="NLM_article-title">Src: a potential target for the treatment of triple-negative breast cancer</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">2234</span><span class="NLM_x">–</span> <span class="NLM_lpage">2240</span><span class="refDoi"> DOI: 10.1093/annonc/mdq757</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1093%2Fannonc%2Fmdq757" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=21357651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A280%3ADC%252BC3MflvFCqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=2234-2240&author=D.+Tryfonopoulosauthor=S.+Walshauthor=D.+Collinsauthor=L.+Flanaganauthor=C.+Quinnauthor=B.+Corkeryauthor=E.+McDermottauthor=D.+Evoyauthor=A.+Pierceauthor=N.+O%E2%80%99Donovan&title=Src%3A+a+potential+target+for+the+treatment+of+triple-negative+breast+cancer&doi=10.1093%2Fannonc%2Fmdq757"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Src: a potential target for the treatment of triple-negative breast cancer</span></div><div class="casAuthors">Tryfonopoulos D; Walsh S; Collins D M; Flanagan L; Quinn C; Corkery B; McDermott E W; Evoy D; Pierce A; O'Donovan N; Crown J; Duffy M J</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2234-40</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Triple-negative breast cancers lack expression of estrogen and progesterone receptors and overexpression of human epidermal growth factor receptor 2 (HER2).  Unlike other subgroups of patients with breast cancer, targeted therapy is currently unavailable for these patients.  The aim of this study was to investigate v-src sarcoma viral oncogene homolog (Src) as a potential target for the treatment of triple-negative breast cancer.  METHODS:  Expression of Src was measured in 87 triple-negative and 93 non-triple-negative breast cancers.  Dasatinib (an inhibitor of Src) was tested in a panel of breast cancer cell lines.  RESULTS:  Cytoplasmic expression of Src was detected in 83 (95%) triple-negative samples versus 78 (84%) non-triple-negative samples (P = 0.012), while membrane Src was detected in 78% triple-negative compared with 38% of non-triple-negative specimens (P < 0.0001).  Dasatinib inhibited growth in three of five triple-negative cell lines (IC(50) < 1 μM).  Dasatinib combined with cisplatin was synergistic in the three dasatinib-sensitive cell lines (combination index < 0.9).  Dasatinib, in combination with 5'-deoxy-5'-fluoruridine, displayed synergy or additivity.  Moderate synergy was observed with docetaxel (Taxotere) in two cell lines but the combination was antagonistic in HCC-1143 cells.  CONCLUSIONS:  We conclude that dasatinib with cisplatin is a rational drug combination for testing in triple-negative breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQRLX-5M5TiggxyojvcjibhfW6udTcc2eazBhP6JQN-xbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MflvFCqsQ%253D%253D&md5=f91860cdb5da0f86ff6e0ef46eb3ff2f</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdq757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdq757%26sid%3Dliteratum%253Aachs%26aulast%3DTryfonopoulos%26aufirst%3DD.%26aulast%3DWalsh%26aufirst%3DS.%26aulast%3DCollins%26aufirst%3DD.%26aulast%3DFlanagan%26aufirst%3DL.%26aulast%3DQuinn%26aufirst%3DC.%26aulast%3DCorkery%26aufirst%3DB.%26aulast%3DMcDermott%26aufirst%3DE.%26aulast%3DEvoy%26aufirst%3DD.%26aulast%3DPierce%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Donovan%26aufirst%3DN.%26atitle%3DSrc%253A%2520a%2520potential%2520target%2520for%2520the%2520treatment%2520of%2520triple-negative%2520breast%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2011%26volume%3D22%26spage%3D2234%26epage%3D2240%26doi%3D10.1093%2Fannonc%2Fmdq757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Finn, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dering, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ginther, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glaspy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tchekmedyian, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slamon, D. J.</span><span> </span><span class="NLM_article-title">Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/″triple-negative″ breast cancer cell lines growing in vitro</span> <span class="citation_source-journal">Breast Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">319</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span><span class="refDoi"> DOI: 10.1007/s10549-006-9463-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1007%2Fs10549-006-9463-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=17268817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFSlsr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2007&pages=319-326&author=R.+S.+Finnauthor=J.+Deringauthor=C.+Gintherauthor=C.+A.+Wilsonauthor=P.+Glaspyauthor=N.+Tchekmedyianauthor=D.+J.+Slamon&title=Dasatinib%2C+an+orally+active+small+molecule+inhibitor+of+both+the+src+and+abl+kinases%2C+selectively+inhibits+growth+of+basal-type%2F%E2%80%B3triple-negative%E2%80%B3+breast+cancer+cell+lines+growing+in+vitro&doi=10.1007%2Fs10549-006-9463-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro</span></div><div class="casAuthors">Finn, Richard S.; Dering, Judy; Ginther, Charles; Wilson, Cindy A.; Glaspy, Padraic; Tchekmedyian, Nishan; Slamon, Dennis J.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">319-326</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Dasatinib is an orally active small mol. kinase inhibitor of both the src and abl proteins.  To evaluate the potential role of dasatinib in breast cancer we used 39 human breast cancer cell lines that have been mol. profiled using Agilent Microarrays.  They represent both luminal and basal breast cancer subtypes based on the relative gene expression of cytokeratin (CK) 8/CK18 and CK5/CK17, resp., and those that have undergone an epithelial-to-mesenchymal transition (post-EMT) based on their expression of vimentin and the loss of CKs.  When treated with 1 μM dasatinib in vitro 8 of them were highly sensitive (>60% growth inhibition), 10 of them were moderately sensitive (40-59% growth inhibition), and 21 were resistant to dasatinib.  A highly significant relationship between breast cancer subtype and sensitivity to dasatinib was obsd. (χ2 = 9.66 and P = 0.008).  Specifically, basal-type and post-EMT breast cancer cell lines were most sensitive to growth inhibition by dasatinib.  In an attempt to identify potential predictive markers of dasatinib response other than breast cancer subtype we analyzed the baseline gene expression profiles for differentially expressed genes.  We identified a set of three biol. relevant genes whose elevated expression is assocd. with dasatinib inhibition including moesin, caveolin-1, and yes-assocd. protein-1 with a sensitivity and specificity of 88 and 86%, resp.  Importantly, these data provide scientific rationale for the clin. development of dasatinib in the treatment of women with "triple-neg." breast cancer, a subtype that is categorized as being aggressive and lacking effective treatments (i.e. hormonal manipulation or trastuzumab).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuiY_J2m5UELVg90H21EOLACvtfcHk0liRNoeUTf2I0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFSlsr3N&md5=82beaf55532a0440f64e215ec57df02e</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1007%2Fs10549-006-9463-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-006-9463-x%26sid%3Dliteratum%253Aachs%26aulast%3DFinn%26aufirst%3DR.%2BS.%26aulast%3DDering%26aufirst%3DJ.%26aulast%3DGinther%26aufirst%3DC.%26aulast%3DWilson%26aufirst%3DC.%2BA.%26aulast%3DGlaspy%26aufirst%3DP.%26aulast%3DTchekmedyian%26aufirst%3DN.%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26atitle%3DDasatinib%252C%2520an%2520orally%2520active%2520small%2520molecule%2520inhibitor%2520of%2520both%2520the%2520src%2520and%2520abl%2520kinases%252C%2520selectively%2520inhibits%2520growth%2520of%2520basal-type%252F%25E2%2580%25B3triple-negative%25E2%2580%25B3%2520breast%2520cancer%2520cell%2520lines%2520growing%2520in%2520vitro%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2007%26volume%3D105%26spage%3D319%26epage%3D326%26doi%3D10.1007%2Fs10549-006-9463-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Finn, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bengala, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roche, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sparano, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strauss, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairchild, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sy, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, L. J.</span><span> </span><span class="NLM_article-title">Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">6905</span><span class="NLM_x">–</span> <span class="NLM_lpage">6913</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-0288</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1158%2F1078-0432.CCR-11-0288" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=22028489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVWlsrzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=6905-6913&author=R.+S.+Finnauthor=C.+Bengalaauthor=N.+Ibrahimauthor=H.+Rocheauthor=J.+Sparanoauthor=L.+C.+Straussauthor=J.+Fairchildauthor=O.+Syauthor=L.+J.+Goldstein&title=Dasatinib+as+a+single+agent+in+triple-negative+breast+cancer%3A+results+of+an+open-label+phase+2+study&doi=10.1158%2F1078-0432.CCR-11-0288"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study</span></div><div class="casAuthors">Finn, Richard S.; Bengala, Carmelo; Ibrahim, Nuhad; Roche, Henri; Sparano, Joseph; Strauss, Lewis C.; Fairchild, Justin; Sy, Oumar; Goldstein, Lori J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6905-6913</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Dasatinib is a potent, oral SRC-family kinase inhibitor with preclin. antiproliferative, antimetastatic, and antiosteoclastic activity suggesting dasatinib sensitivity in triple-neg., or basal-like, breast cancer cell lines.  This phase 2 trial assessed efficacy and safety of single-agent dasatinib in patients with advanced triple-neg. breast cancer (TNBC).  Exptl. Design: Female patients with measurable, locally advanced or metastatic TNBC initially received dasatinib 100 mg twice daily (BID); to improve tolerability, the protocol was amended and subsequent patients received 70 mg BID.  Primary endpoint was Response Evaluation Criteria in Solid Tumors-defined objective response rate (ORR); secondary endpoints included progression-free survival (PFS), disease control rate (DCR), safety, and limited pharmacokinetics.  RESULTS: Of the 44 treated patients, 43 were response evaluable.  ORR was 4.7%: two patients had confirmed partial responses lasting 14 and 58 wk, resp.  Of 11 patients with stable disease, two continued for more than 16 wk, thus protocol-defined DCR was 9.3%.  Median PFS was 8.3 wk (95% CI: 7.3-15.3).  Five patients discontinued before first tumor assessment.  No grade 4 adverse events (AE) were reported; grade 3 AEs occurring in more than 5% of patients were fatigue (9.1%), diarrhea, pleural effusion, and dyspnea (all 6.8%).  Lab. abnormalities were uncommon.  Dasatinib at 100 mg BID was not well tolerated; rates of treatment interruption, dose redn., and serious AEs were lower with dasatinib 70 mg BID.  CONCLUSIONS: Single-agent dasatinib has limited activity in unselected patients with TNBC.  Dasatinib 70 mg BID was better tolerated than 100 mg BID.  Future studies will investigate dasatinib in other breast cancer settings, including chemotherapy combinations.  Clin Cancer Res; 17(21); 6905-13.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1kTbssh-wALVg90H21EOLACvtfcHk0liTKcIMEiDjAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVWlsrzE&md5=a9133015486c0f5d61a2b6cc33ab7e53</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-0288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-0288%26sid%3Dliteratum%253Aachs%26aulast%3DFinn%26aufirst%3DR.%2BS.%26aulast%3DBengala%26aufirst%3DC.%26aulast%3DIbrahim%26aufirst%3DN.%26aulast%3DRoche%26aufirst%3DH.%26aulast%3DSparano%26aufirst%3DJ.%26aulast%3DStrauss%26aufirst%3DL.%2BC.%26aulast%3DFairchild%26aufirst%3DJ.%26aulast%3DSy%26aufirst%3DO.%26aulast%3DGoldstein%26aufirst%3DL.%2BJ.%26atitle%3DDasatinib%2520as%2520a%2520single%2520agent%2520in%2520triple-negative%2520breast%2520cancer%253A%2520results%2520of%2520an%2520open-label%2520phase%25202%2520study%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D6905%26epage%3D6913%26doi%3D10.1158%2F1078-0432.CCR-11-0288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Das, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padmanabha, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moquin, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doweyko, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Fex, H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuster, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillooly, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behnia, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schieven, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wityak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span> </span><span class="NLM_article-title">2-Aminothiazole as a novel kinase inhibitor template. Structure–activity relationship studies toward the discovery of N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (Dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6819</span><span class="NLM_x">–</span> <span class="NLM_lpage">6832</span><span class="refDoi"> DOI: 10.1021/jm060727j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060727j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6819-6832&author=J.+Dasauthor=P.+Chenauthor=D.+Norrisauthor=R.+Padmanabhaauthor=J.+Linauthor=R.+V.+Moquinauthor=Z.+Shenauthor=L.+S.+Cookauthor=A.+M.+Doweykoauthor=S.+Pittauthor=S.+Pangauthor=D.+R.+Shenauthor=Q.+Fangauthor=H.+F.+de+Fexauthor=K.+W.+McIntyreauthor=D.+J.+Shusterauthor=K.+M.+Gilloolyauthor=K.+Behniaauthor=G.+L.+Schievenauthor=J.+Wityakauthor=J.+C.+Barrish&title=2-Aminothiazole+as+a+novel+kinase+inhibitor+template.+Structure%E2%80%93activity+relationship+studies+toward+the+discovery+of+N-%282-Chloro-6-methylphenyl%29-2-%5B%5B6-%5B4-%282-hydroxyethyl%29-1-+piperazinyl%29%5D-2-methyl-4-pyrimidinyl%5Damino%29%5D-1%2C3-thiazole-5-carboxamide+%28Dasatinib%2C+BMS-354825%29+as+a+potent+pan-Src+kinase+inhibitor&doi=10.1021%2Fjm060727j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm060727j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060727j%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DNorris%26aufirst%3DD.%26aulast%3DPadmanabha%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DMoquin%26aufirst%3DR.%2BV.%26aulast%3DShen%26aufirst%3DZ.%26aulast%3DCook%26aufirst%3DL.%2BS.%26aulast%3DDoweyko%26aufirst%3DA.%2BM.%26aulast%3DPitt%26aufirst%3DS.%26aulast%3DPang%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DD.%2BR.%26aulast%3DFang%26aufirst%3DQ.%26aulast%3Dde%2BFex%26aufirst%3DH.%2BF.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DShuster%26aufirst%3DD.%2BJ.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DBehnia%26aufirst%3DK.%26aulast%3DSchieven%26aufirst%3DG.%2BL.%26aulast%3DWityak%26aufirst%3DJ.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26atitle%3D2-Aminothiazole%2520as%2520a%2520novel%2520kinase%2520inhibitor%2520template.%2520Structure%25E2%2580%2593activity%2520relationship%2520studies%2520toward%2520the%2520discovery%2520of%2520N-%25282-Chloro-6-methylphenyl%2529-2-%255B%255B6-%255B4-%25282-hydroxyethyl%2529-1-%2520piperazinyl%2529%255D-2-methyl-4-pyrimidinyl%255Damino%2529%255D-1%252C3-thiazole-5-carboxamide%2520%2528Dasatinib%252C%2520BMS-354825%2529%2520as%2520a%2520potent%2520pan-Src%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6819%26epage%3D6832%26doi%3D10.1021%2Fjm060727j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Mayer, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abramson, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehmann, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietenpol, J. A.</span><span> </span><span class="NLM_article-title">New strategies for triple-negative breast cancer--deciphering the heterogeneity</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">782</span><span class="NLM_x">–</span> <span class="NLM_lpage">790</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-0583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1158%2F1078-0432.CCR-13-0583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=24536073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivVejsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=782-790&author=I.+A.+Mayerauthor=V.+G.+Abramsonauthor=B.+D.+Lehmannauthor=J.+A.+Pietenpol&title=New+strategies+for+triple-negative+breast+cancer%2D%2Ddeciphering+the+heterogeneity&doi=10.1158%2F1078-0432.CCR-13-0583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">New Strategies for Triple-Negative Breast Cancer-Deciphering the Heterogeneity</span></div><div class="casAuthors">Mayer, Ingrid A.; Abramson, Vandana G.; Lehmann, Brian D.; Pietenpol, Jennifer A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">782-790</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Triple-neg. breast cancer (TNBC) is a heterogeneous disease; gene expression analyses recently identified six distinct TNBC subtypes, each displaying a unique biol.  Exploring novel approaches to treatment of these subtypes is crit. because less than 30% of women with metastatic breast cancer survive five years and virtually all women with metastatic TNBC will ultimately die of their disease despite systemic therapy.  To date, not a single targeted therapy has been approved for the treatment of TNBC and cytotoxic chemotherapy remains the std. treatment.  We discuss the current and upcoming therapeutic strategies being explored in an attempt to "target" TNBC.  Clin Cancer Res; 20(4); 782-90. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdvsR_JjXMyLVg90H21EOLACvtfcHk0liTKcIMEiDjAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivVejsb0%253D&md5=4ce0876cb914096f913a7a637d7b63d5</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0583%26sid%3Dliteratum%253Aachs%26aulast%3DMayer%26aufirst%3DI.%2BA.%26aulast%3DAbramson%26aufirst%3DV.%2BG.%26aulast%3DLehmann%26aufirst%3DB.%2BD.%26aulast%3DPietenpol%26aufirst%3DJ.%2BA.%26atitle%3DNew%2520strategies%2520for%2520triple-negative%2520breast%2520cancer--deciphering%2520the%2520heterogeneity%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D782%26epage%3D790%26doi%3D10.1158%2F1078-0432.CCR-13-0583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Kalimutho, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mittal, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">López, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srihari, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khanna, K. K.</span><span> </span><span class="NLM_article-title">Targeted therapies for triple-negative breast cancer: combating a stubborn disease</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">822</span><span class="NLM_x">–</span> <span class="NLM_lpage">846</span><span class="refDoi"> DOI: 10.1016/j.tips.2015.08.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1016%2Fj.tips.2015.08.009" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=822-846&author=M.+Kalimuthoauthor=K.+Parsonsauthor=D.+Mittalauthor=J.+A.+L%C3%B3pezauthor=S.+Srihariauthor=K.+K.+Khanna&title=Targeted+therapies+for+triple-negative+breast+cancer%3A+combating+a+stubborn+disease&doi=10.1016%2Fj.tips.2015.08.009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2015.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2015.08.009%26sid%3Dliteratum%253Aachs%26aulast%3DKalimutho%26aufirst%3DM.%26aulast%3DParsons%26aufirst%3DK.%26aulast%3DMittal%26aufirst%3DD.%26aulast%3DL%25C3%25B3pez%26aufirst%3DJ.%2BA.%26aulast%3DSrihari%26aufirst%3DS.%26aulast%3DKhanna%26aufirst%3DK.%2BK.%26atitle%3DTargeted%2520therapies%2520for%2520triple-negative%2520breast%2520cancer%253A%2520combating%2520a%2520stubborn%2520disease%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2015%26volume%3D36%26spage%3D822%26epage%3D846%26doi%3D10.1016%2Fj.tips.2015.08.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Giltnane, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balko, J. M.</span><span> </span><span class="NLM_article-title">Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancer</span> <span class="citation_source-journal">Discovery Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">275</span><span class="NLM_x">–</span> <span class="NLM_lpage">283</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=24882719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A280%3ADC%252BC2cjot1Khsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2014&pages=275-283&author=J.+M.+Giltnaneauthor=J.+M.+Balko&title=Rationale+for+targeting+the+Ras%2FMAPK+pathway+in+triple-negative+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancer</span></div><div class="casAuthors">Giltnane Jennifer M; Balko Justin M</div><div class="citationInfo"><span class="NLM_cas:title">Discovery medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">95</span>),
    <span class="NLM_cas:pages">275-83</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">"Triple negative" breast cancer (TNBC) is the most aggressive and least common clinical subtype of breast cancer.  As its nomenclature implies, TNBC lacks specific biomarker expression marking response to an effective targeted therapy.  The incidence of TNBC is higher in young minority women who suffer from high rates of early recurrence and death from their disease.  Mounting preclinical evidence supports targeting the Ras/MAPK cell signaling pathway in the TNBC subtype, despite large genomic surveys such as The Cancer Genome Atlas demonstrating infrequent canonical mutations in this pathway.  Due to the early spread of TNBC, targeted treatment in the neoadjuvant setting may offer the effective therapeutic punch needed to eliminate micro-metastatic disease and reduce mortality.  Herein, we will review the evidence supporting clinical trials of targeted inhibitors of the Ras/MAPK pathway in TNBC, and discuss the obstacles and opportunities of this approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRuQgkh0x-AT-kdrW1FkXG-fW6udTcc2eZkrond315dlLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cjot1Khsg%253D%253D&md5=b9ce19b319c945165e53f77dcc6e290b</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGiltnane%26aufirst%3DJ.%2BM.%26aulast%3DBalko%26aufirst%3DJ.%2BM.%26atitle%3DRationale%2520for%2520targeting%2520the%2520Ras%252FMAPK%2520pathway%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DDiscovery%2520Med.%26date%3D2014%26volume%3D17%26spage%3D275%26epage%3D283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Bianchi-Smiraglia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paesante, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bakin, A. V.</span><span> </span><span class="NLM_article-title">Integrin β5 contributes to the tumorigenic potential of breast cancer cells through the Src-FAK and MEK-ERK signaling pathways</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">3049</span><span class="NLM_x">–</span> <span class="NLM_lpage">3058</span><span class="refDoi"> DOI: 10.1038/onc.2012.320</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1038%2Fonc.2012.320" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=22824793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOisrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=3049-3058&author=A.+Bianchi-Smiragliaauthor=S.+Paesanteauthor=A.+V.+Bakin&title=Integrin+%CE%B25+contributes+to+the+tumorigenic+potential+of+breast+cancer+cells+through+the+Src-FAK+and+MEK-ERK+signaling+pathways&doi=10.1038%2Fonc.2012.320"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Integrin β5 contributes to the tumorigenic potential of breast cancer cells through the Src-FAK and MEK-ERK signaling pathways</span></div><div class="casAuthors">Bianchi-Smiraglia, A.; Paesante, S.; Bakin, A. V.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">3049-3058</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancer progression, response to therapy and metastasis depend on tumor microenvironment.  Integrins are cell-adhesion receptors that mediate interactions of cells with extracellular matrix.  The αv-β-family of integrins contributes to tumorigenesis, response to therapy and cancer stem cell biol.  Thus, understanding the function of specific integrins in cancer is crit. for the development of therapeutic approaches targeting integrins.  The study investigated the role of integrin β5 in breast carcinomas by depleting integrin β5 using RNA interference and reexpression of integrin β5.  Depletion of integrin β5 in triple-neg. breast carcinoma cells markedly reduced tumor take, growth and tumor angiogenesis, whereas reexpression of integrin β5 rescued this phenotype.  Redn. in tumor angiogenesis is assocd. with lower expression of vascular endothelial growth factor-A in integrin β5-depleted tumors.  Tumor cells deficient in integrin β5 have lower migration and proliferative capacities.  Biochem. assays revealed that integrin β5 mediates the Src-focal adhesion kinase and MEK-extracellular signal-regulated kinase signaling events that operate independently, and inhibition of these pathways phenocopies integrin β5 deficiency.  Breast carcinoma cells express high levels of integrin β5, whereas expression of integrin β3 is limited to stromal compartments and integrin β6 is lost in metastatic cells.  Together, these findings show a crit. role for integrin β5 in the tumorigenic potential of breast carcinoma cells and therapeutic targeting of integrin β5 is esp. attractive for triple-neg. breast carcinomas, which are refractory to most of the current therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtxbA3BTsodrVg90H21EOLACvtfcHk0lgN-Lra4DUQiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOisrnF&md5=c11d07878b3158c26f34574e94f6865c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fonc.2012.320&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2012.320%26sid%3Dliteratum%253Aachs%26aulast%3DBianchi-Smiraglia%26aufirst%3DA.%26aulast%3DPaesante%26aufirst%3DS.%26aulast%3DBakin%26aufirst%3DA.%2BV.%26atitle%3DIntegrin%2520%25CE%25B25%2520contributes%2520to%2520the%2520tumorigenic%2520potential%2520of%2520breast%2520cancer%2520cells%2520through%2520the%2520Src-FAK%2520and%2520MEK-ERK%2520signaling%2520pathways%26jtitle%3DOncogene%26date%3D2013%26volume%3D32%26spage%3D3049%26epage%3D3058%26doi%3D10.1038%2Fonc.2012.320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">El Touny, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vieira, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendoza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khanna, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoenerhoff, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, J. E.</span><span> </span><span class="NLM_article-title">Combined SFK/MEK inhibition prevents metastatic outgrowth of dormant tumor cells</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">124</span><span class="NLM_x">, </span> <span class="NLM_fpage">156</span><span class="NLM_x">–</span> <span class="NLM_lpage">168</span><span class="refDoi"> DOI: 10.1172/JCI70259</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1172%2FJCI70259" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=156-168&author=L.+H.+El+Tounyauthor=A.+Vieiraauthor=A.+Mendozaauthor=C.+Khannaauthor=M.+J.+Hoenerhoffauthor=J.+E.+Green&title=Combined+SFK%2FMEK+inhibition+prevents+metastatic+outgrowth+of+dormant+tumor+cells&doi=10.1172%2FJCI70259"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1172%2FJCI70259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI70259%26sid%3Dliteratum%253Aachs%26aulast%3DEl%2BTouny%26aufirst%3DL.%2BH.%26aulast%3DVieira%26aufirst%3DA.%26aulast%3DMendoza%26aufirst%3DA.%26aulast%3DKhanna%26aufirst%3DC.%26aulast%3DHoenerhoff%26aufirst%3DM.%2BJ.%26aulast%3DGreen%26aufirst%3DJ.%2BE.%26atitle%3DCombined%2520SFK%252FMEK%2520inhibition%2520prevents%2520metastatic%2520outgrowth%2520of%2520dormant%2520tumor%2520cells%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2014%26volume%3D124%26spage%3D156%26epage%3D168%26doi%3D10.1172%2FJCI70259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Zhang, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, X. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, X. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S. Y.</span><span> </span><span class="NLM_article-title">Design, synthesis, and structure-activity relationship studies of 3-(phenylethynyl)-1H-pyrazolo 3,4-d pyrimidin-4-amine derivatives as a new class of Src inhibitors with potent activities in models of triple negative breast cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">3957</span><span class="NLM_x">–</span> <span class="NLM_lpage">3974</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00270</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00270" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3957-3974&author=C.+H.+Zhangauthor=M.+W.+Zhengauthor=Y.+P.+Liauthor=X.+D.+Linauthor=M.+Huangauthor=L.+Zhongauthor=G.+B.+Liauthor=R.+J.+Zhangauthor=W.+T.+Linauthor=Y.+Jiaoauthor=X.+A.+Wuauthor=J.+Yangauthor=R.+Xiangauthor=L.+J.+Chenauthor=Y.+L.+Zhaoauthor=W.+Chengauthor=Y.+Q.+Weiauthor=S.+Y.+Yang&title=Design%2C+synthesis%2C+and+structure-activity+relationship+studies+of+3-%28phenylethynyl%29-1H-pyrazolo+3%2C4-d+pyrimidin-4-amine+derivatives+as+a+new+class+of+Src+inhibitors+with+potent+activities+in+models+of+triple+negative+breast+cancer&doi=10.1021%2Facs.jmedchem.5b00270"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00270%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%2BH.%26aulast%3DZheng%26aufirst%3DM.%2BW.%26aulast%3DLi%26aufirst%3DY.%2BP.%26aulast%3DLin%26aufirst%3DX.%2BD.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DZhong%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DG.%2BB.%26aulast%3DZhang%26aufirst%3DR.%2BJ.%26aulast%3DLin%26aufirst%3DW.%2BT.%26aulast%3DJiao%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DX.%2BA.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DXiang%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DL.%2BJ.%26aulast%3DZhao%26aufirst%3DY.%2BL.%26aulast%3DCheng%26aufirst%3DW.%26aulast%3DWei%26aufirst%3DY.%2BQ.%26aulast%3DYang%26aufirst%3DS.%2BY.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520structure-activity%2520relationship%2520studies%2520of%25203-%2528phenylethynyl%2529-1H-pyrazolo%25203%252C4-d%2520pyrimidin-4-amine%2520derivatives%2520as%2520a%2520new%2520class%2520of%2520Src%2520inhibitors%2520with%2520potent%2520activities%2520in%2520models%2520of%2520triple%2520negative%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3957%26epage%3D3974%26doi%3D10.1021%2Facs.jmedchem.5b00270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Sanguinetti, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tristani-Firouzi, M.</span><span> </span><span class="NLM_article-title">hERG potassium channels and cardiac arrhythmia</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">440</span><span class="NLM_x">, </span> <span class="NLM_fpage">463</span><span class="NLM_x">–</span> <span class="NLM_lpage">469</span><span class="refDoi"> DOI: 10.1038/nature04710</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1038%2Fnature04710" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=16554806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BD28Xis1OlsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=440&publication_year=2006&pages=463-469&author=M.+C.+Sanguinettiauthor=M.+Tristani-Firouzi&title=hERG+potassium+channels+and+cardiac+arrhythmia&doi=10.1038%2Fnature04710"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">hERG potassium channels and cardiac arrhythmia</span></div><div class="casAuthors">Sanguinetti, Michael C.; Tristani-Firouzi, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">440</span>
        (<span class="NLM_cas:issue">7083</span>),
    <span class="NLM_cas:pages">463-469</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  HERG potassium channels are essential for normal elec. activity in the heart.  Inherited mutations in the HERG gene cause long QT syndrome, a disorder that predisposes individuals to life-threatening arrhythmias.  Arrhythmia can also be induced by a blockage of hERG channels by a surprisingly diverse group of drugs.  This side effect is a common reason for drug failure in preclin. safety trials.  Insights gained from the crystal structures of other potassium channels have helped our understanding of the block of hERG channels and the mechanisms of gating.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopS3WBEpuAUrVg90H21EOLACvtfcHk0lhT_yumYHFOGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xis1OlsLs%253D&md5=3f355dcd51da3488d73c7c91cbe8d3b8</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnature04710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature04710%26sid%3Dliteratum%253Aachs%26aulast%3DSanguinetti%26aufirst%3DM.%2BC.%26aulast%3DTristani-Firouzi%26aufirst%3DM.%26atitle%3DhERG%2520potassium%2520channels%2520and%2520cardiac%2520arrhythmia%26jtitle%3DNature%26date%3D2006%26volume%3D440%26spage%3D463%26epage%3D469%26doi%3D10.1038%2Fnature04710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Knight, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">Targeting the cancer kinome through polypharmacology</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">130</span><span class="NLM_x">–</span> <span class="NLM_lpage">137</span><span class="refDoi"> DOI: 10.1038/nrc2787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1038%2Fnrc2787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=20094047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=130-137&author=Z.+A.+Knightauthor=H.+Linauthor=K.+M.+Shokat&title=Targeting+the+cancer+kinome+through+polypharmacology&doi=10.1038%2Fnrc2787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the cancer kinome through polypharmacology</span></div><div class="casAuthors">Knight, Zachary A.; Lin, Henry; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-137</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Kinase inhibitors are the largest class of new cancer drugs.  However, it is already apparent that most tumors can escape from the inhibition of any single kinase.  If it is necessary to inhibit multiple kinases, how do we choose which ones.  In this Opinion article, we discuss some of the strategies that are currently being used to identify new therapeutic combinations of kinase targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkDv2FeeH58rVg90H21EOLACvtfcHk0lhT_yumYHFOGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D&md5=9aaa314e54b43889e147a9f11ac77072</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnrc2787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2787%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DTargeting%2520the%2520cancer%2520kinome%2520through%2520polypharmacology%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D130%26epage%3D137%26doi%3D10.1038%2Fnrc2787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Davis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hocker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">Comprehensive analysis of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1046</span><span class="NLM_x">–</span> <span class="NLM_lpage">1051</span><span class="refDoi"> DOI: 10.1038/nbt.1990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1038%2Fnbt.1990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=22037378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1046-1051&author=M.+I.+Davisauthor=J.+P.+Huntauthor=S.+Herrgardauthor=P.+Ciceriauthor=L.+M.+Wodickaauthor=G.+Pallaresauthor=M.+Hockerauthor=D.+K.+Treiberauthor=P.+P.+Zarrinkar&title=Comprehensive+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt.1990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Davis, Mindy I.; Hunt, Jeremy P.; Herrgard, Sanna; Ciceri, Pietro; Wodicka, Lisa M.; Pallares, Gabriel; Hocker, Michael; Treiber, Daniel K.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1046-1051</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We tested the interaction of 72 kinase inhibitors with 442 kinases covering >80% of the human catalytic protein kinome.  Our data show that, as a class, type II inhibitors are more selective than type I inhibitors, but that there are important exceptions to this trend.  The data further illustrate that selective inhibitors have been developed against the majority of kinases targeted by the compds. tested.  Anal. of the interaction patterns reveals a class of 'group-selective' inhibitors broadly active against a single subfamily of kinases, but selective outside that subfamily.  The data set suggests compds. to use as tools to study kinases for which no dedicated inhibitors exist.  It also provides a foundation for further exploring kinase inhibitor biol. and toxicity, as well as for studying the structural basis of the obsd. interaction patterns.  Our findings will help to realize the direct enabling potential of genomics for drug development and basic research about cellular signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEZnKVs6Xt5rVg90H21EOLACvtfcHk0lhT_yumYHFOGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK&md5=67639f702cb48ffb2c60e9a250f0df5e</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1990%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DHocker%26aufirst%3DM.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DComprehensive%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D1046%26epage%3D1051%26doi%3D10.1038%2Fnbt.1990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Sánchez-Bailón, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calcabrini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gómez-Domínguez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morte, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martín-Forero, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gómez-López, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molinari, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, K.-U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martín-Pérez, J.</span><span> </span><span class="NLM_article-title">Src kinases catalytic activity regulates proliferation, migration and invasiveness of MDA-MB-231 breast cancer cells</span> <span class="citation_source-journal">Cell. Signalling</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1276</span><span class="NLM_x">–</span> <span class="NLM_lpage">1286</span><span class="refDoi"> DOI: 10.1016/j.cellsig.2012.02.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1016%2Fj.cellsig.2012.02.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=22570868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvF2itrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2012&pages=1276-1286&author=M.+P.+S%C3%A1nchez-Bail%C3%B3nauthor=A.+Calcabriniauthor=D.+G%C3%B3mez-Dom%C3%ADnguezauthor=B.+Morteauthor=E.+Mart%C3%ADn-Foreroauthor=G.+G%C3%B3mez-L%C3%B3pezauthor=A.+Molinariauthor=K.-U.+Wagnerauthor=J.+Mart%C3%ADn-P%C3%A9rez&title=Src+kinases+catalytic+activity+regulates+proliferation%2C+migration+and+invasiveness+of+MDA-MB-231+breast+cancer+cells&doi=10.1016%2Fj.cellsig.2012.02.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Src kinases catalytic activity regulates proliferation, migration and invasiveness of MDA-MB-231 breast cancer cells</span></div><div class="casAuthors">Sanchez-Bailon, Maria Pilar; Calcabrini, Annarica; Gomez-Dominguez, Daniel; Morte, Beatriz; Martin-Forero, Esther; Gomez-Lopez, Gonzalo; Molinari, Agnese; Wagner, Kay-Uwe; Martin-Perez, Jorge</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1276-1286</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">SFKs are frequently deregulated in cancer where they control cellular proliferation, migration, survival and metastasis.  Here we study the role of SFKs catalytic activity in triple-neg./basal-like and metastatic human breast cancer MDA-MB-231 cells employing three well-established inhibitors: Dasatinib, PP2 and SU6656.  These compds. inhibited migration and invasion.  Concomitantly, they reduced Fak, paxillin, p130CAS, caveolin-1 phosphorylation and altered cytoskeletal structures.  They also inhibited cell proliferation, but in different manners.  Dasatinib and PP2 increased p27Kip1 expression and reduced c-Myc levels, restraining G1-S transition.  In contrast, SU6656 did not modify p27Kip1 expression, slightly altered c-Myc levels and generated polyploid multinucleated cells, indicating inhibition of cytokinesis.  These later effects were also obsd. in SYF fibroblasts, suggesting a SFKs-independent action.  ZM447439, an Aurora B kinase inhibitor, produced similar cell cycle and morphol. alterations in MDA-MB-231 cells, indicating that SU6656 blocked Aurora B kinase.  This was confirmed by inhibition of histone H3 phosphorylation, the canonical Aurora B kinase substrate.  Furthermore, hierarchical clustering anal. of gene expression profiles showed that SU6656 defined a set of genes that differed from Dasatinib and PP2.  Addnl., Gene Set Enrichment Analyses revealed that SU6656 significantly reduces the Src pathway.  Together, these results show the importance of SFKs catalytic activity for MDA-MB-231 proliferation, migration and invasiveness.  They also illustrate that SU6656 acts as dual SFKs and Aurora B kinase inhibitor, suggesting its possible use as a therapeutic agent in breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxhZ62Ycaq7bVg90H21EOLACvtfcHk0lhtF2eK4GuCvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvF2itrw%253D&md5=527ed67289deb9acc1ab9a6fe15b527d</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2012.02.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2012.02.011%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25A1nchez-Bail%25C3%25B3n%26aufirst%3DM.%2BP.%26aulast%3DCalcabrini%26aufirst%3DA.%26aulast%3DG%25C3%25B3mez-Dom%25C3%25ADnguez%26aufirst%3DD.%26aulast%3DMorte%26aufirst%3DB.%26aulast%3DMart%25C3%25ADn-Forero%26aufirst%3DE.%26aulast%3DG%25C3%25B3mez-L%25C3%25B3pez%26aufirst%3DG.%26aulast%3DMolinari%26aufirst%3DA.%26aulast%3DWagner%26aufirst%3DK.-U.%26aulast%3DMart%25C3%25ADn-P%25C3%25A9rez%26aufirst%3DJ.%26atitle%3DSrc%2520kinases%2520catalytic%2520activity%2520regulates%2520proliferation%252C%2520migration%2520and%2520invasiveness%2520of%2520MDA-MB-231%2520breast%2520cancer%2520cells%26jtitle%3DCell.%2520Signalling%26date%3D2012%26volume%3D24%26spage%3D1276%26epage%3D1286%26doi%3D10.1016%2Fj.cellsig.2012.02.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Egan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durda, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujita, D. J.</span><span> </span><span class="NLM_article-title">Activation of Src in human breast tumor cell lines: elevated levels of phosphotyrosine phosphatase activity that preferentially recognizes the Src carboxy terminal negative regulatory tyrosine 530</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1227</span><span class="NLM_x">–</span> <span class="NLM_lpage">1237</span><span class="refDoi"> DOI: 10.1038/sj.onc.1202233</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1038%2Fsj.onc.1202233" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1999&pages=1227-1237&author=C.+Eganauthor=A.+Pangauthor=D.+Durdaauthor=H.+C.+Chengauthor=J.+H.+Wangauthor=D.+J.+Fujita&title=Activation+of+Src+in+human+breast+tumor+cell+lines%3A+elevated+levels+of+phosphotyrosine+phosphatase+activity+that+preferentially+recognizes+the+Src+carboxy+terminal+negative+regulatory+tyrosine+530&doi=10.1038%2Fsj.onc.1202233"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1202233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1202233%26sid%3Dliteratum%253Aachs%26aulast%3DEgan%26aufirst%3DC.%26aulast%3DPang%26aufirst%3DA.%26aulast%3DDurda%26aufirst%3DD.%26aulast%3DCheng%26aufirst%3DH.%2BC.%26aulast%3DWang%26aufirst%3DJ.%2BH.%26aulast%3DFujita%26aufirst%3DD.%2BJ.%26atitle%3DActivation%2520of%2520Src%2520in%2520human%2520breast%2520tumor%2520cell%2520lines%253A%2520elevated%2520levels%2520of%2520phosphotyrosine%2520phosphatase%2520activity%2520that%2520preferentially%2520recognizes%2520the%2520Src%2520carboxy%2520terminal%2520negative%2520regulatory%2520tyrosine%2520530%26jtitle%3DOncogene%26date%3D1999%26volume%3D18%26spage%3D1227%26epage%3D1237%26doi%3D10.1038%2Fsj.onc.1202233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Stonans, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stonane, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rußwurm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deigner, H.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Böhm, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiederhold, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jäger, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reinhart, K.</span><span> </span><span class="NLM_article-title">HepG2 human hepatoma cells express multiple cytokine genes</span> <span class="citation_source-journal">Cytokine</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">151</span><span class="NLM_x">–</span> <span class="NLM_lpage">156</span><span class="refDoi"> DOI: 10.1006/cyto.1998.0366</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1006%2Fcyto.1998.0366" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1999&pages=151-156&author=I.+Stonansauthor=E.+Stonaneauthor=S.+Ru%C3%9Fwurmauthor=H.-P.+Deignerauthor=K.+J.+B%C3%B6hmauthor=M.+Wiederholdauthor=L.+J%C3%A4gerauthor=K.+Reinhart&title=HepG2+human+hepatoma+cells+express+multiple+cytokine+genes&doi=10.1006%2Fcyto.1998.0366"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1006%2Fcyto.1998.0366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fcyto.1998.0366%26sid%3Dliteratum%253Aachs%26aulast%3DStonans%26aufirst%3DI.%26aulast%3DStonane%26aufirst%3DE.%26aulast%3DRu%25C3%259Fwurm%26aufirst%3DS.%26aulast%3DDeigner%26aufirst%3DH.-P.%26aulast%3DB%25C3%25B6hm%26aufirst%3DK.%2BJ.%26aulast%3DWiederhold%26aufirst%3DM.%26aulast%3DJ%25C3%25A4ger%26aufirst%3DL.%26aulast%3DReinhart%26aufirst%3DK.%26atitle%3DHepG2%2520human%2520hepatoma%2520cells%2520express%2520multiple%2520cytokine%2520genes%26jtitle%3DCytokine%26date%3D1999%26volume%3D11%26spage%3D151%26epage%3D156%26doi%3D10.1006%2Fcyto.1998.0366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Rational design of inhibitors that bind to inactive kinase conformations</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">358</span><span class="NLM_x">–</span> <span class="NLM_lpage">364</span><span class="refDoi"> DOI: 10.1038/nchembio799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1038%2Fnchembio799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=16783341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=358-364&author=Y.+Liuauthor=N.+S.+Gray&title=Rational+design+of+inhibitors+that+bind+to+inactive+kinase+conformations&doi=10.1038%2Fnchembio799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of inhibitors that bind to inactive kinase conformations</span></div><div class="casAuthors">Liu, Yi; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">358-364</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The majority of kinase inhibitors, known as type I inhibitors that have been developed so far target the ATP binding site of the kinase in its active conformation, in which the activation loop is phosphorylated.  Recently, crystal structures of inhibitors such as imatinib, BIRB796, and sorafenib (BAY43-9006), known as type II inhibitors, have revealed a new binding mode that exploits an addnl. binding site immediately adjacent to the region occupied by ATP.  This pocket is made accessible by an activation-loop rearrangement that is characteristic of kinases in an inactive conformation.  The examn. of binding features of known type II inhibitors is discussed and a pharmacophore model currently used in the design of a new generation of structurally diverse type II inhibitors is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxahsMPlhgDbVg90H21EOLACvtfcHk0lhtF2eK4GuCvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D&md5=4a9347a44a2cf4a412c9741fdcc5696b</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fnchembio799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio799%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DRational%2520design%2520of%2520inhibitors%2520that%2520bind%2520to%2520inactive%2520kinase%2520conformations%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2006%26volume%3D2%26spage%3D358%26epage%3D364%26doi%3D10.1038%2Fnchembio799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span> </span><span class="NLM_article-title">Discovery and optimization of 3-(2-(pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">3281</span><span class="NLM_x">–</span> <span class="NLM_lpage">3295</span><span class="refDoi"> DOI: 10.1021/jm301824k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301824k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksFSktLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=3281-3295&author=M.+Gaoauthor=L.+Duanauthor=J.+Luoauthor=L.+Zhangauthor=X.+Luauthor=Y.+Zhangauthor=Z.+Zhangauthor=Z.+Tuauthor=Y.+Xuauthor=X.+Renauthor=K.+Ding&title=Discovery+and+optimization+of+3-%282-%28pyrazolo%5B1%2C5-a%5Dpyrimidin-6-yl%29ethynyl%29benzamides+as+novel+selective+and+orally+bioavailable+discoidin+domain+receptor+1+%28DDR1%29+inhibitors&doi=10.1021%2Fjm301824k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as Novel Selective and Orally Bioavailable Discoidin Domain Receptor 1 (DDR1) Inhibitors</span></div><div class="casAuthors">Gao, Mingshan; Duan, Lei; Luo, Jinfeng; Zhang, Lianwen; Lu, Xiaoyun; Zhang, Yan; Zhang, Zhang; Tu, Zhengchao; Xu, Yong; Ren, Xiaomei; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3281-3295</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Discoidin domain receptor 1 (DDR1) is an emerging potential mol. target for new anticancer drug discovery.  The authors have discovered a series of 3-(2-(pyrazolo[1,5-a]pyrimidin-6-yl) ethynyl)benzamides that are selective and orally bioavailable DDR1 inhibitors.  The two most promising compds. (I and II) inhibited the enzymic activity of DDR1, with IC50 values of 6.8 and 7.0 nM, resp., but were significantly less potent in suppressing the kinase activities of DDR2, Bcr-Abl, and c-Kit.  Further study revealed that I bound with DDR1 with a Kd value of 0.6 nM, while it was significantly less potent to the other 455 kinases tested.  The S(35) and S(10) selectivity scores of I were 0.035 and 0.008, resp.  The compds. also potently inhibited the proliferation of cancer cells expressing high levels of DDR1 and strongly suppressed cancer cell invasion, adhesion, and tumorigenicity.  Preliminary pharmacokinetic studies suggested that they possessed good PK profiles, with oral bioavailabilities of 67.4% and 56.2%, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoP2AZAoE5zU7Vg90H21EOLACvtfcHk0liVzxqotuu6iA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksFSktLo%253D&md5=7b3adcc8175907627727c4653b93be2c</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm301824k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301824k%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DM.%26aulast%3DDuan%26aufirst%3DL.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDiscovery%2520and%2520optimization%2520of%25203-%25282-%2528pyrazolo%255B1%252C5-a%255Dpyrimidin-6-yl%2529ethynyl%2529benzamides%2520as%2520novel%2520selective%2520and%2520orally%2520bioavailable%2520discoidin%2520domain%2520receptor%25201%2520%2528DDR1%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D3281%26epage%3D3295%26doi%3D10.1021%2Fjm301824k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Tan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomanbhoy, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurbani, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patricelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herhaus, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauls, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ham, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buhrlage, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sim, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sapkota, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westover, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Discovery of type II inhibitors of TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">183</span><span class="NLM_x">–</span> <span class="NLM_lpage">196</span><span class="refDoi"> DOI: 10.1021/jm500480k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500480k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFyiurrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=183-196&author=L.+Tanauthor=T.+Nomanbhoyauthor=D.+Gurbaniauthor=M.+Patricelliauthor=J.+Hunterauthor=J.+Gengauthor=L.+Herhausauthor=J.+Zhangauthor=E.+Paulsauthor=Y.+Hamauthor=H.+G.+Choiauthor=T.+Xieauthor=X.+Dengauthor=S.+J.+Buhrlageauthor=T.+Simauthor=P.+Cohenauthor=G.+Sapkotaauthor=K.+D.+Westoverauthor=N.+S.+Gray&title=Discovery+of+type+II+inhibitors+of+TGF%CE%B2-activated+kinase+1+%28TAK1%29+and+mitogen-activated+protein+kinase+kinase+kinase+kinase+2+%28MAP4K2%29&doi=10.1021%2Fjm500480k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Type II Inhibitors of TGFβ-Activated Kinase 1 (TAK1) and Mitogen-Activated Protein Kinase Kinase Kinase Kinase 2 (MAP4K2)</span></div><div class="casAuthors">Tan, Li; Nomanbhoy, Tyzoon; Gurbani, Deepak; Patricelli, Matthew; Hunter, John; Geng, Jiefei; Herhaus, Lina; Zhang, Jianming; Pauls, Eduardo; Ham, Youngjin; Choi, Hwan Geun; Xie, Ting; Deng, Xianming; Buhrlage, Sara J.; Sim, Taebo; Cohen, Philip; Sapkota, Gopal; Westover, Kenneth D.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">183-196</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors developed a pharmacophore model for type II inhibitors that was used to guide the construction of a library of kinase inhibitors.  Kinome-wide selectivity profiling of the library resulted in the identification of a series of 4-substituted 1H-pyrrolo[2,3-b]pyridines that exhibited potent inhibitory activity against two mitogen-activated protein kinases (MAPKs), TAK1 (MAP3K7) and MAP4K2, as well as pharmacol. well interrogated kinases such as p38α (MAPK14) and ABL.  Further investigation of the structure-activity relationship (SAR) resulted in the identification effect two potent dual TAK1 and MAP4K2 inhibitors such as I as well as two MAP4K2 selective inhibitors such as II.  Some of these inhibitors possess good pharmacokinetic properties that will enable their use in pharmacol. studies in vivo.  A 2.4 Å cocrystal structure of TAK1 in complex with 1 confirms that the activation loop of TAK1 assumes the DFG-out conformation characteristic of type II inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzjzVF_V_qSLVg90H21EOLACvtfcHk0liVzxqotuu6iA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFyiurrJ&md5=288a6be4b9b4a5a6a5b925673cadd47a</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm500480k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500480k%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DL.%26aulast%3DNomanbhoy%26aufirst%3DT.%26aulast%3DGurbani%26aufirst%3DD.%26aulast%3DPatricelli%26aufirst%3DM.%26aulast%3DHunter%26aufirst%3DJ.%26aulast%3DGeng%26aufirst%3DJ.%26aulast%3DHerhaus%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DPauls%26aufirst%3DE.%26aulast%3DHam%26aufirst%3DY.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DXie%26aufirst%3DT.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DBuhrlage%26aufirst%3DS.%2BJ.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DSapkota%26aufirst%3DG.%26aulast%3DWestover%26aufirst%3DK.%2BD.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520type%2520II%2520inhibitors%2520of%2520TGF%25CE%25B2-activated%2520kinase%25201%2520%2528TAK1%2529%2520and%2520mitogen-activated%2520protein%2520kinase%2520kinase%2520kinase%2520kinase%25202%2520%2528MAP4K2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D183%26epage%3D196%26doi%3D10.1021%2Fjm500480k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poluzzi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Ponti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Recanatini, M.</span><span> </span><span class="NLM_article-title">Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K+ channel blockers</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">3844</span><span class="NLM_x">–</span> <span class="NLM_lpage">3853</span><span class="refDoi"> DOI: 10.1021/jm0208875</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0208875" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BD38XlsFalsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=3844-3853&author=A.+Cavalliauthor=E.+Poluzziauthor=F.+De+Pontiauthor=M.+Recanatini&title=Toward+a+pharmacophore+for+drugs+inducing+the+long+QT+syndrome%3A+insights+from+a+CoMFA+study+of+HERG+K%2B+channel+blockers&doi=10.1021%2Fjm0208875"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K+ channel blockers</span></div><div class="casAuthors">Cavalli, Andrea; Poluzzi, Elisabetta; De Ponti, Fabrizio; Recanatini, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3844-3853</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this paper, we present a pharmacophore for QT-prolonging drugs, along with a 3D QSAR (CoMFA) study for a series of very structurally variegate HERG K+ channel blockers.  The blockade of HERG K+ channels is one of the most important mol. mechanisms through which QT-prolonging drugs increase cardiac action potential duration.  Since QT prolongation is one of the most undesirable side effects of drugs, we first tried to identify the min. set of mol. features responsible for this action and then we attempted to develop a quant. model correlating the 3D stereoelectronic characteristics of the mols. with their HERG blocking potency.  Having considered an initial set of 31 QT-prolonging drugs for which the HERG K+ channel blocking activity was measured on mammalian transfected cells, we started the construction of a theor. screening tool able to predict whether a new mol. can interact with the HERG channel and eventually induce the long QT syndrome.  This in silico tool might be useful in the design of new drug candidates devoid of the physicochem. features likely to cause the above-mentioned side effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7WFt3kf6ZVLVg90H21EOLACvtfcHk0ljX531DXfD2kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlsFalsrk%253D&md5=5e980476ccc9a8a6244aaab230eeb701</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm0208875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0208875%26sid%3Dliteratum%253Aachs%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DPoluzzi%26aufirst%3DE.%26aulast%3DDe%2BPonti%26aufirst%3DF.%26aulast%3DRecanatini%26aufirst%3DM.%26atitle%3DToward%2520a%2520pharmacophore%2520for%2520drugs%2520inducing%2520the%2520long%2520QT%2520syndrome%253A%2520insights%2520from%2520a%2520CoMFA%2520study%2520of%2520HERG%2520K%252B%2520channel%2520blockers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D3844%26epage%3D3853%26doi%3D10.1021%2Fjm0208875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Aronov, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, B. B.</span><span> </span><span class="NLM_article-title">A model for identifying HERG K+ channel blockers</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">2307</span><span class="NLM_x">–</span> <span class="NLM_lpage">2315</span><span class="refDoi"> DOI: 10.1016/j.bmc.2004.02.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1016%2Fj.bmc.2004.02.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=15080928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjtVKqu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2004&pages=2307-2315&author=A.+M.+Aronovauthor=B.+B.+Goldman&title=A+model+for+identifying+HERG+K%2B+channel+blockers&doi=10.1016%2Fj.bmc.2004.02.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">A model for identifying HERG K+ channel blockers</span></div><div class="casAuthors">Aronov, Alex M.; Goldman, Brian B.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2307-2315</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Acquired long QT syndrome (LQTS) occurs frequently as a side effect of blockade of cardiac HERG K+ channels by commonly used medications.  A large no. of structurally diverse compds. have been shown to inhibit K+ current through HERG.  There is considerable interest in developing in silico tools to filter out potential HERG blockers early in the drug discovery process.  We describe a binary classification model that combines a 2D topol. similarity filter with a 3D pharmacophore ensemble procedure to discriminate between HERG actives and inactives with an overall accuracy of 82%, with false neg. and false pos. rates of 29% and 15%, resp.  This model should be generally applicable in virtual library counterscreening against HERG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK7a2-P1CNkLVg90H21EOLACvtfcHk0ljX531DXfD2kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjtVKqu7g%253D&md5=acfa27de5815ccbe7cb1ebbefefc99e2</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2004.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2004.02.003%26sid%3Dliteratum%253Aachs%26aulast%3DAronov%26aufirst%3DA.%2BM.%26aulast%3DGoldman%26aufirst%3DB.%2BB.%26atitle%3DA%2520model%2520for%2520identifying%2520HERG%2520K%252B%2520channel%2520blockers%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2004%26volume%3D12%26spage%3D2307%26epage%3D2315%26doi%3D10.1016%2Fj.bmc.2004.02.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Kim, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, E.-J.</span><span> </span><span class="NLM_article-title">Pathological roles of MAPK signaling pathways in human diseases</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Mol. Basis Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1802</span><span class="NLM_x">, </span> <span class="NLM_fpage">396</span><span class="NLM_x">–</span> <span class="NLM_lpage">405</span><span class="refDoi"> DOI: 10.1016/j.bbadis.2009.12.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1016%2Fj.bbadis.2009.12.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=20079433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitlSntLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1802&publication_year=2010&pages=396-405&author=E.+K.+Kimauthor=E.-J.+Choi&title=Pathological+roles+of+MAPK+signaling+pathways+in+human+diseases&doi=10.1016%2Fj.bbadis.2009.12.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Pathological roles of MAPK signaling pathways in human diseases</span></div><div class="casAuthors">Kim, Eun Kyung; Choi, Eui-Ju</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Basis of Disease</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1802</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">396-405</span>CODEN:
                <span class="NLM_cas:coden">BBADEX</span>;
        ISSN:<span class="NLM_cas:issn">0925-4439</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  The mammalian family of mitogen-activated protein kinases (MAPKs) includes extracellular signal-regulated kinase (ERK), p38, and c-Jun N-terminal kinase (JNK), with each MAPK signaling pathway consisting of at least three components, a MAPK kinase kinase (MAP3K), a MAPK kinase (MAP2K), and a MAPK.  The MAPK pathways are activated by diverse extracellular and intracellular stimuli including peptide growth factors, cytokines, hormones, and various cellular stressors such as oxidative stress and endoplasmic reticulum stress.  These signaling pathways regulate a variety of cellular activities including proliferation, differentiation, survival, and death.  Deviation from the strict control of MAPK signaling pathways has been implicated in the development of many human diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and various types of cancers.  Persistent activation of the JNK or p38 signaling pathways has been suggested to mediate neuronal apoptosis in AD, PD, and ALS, whereas the ERK signaling pathway plays a key role in several steps of tumorigenesis including cancer cell proliferation, migration, and invasion.  In this review, we summarize recent findings on the roles of MAPK signaling pathways in human disorders, focusing on cancer and neurodegenerative diseases including AD, PD, and ALS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH-o9cqFzUgLVg90H21EOLACvtfcHk0ljX531DXfD2kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitlSntLY%253D&md5=dff0ef076a287270ae2dd59c21cef333</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.bbadis.2009.12.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbadis.2009.12.009%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DE.%2BK.%26aulast%3DChoi%26aufirst%3DE.-J.%26atitle%3DPathological%2520roles%2520of%2520MAPK%2520signaling%2520pathways%2520in%2520human%2520diseases%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Basis%2520Dis.%26date%3D2010%26volume%3D1802%26spage%3D396%26epage%3D405%26doi%3D10.1016%2Fj.bbadis.2009.12.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Ongusaha, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. i.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yancopoulos, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aaronson, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. W.</span><span> </span><span class="NLM_article-title">p53 induction and activation of DDR1 kinase counteract p53 - mediated apoptosis and influence p53 regulation through a positive feedback loop</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1289</span><span class="NLM_x">–</span> <span class="NLM_lpage">1301</span><span class="refDoi"> DOI: 10.1093/emboj/cdg129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1093%2Femboj%2Fcdg129" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2003&pages=1289-1301&author=P.+P.+Ongusahaauthor=J.+i.+Kimauthor=L.+Fangauthor=T.+W.+Wongauthor=G.+D.+Yancopoulosauthor=S.+A.+Aaronsonauthor=S.+W.+Lee&title=p53+induction+and+activation+of+DDR1+kinase+counteract+p53+-+mediated+apoptosis+and+influence+p53+regulation+through+a+positive+feedback+loop&doi=10.1093%2Femboj%2Fcdg129"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1093%2Femboj%2Fcdg129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252Fcdg129%26sid%3Dliteratum%253Aachs%26aulast%3DOngusaha%26aufirst%3DP.%2BP.%26aulast%3DKim%26aufirst%3DJ.%2Bi.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DWong%26aufirst%3DT.%2BW.%26aulast%3DYancopoulos%26aufirst%3DG.%2BD.%26aulast%3DAaronson%26aufirst%3DS.%2BA.%26aulast%3DLee%26aufirst%3DS.%2BW.%26atitle%3Dp53%2520induction%2520and%2520activation%2520of%2520DDR1%2520kinase%2520counteract%2520p53%2520-%2520mediated%2520apoptosis%2520and%2520influence%2520p53%2520regulation%2520through%2520a%2520positive%2520feedback%2520loop%26jtitle%3DEMBO%2520J.%26date%3D2003%26volume%3D22%26spage%3D1289%26epage%3D1301%26doi%3D10.1093%2Femboj%2Fcdg129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Pennati, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sbarra, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Cesare, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopergolo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Locatelli, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daidone, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlo-Stella, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gianni, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaffaroni, N.</span><span> </span><span class="NLM_article-title">YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">136</span><span class="NLM_x">, </span> <span class="NLM_fpage">299</span><span class="NLM_x">–</span> <span class="NLM_lpage">309</span><span class="refDoi"> DOI: 10.1002/ijc.28993</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1002%2Fijc.28993" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=24866585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptlKrtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2015&pages=299-309&author=M.+Pennatiauthor=S.+Sbarraauthor=M.+De+Cesareauthor=A.+Lopergoloauthor=S.+L.+Locatelliauthor=E.+Campiauthor=M.+G.+Daidoneauthor=C.+Carlo-Stellaauthor=A.+M.+Gianniauthor=N.+Zaffaroni&title=YM155+sensitizes+triple-negative+breast+cancer+to+membrane-bound+TRAIL+through+p38+MAPK-+and+CHOP-mediated+DR5+upregulation&doi=10.1002%2Fijc.28993"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation</span></div><div class="casAuthors">Pennati, Marzia; Sbarra, Stefania; De Cesare, Michelandrea; Lopergolo, Alessia; Locatelli, Silvia L.; Campi, Elisa; Daidone, Maria Grazia; Carlo-Stella, Carmelo; Gianni, Alessandro M.; Zaffaroni, Nadia</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">299-309</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Because available treatments have limited efficacy in triple-neg. breast cancer (TNBC), the identification of new therapeutic strategies to improve patients' outcome is urgently needed.  In our study, we investigated the effects of the administration of the small mol. selective survivin suppressant YM155, alone or in assocn. with CD34+ cells transduced with a replication-deficient adenovirus encoding the human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene (CD34-TRAIL+ cells), in three TNBC cell models.  YM155 exposure significantly impaired TNBC cell growth and selectively modulated survivin expression at both mRNA and protein level.  In addn., co-culturing YM155-treated TNBC cells with CD34-TRAIL+ cells resulted in markedly increased cytotoxic effect and apoptotic response in comparison with single treatments.  Such a chemosensitizing effect was obsd. only in TNBC cells inherently expressing DR5 and relied on the ability of YM155 to upregulate DR5 expression through a p38 MAPK- and CHOP-dependent mechanism.  YM155/CD34-TRAIL+ combination also showed a significant inhibitory effect on the growth of DR5-expressing TNBC cells following xenotransplantation into NOD/SCID mice, in the absence of toxicity.  Overall, our data (i) provide, for the first time, evidence that YM155 sensitizes TNBC cells to CD34-TRAIL+ cells-induced apoptosis by a mechanism involving the downregulation of survivin and the simultaneous p38 MAPK- and CHOP-mediated upregulation of DR5, and (ii) suggest the combination of YM155 with TRAIL-armed CD34+ progenitor cells as a promising therapeutic option for patients with TNBC expressing DR5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvyPRRqGE5aLVg90H21EOLACvtfcHk0lgzetcuXhbtsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptlKrtr8%253D&md5=0eb641407663c2b843a2519d8bef8d1e</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fijc.28993&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.28993%26sid%3Dliteratum%253Aachs%26aulast%3DPennati%26aufirst%3DM.%26aulast%3DSbarra%26aufirst%3DS.%26aulast%3DDe%2BCesare%26aufirst%3DM.%26aulast%3DLopergolo%26aufirst%3DA.%26aulast%3DLocatelli%26aufirst%3DS.%2BL.%26aulast%3DCampi%26aufirst%3DE.%26aulast%3DDaidone%26aufirst%3DM.%2BG.%26aulast%3DCarlo-Stella%26aufirst%3DC.%26aulast%3DGianni%26aufirst%3DA.%2BM.%26aulast%3DZaffaroni%26aufirst%3DN.%26atitle%3DYM155%2520sensitizes%2520triple-negative%2520breast%2520cancer%2520to%2520membrane-bound%2520TRAIL%2520through%2520p38%2520MAPK-%2520and%2520CHOP-mediated%2520DR5%2520upregulation%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2015%26volume%3D136%26spage%3D299%26epage%3D309%26doi%3D10.1002%2Fijc.28993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Qi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lepp, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jing, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dwinell, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chitambar, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, G.</span><span> </span><span class="NLM_article-title">p38γ MAPK is a therapeutic target for triple-negative breast cancer by stimulation of cancer stem-like cell expansion</span> <span class="citation_source-journal">Stem Cells</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">2738</span><span class="NLM_x">–</span> <span class="NLM_lpage">2747</span><span class="refDoi"> DOI: 10.1002/stem.2068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1002%2Fstem.2068" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=2738-2747&author=X.+Qiauthor=N.+Yinauthor=S.+Maauthor=A.+Leppauthor=J.+Tangauthor=W.+Jingauthor=B.+Johnsonauthor=M.+B.+Dwinellauthor=C.+R.+Chitambarauthor=G.+Chen&title=p38%CE%B3+MAPK+is+a+therapeutic+target+for+triple-negative+breast+cancer+by+stimulation+of+cancer+stem-like+cell+expansion&doi=10.1002%2Fstem.2068"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1002%2Fstem.2068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fstem.2068%26sid%3Dliteratum%253Aachs%26aulast%3DQi%26aufirst%3DX.%26aulast%3DYin%26aufirst%3DN.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DLepp%26aufirst%3DA.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DJing%26aufirst%3DW.%26aulast%3DJohnson%26aufirst%3DB.%26aulast%3DDwinell%26aufirst%3DM.%2BB.%26aulast%3DChitambar%26aufirst%3DC.%2BR.%26aulast%3DChen%26aufirst%3DG.%26atitle%3Dp38%25CE%25B3%2520MAPK%2520is%2520a%2520therapeutic%2520target%2520for%2520triple-negative%2520breast%2520cancer%2520by%2520stimulation%2520of%2520cancer%2520stem-like%2520cell%2520expansion%26jtitle%3DStem%2520Cells%26date%3D2015%26volume%3D33%26spage%3D2738%26epage%3D2747%26doi%3D10.1002%2Fstem.2068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Shin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blenis, J.</span><span> </span><span class="NLM_article-title">ERK2/Fra1/ZEB pathway induces epithelial-to-mesenchymal transition</span> <span class="citation_source-journal">Cell Cycle</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">2483</span><span class="NLM_x">–</span> <span class="NLM_lpage">2484</span><span class="refDoi"> DOI: 10.4161/cc.9.13.12270</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.4161%2Fcc.9.13.12270" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=2483-2484&author=S.+Shinauthor=J.+Blenis&title=ERK2%2FFra1%2FZEB+pathway+induces+epithelial-to-mesenchymal+transition&doi=10.4161%2Fcc.9.13.12270"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.4161%2Fcc.9.13.12270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.9.13.12270%26sid%3Dliteratum%253Aachs%26aulast%3DShin%26aufirst%3DS.%26aulast%3DBlenis%26aufirst%3DJ.%26atitle%3DERK2%252FFra1%252FZEB%2520pathway%2520induces%2520epithelial-to-mesenchymal%2520transition%26jtitle%3DCell%2520Cycle%26date%3D2010%26volume%3D9%26spage%3D2483%26epage%3D2484%26doi%3D10.4161%2Fcc.9.13.12270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Porter, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janicke, R. U.</span><span> </span><span class="NLM_article-title">Emerging roles of caspase-3 in apoptosis</span> <span class="citation_source-journal">Cell Death Differ.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">99</span><span class="NLM_x">–</span> <span class="NLM_lpage">104</span><span class="refDoi"> DOI: 10.1038/sj.cdd.4400476</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1038%2Fsj.cdd.4400476" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10200555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADyaK1MXhs1Cgu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1999&pages=99-104&author=A.+G.+Porterauthor=R.+U.+Janicke&title=Emerging+roles+of+caspase-3+in+apoptosis&doi=10.1038%2Fsj.cdd.4400476"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging roles of caspase-3 in apoptosis</span></div><div class="casAuthors">Porter, Alan G.; Janicke, Reiner U.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death and Differentiation</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">99-104</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Stockton Press</span>)
        </div><div class="casAbstract">A review with 41 refs.  Caspases are crucial mediators of programmed cell death (apoptosis).  Among them, caspase-3 is a frequently activated death protease, catalyzing the specific cleavage of many key cellular proteins.  However, the specific requirements of this (or any other) caspase in apoptosis have remained largely unknown until now.  Pathways to caspase-3 activation have been identified that are either dependent on or independent of mitochondrial cytochrome c release and caspase-9 function.  Caspase-3 is essential for normal brain development and is important or essential in other apoptotic scenarios in a remarkable tissue-, cell type- or death stimulus-specific manner.  Caspase-3 is also required for some typical hallmarks of apoptosis, and is indispensable for apoptotic chromatin condensation and DNA fragmentation in all cell types examd.  Thus, caspase-3 is essential for certain processes assocd. with the dismantling of the cell and the formation of apoptotic bodies, but it may also function before or at the stage when commitment to loss of cell viability is made.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvEdRSRLukZbVg90H21EOLACvtfcHk0lgzetcuXhbtsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhs1Cgu7c%253D&md5=8d45a2f52ffed84897d36061c3dca019</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fsj.cdd.4400476&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.cdd.4400476%26sid%3Dliteratum%253Aachs%26aulast%3DPorter%26aufirst%3DA.%2BG.%26aulast%3DJanicke%26aufirst%3DR.%2BU.%26atitle%3DEmerging%2520roles%2520of%2520caspase-3%2520in%2520apoptosis%26jtitle%3DCell%2520Death%2520Differ.%26date%3D1999%26volume%3D6%26spage%3D99%26epage%3D104%26doi%3D10.1038%2Fsj.cdd.4400476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Delano, W. L.</span> <span class="citation_source-book">The PyMOL Molecular Graphics System</span>, version 1.7; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=W.+L.+Delano&title=The+PyMOL+Molecular+Graphics+System"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DDelano%26aufirst%3DW.%2BL.%26btitle%3DThe%2520PyMOL%2520Molecular%2520Graphics%2520System%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Yang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span> </span><span class="NLM_article-title">Discovery of a teraryl oxazolidinone compound (S)-N-((3-(3-fluoro-4-(4-(pyridin-2-yl)-1H-pyrazol-1-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)acetamide phosphate as a novel antimicrobial agent with enhanced safety profile and efficacies</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">6389</span><span class="NLM_x">–</span> <span class="NLM_lpage">6409</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00152</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00152" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1altb7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6389-6409&author=T.+Yangauthor=G.+Chenauthor=Z.+Sangauthor=Y.+Liuauthor=X.+Yangauthor=Y.+Changauthor=H.+Longauthor=W.+Angauthor=J.+Tangauthor=Z.+Wangauthor=G.+Liauthor=S.+Yangauthor=J.+Zhangauthor=Y.+Weiauthor=Y.+Luo&title=Discovery+of+a+teraryl+oxazolidinone+compound+%28S%29-N-%28%283-%283-fluoro-4-%284-%28pyridin-2-yl%29-1H-pyrazol-1-yl%29phenyl%29-2-oxooxazolidin-5-yl%29methyl%29acetamide+phosphate+as+a+novel+antimicrobial+agent+with+enhanced+safety+profile+and+efficacies&doi=10.1021%2Facs.jmedchem.5b00152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Teraryl Oxazolidinone Compound (S)-N-((3-(3-Fluoro-4-(4-(pyridin-2-yl)-1H-pyrazol-1-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)acetamide Phosphate as a Novel Antimicrobial Agent with Enhanced Safety Profile and Efficacies</span></div><div class="casAuthors">Yang, Tao; Chen, Gong; Sang, Zitai; Liu, Yuanyuan; Yang, Xiaoyan; Chang, Ying; Long, Haiyue; Wei, Ang; Tang, Jianying; Wang, Zhenling; Li, Guobo; Yang, Shengyong; Zhang, Jingren; Wei, Yuquan; Luo, Youfu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6389-6409</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel teraryl oxazolidinone compds. was designed, synthesized, and evaluated for their antimicrobial activity and toxicities.  The compds. with arom. N-heterocyclic substituents at the 4-position of pyrazolyl ring showed better antibacterial activity against the tested bacteria than other compds. with different patterns of substitution.  Among all potent compds., I exhibited promising safety profile in MTT assays and in hERG K+ channel inhibition test.  Furthermore, its phosphate was found to be highly sol. in water (47.1 mg/mL), which is beneficial for the subsequent in vivo test.  In MRSA systemic infection mice models, I phosphate exerted significantly improved survival protection compared with linezolid.  The compd. also demonstrated high oral bioavailability (F = 99.1%).  Moreover, from the results of in vivo toxicol. expts., I phosphate would be predicted to have less bone marrow suppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2zOHxUIAO2bVg90H21EOLACvtfcHk0ljv0uysQnaS-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1altb7E&md5=69b436025095d8fc3fcd25c2c7530a94</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00152%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DSang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DChang%26aufirst%3DY.%26aulast%3DLong%26aufirst%3DH.%26aulast%3DAng%26aufirst%3DW.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520a%2520teraryl%2520oxazolidinone%2520compound%2520%2528S%2529-N-%2528%25283-%25283-fluoro-4-%25284-%2528pyridin-2-yl%2529-1H-pyrazol-1-yl%2529phenyl%2529-2-oxooxazolidin-5-yl%2529methyl%2529acetamide%2520phosphate%2520as%2520a%2520novel%2520antimicrobial%2520agent%2520with%2520enhanced%2520safety%2520profile%2520and%2520efficacies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6389%26epage%3D6409%26doi%3D10.1021%2Facs.jmedchem.5b00152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Chartier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chenard, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Najmanovich, R.</span><span> </span><span class="NLM_article-title">Kinome Render: a stand-alone and web-accessible tool to annotate the human protein kinome tree</span> <span class="citation_source-journal">PeerJ</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">e126</span><span class="refDoi"> DOI: 10.7717/peerj.126</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.7717%2Fpeerj.126" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=23940838" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2013&pages=e126&author=M.+Chartierauthor=T.+Chenardauthor=J.+Barkerauthor=R.+Najmanovich&title=Kinome+Render%3A+a+stand-alone+and+web-accessible+tool+to+annotate+the+human+protein+kinome+tree&doi=10.7717%2Fpeerj.126"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.7717%2Fpeerj.126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7717%252Fpeerj.126%26sid%3Dliteratum%253Aachs%26aulast%3DChartier%26aufirst%3DM.%26aulast%3DChenard%26aufirst%3DT.%26aulast%3DBarker%26aufirst%3DJ.%26aulast%3DNajmanovich%26aufirst%3DR.%26atitle%3DKinome%2520Render%253A%2520a%2520stand-alone%2520and%2520web-accessible%2520tool%2520to%2520annotate%2520the%2520human%2520protein%2520kinome%2520tree%26jtitle%3DPeerJ%26date%3D2013%26volume%3D1%26spage%3De126%26doi%3D10.7717%2Fpeerj.126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Shen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hao, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, R.</span><span> </span><span class="NLM_article-title">TIFA suppresses hepatocellular carcinoma progression via MALT1-dependent and -independent signaling pathways</span> <span class="citation_source-journal">Signal Transduct. Target. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">16013</span><span class="refDoi"> DOI: 10.1038/sigtrans.2016.13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1038%2Fsigtrans.2016.13" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2016&pages=16013&author=W.+Shenauthor=R.+Duauthor=J.+Liauthor=X.+Luoauthor=S.+Zhaoauthor=A.+Changauthor=W.+Zhouauthor=R.+Gaoauthor=D.+Luoauthor=J.+Wangauthor=N.+Haoauthor=Y.+Liuauthor=Y.+Chenauthor=Y.+Luoauthor=P.+Sunauthor=S.+Yangauthor=N.+Luoauthor=R.+Xiang&title=TIFA+suppresses+hepatocellular+carcinoma+progression+via+MALT1-dependent+and+-independent+signaling+pathways&doi=10.1038%2Fsigtrans.2016.13"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2Fsigtrans.2016.13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsigtrans.2016.13%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DW.%26aulast%3DDu%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DGao%26aufirst%3DR.%26aulast%3DLuo%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DHao%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DN.%26aulast%3DXiang%26aufirst%3DR.%26atitle%3DTIFA%2520suppresses%2520hepatocellular%2520carcinoma%2520progression%2520via%2520MALT1-dependent%2520and%2520-independent%2520signaling%2520pathways%26jtitle%3DSignal%2520Transduct.%2520Target.%2520Ther.%26date%3D2016%26volume%3D1%26spage%3D16013%26doi%3D10.1038%2Fsigtrans.2016.13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Wert, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahajan, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tosi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagasaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janisch, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grant, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahajan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bassuk, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsang, S. H.</span><span> </span><span class="NLM_article-title">Neuroretinal hypoxic signaling in a new preclinical murine model for proliferative diabetic retinopathy</span> <span class="citation_source-journal">Signal Transduct. Target. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">16005</span><span class="refDoi"> DOI: 10.1038/sigtrans.2016.5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1038%2Fsigtrans.2016.5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=27195131" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2016&pages=16005&author=K.+J.+Wertauthor=V.+B.+Mahajanauthor=L.+Zhangauthor=Y.+Yanauthor=Y.+Liauthor=J.+Tosiauthor=C.+W.+Hsuauthor=T.+Nagasakiauthor=K.+M.+Janischauthor=M.+B.+Grantauthor=M.+Mahajanauthor=A.+G.+Bassukauthor=S.+H.+Tsang&title=Neuroretinal+hypoxic+signaling+in+a+new+preclinical+murine+model+for+proliferative+diabetic+retinopathy&doi=10.1038%2Fsigtrans.2016.5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fsigtrans.2016.5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsigtrans.2016.5%26sid%3Dliteratum%253Aachs%26aulast%3DWert%26aufirst%3DK.%2BJ.%26aulast%3DMahajan%26aufirst%3DV.%2BB.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DTosi%26aufirst%3DJ.%26aulast%3DHsu%26aufirst%3DC.%2BW.%26aulast%3DNagasaki%26aufirst%3DT.%26aulast%3DJanisch%26aufirst%3DK.%2BM.%26aulast%3DGrant%26aufirst%3DM.%2BB.%26aulast%3DMahajan%26aufirst%3DM.%26aulast%3DBassuk%26aufirst%3DA.%2BG.%26aulast%3DTsang%26aufirst%3DS.%2BH.%26atitle%3DNeuroretinal%2520hypoxic%2520signaling%2520in%2520a%2520new%2520preclinical%2520murine%2520model%2520for%2520proliferative%2520diabetic%2520retinopathy%26jtitle%3DSignal%2520Transduct.%2520Target.%2520Ther.%26date%3D2016%26volume%3D1%26spage%3D16005%26doi%3D10.1038%2Fsigtrans.2016.5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">He, Z.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, M.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, S.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">But, P. P.-H.</span><span> </span><span class="NLM_article-title">Anti-angiogenic effects of rhubarb and its anthraquinone derivatives</span> <span class="citation_source-journal">J. Ethnopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">121</span><span class="NLM_x">, </span> <span class="NLM_fpage">313</span><span class="NLM_x">–</span> <span class="NLM_lpage">317</span><span class="refDoi"> DOI: 10.1016/j.jep.2008.11.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=10.1016%2Fj.jep.2008.11.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=19061946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVGnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2009&pages=313-317&author=Z.-H.+Heauthor=M.-F.+Heauthor=S.-C.+Maauthor=P.+P.-H.+But&title=Anti-angiogenic+effects+of+rhubarb+and+its+anthraquinone+derivatives&doi=10.1016%2Fj.jep.2008.11.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-angiogenic effects of rhubarb and its anthraquinone derivatives</span></div><div class="casAuthors">He, Zhi-Heng; He, Ming-Fang; Ma, Shuang-Cheng; But, Paul Pui-Hay</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Ethnopharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">313-317</span>CODEN:
                <span class="NLM_cas:coden">JOETD7</span>;
        ISSN:<span class="NLM_cas:issn">0378-8741</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Ethnopharmacol. relevance: Rhubarb root (Dahuang) is often included as an ingredient in traditional Chinese compd. prescriptions for the treatment of inflammatory diseases.  This application may possibly be mediated through anti-angiogensis and thus would shed light on its potential value in cancer therapy.  Aim of the study: To elucidate the anti-angiogenic properties of rhubarb root, we tested the inhibitory effects of different fractions and a series of anthraquinone derivs. against vessel formation in zebrafish embryos.  Materials and methods: The 95% ethanol ext. and four subsequent fractions (n-hexane, Et acetate, n-butanol and aq. fractions) of rhubarb root and five anthraquinone derivs. were investigated on zebrafish model by quant. endogenous alk. phosphatase assay and staining assay.  Results: Et acetate fraction showed the strongest inhibition of vessel formation by 52%.  Three anthraquinones (aloe-emodin, emodin and rhein) displayed potent anti-angiogenic activities.  Conclusions: The angiogenic properties of rhubarb root may partly account for its use in inflammatory diseases.  The anthraquinones with acidic or polar, hydrophilic substitution at C-6 or C-3 positions played a substantial role in inhibiting angiogenesis.  The value of the zebrafish angiogenic model is further supported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrNorUWMZNArVg90H21EOLACvtfcHk0ljAm6FbmfdNNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVGnsw%253D%253D&md5=d0a7ab359f9c9cbeff33ee80f5ad4e45</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.jep.2008.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jep.2008.11.008%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DZ.-H.%26aulast%3DHe%26aufirst%3DM.-F.%26aulast%3DMa%26aufirst%3DS.-C.%26aulast%3DBut%26aufirst%3DP.%2BP.-H.%26atitle%3DAnti-angiogenic%2520effects%2520of%2520rhubarb%2520and%2520its%2520anthraquinone%2520derivatives%26jtitle%3DJ.%2520Ethnopharmacol.%26date%3D2009%26volume%3D121%26spage%3D313%26epage%3D317%26doi%3D10.1016%2Fj.jep.2008.11.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3EL7" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3EL7','PDB','3EL7'); return false;">PDB: 3EL7</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i102"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00943">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_17540"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b00943">10.1021/acs.jmedchem.6b00943</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Chemical data of key intermediates, acute toxicity evaluation of compound <b>1</b> and <b>13an</b>, mappings of <b>13b</b> and <b>13ai</b> with the pharmacophore hypothesis of hERG blockers, and kinase profiling results of <b>13an</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00943/suppl_file/jm6b00943_si_001.pdf">PDF</a>)</p></li><li><p class="inline">SMILES data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00943/suppl_file/jm6b00943_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00943/suppl_file/jm6b00943_si_001.pdf">jm6b00943_si_001.pdf (1.38 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00943/suppl_file/jm6b00943_si_002.csv">jm6b00943_si_002.csv (6.47 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b00943&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b00943%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-21%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b00943" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                9MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67996d245d743cb8","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
